2-substituted thiazole HSD17B13 inhibitors and uses thereof
Selective inhibition of HSD17B13 through a specific compound or pharmaceutical composition solves the problem of difficulty in reducing HSD17B13 expression in the prior art, significantly improves the therapeutic effect of NAFLD and NASH, and has potential for the treatment and prevention of chronic liver disease.
Patent Information
- Application Number
- CN202380029208.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-09-28
- Filing Date
- 2023-01-25
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to effectively reduce the expression or activity of HSD17B13, resulting in poor treatment of non-alcoholic fatty liver disease (NAFLD) and related chronic liver diseases.
A compound or pharmaceutical composition is provided with the activity of selectively inhibiting HSD17B13 for the treatment of NAFLD, NASH and other liver diseases associated with HSD17B13. This compound has a thiazolyl structure and is composed of specific groups such as alkyl, haloalkyl, amino, etc., which can selectively inhibit HSD17B13 and reduce its expression and activity in the liver.
By inhibiting HSD17B13, it significantly reduces lipid accumulation in the liver and improves the condition of NAFLD and NASH, and has potential effects on the treatment and prevention of chronic liver disease.
Smart Images

Figure BDA0005052600670000021 
Figure BDA0005052600670000051 
Figure BDA0005052600670000052
Abstract
Description
[0001] Cross-references
[0002] This application claims the benefit of Indian Application No. 202211004338 filed on January 26, 2022; U.S. Provisional Application Serial No. 63 / 342,786 filed on May 17, 2022; and U.S. Provisional Application Serial No. 63 / 377,421 filed on September 28, 2022; which are hereby incorporated by reference in their entirety. Background Art
[0003] Non-alcoholic fatty liver disease (NAFLD), including NASH (non-alcoholic steatohepatitis), is considered to be a liver manifestation of metabolic syndrome and is characterized by the accumulation of triglycerides in the liver of patients without a history of excessive drinking. Most NAFLD patients are obese or morbidly obese and have insulin resistance. In line with the increasing prevalence of obesity, the incidence of NAFLD / NASH is increasing rapidly worldwide, and it is currently the most common chronic liver disease.
[0004] NAFLD is classified into simple steatosis, in which only hepatic steatosis is observed; and NASH, in which intralobular inflammation and ballooning of hepatocytes are observed together with hepatic steatosis. The proportion of NAFLD patients suffering from NASH remains unclear, but may be in the range of 20-40%. NASH is a progressive disease and can lead to cirrhosis and hepatocellular carcinoma. It is reported that 20% of NASH patients develop cirrhosis, and 30-40% of NASH cirrhosis patients suffer liver-related deaths. Recently, NASH has become the third most common indication for liver transplantation in the United States. Currently, the main treatment for NAFLD / NASH is lifestyle changes through diet and exercise. However, drug therapy is essential because obese patients with NAFLD often have difficulty maintaining an improved lifestyle.
[0005] 17β-Hydroxysteroid dehydrogenase (HSD17B) includes a large family of 15 members, some of which are involved in sex hormone metabolism. Some HSD17B enzymes also play a key role in cholesterol and fatty acid metabolism. A recent study showed that hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) as an enzyme with unknown biological function is a novel liver-specific lipid droplet (LD)-associated protein in mice and humans. In patients and mice with non-alcoholic fatty liver disease (NAFLD), HSD17B13 expression is significantly upregulated. Overexpression of HSD17B13 in the liver promotes lipid accumulation in the liver. HSD17B13 may also have the potential to be a biomarker for chronic liver disease, such as alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD) (e.g., steatosis, non-alcoholic steatohepatitis (NASH), NASH-fibrosis or cirrhosis), steatohepatitis and liver cancer. Summary of the invention
[0006] Provided herein are methods, compounds and compositions that can be used to reduce the expression or activity of HSD17B13 in a subject in need thereof. In addition, provided herein are methods, compounds and compositions comprising HSD17B13-specific inhibitors that can be used to reduce the incidence of HSD17B13-related diseases or conditions in a subject in need thereof. Such methods, compounds and compositions can be used, for example, to treat, prevent, delay or ameliorate liver disease, metabolic disease or cardiovascular disease.
[0007] Disclosed herein is a compound of formula (I) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
[0008]
[0009] in:
[0010] Ring A is thiazolyl;
[0011] R 1 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl or C1-C6 aminoalkyl;
[0012] R 2 is hydrogen or C1-C6 alkyl;
[0013] R 3 It is C1-C 10 Alkyl, C1-C 10 Halogenated alkyl, C1-C 10 Deuterated alkyl, C1-C 10 Hydroxyalkyl, C1-C 10 Aminoalkyl, C1-C 10 Heteroalkyl, C2-C10 Alkenyl, C2-C 10 wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 3a replace;
[0014] Each R 3a are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NHS(=O)2R a 、-C(=O)R a 、-C(=O)C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d 、-C(=O)C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;
[0015] or two R on the same atom 3a Together they form an oxo group;
[0016] R 4is deuterium, halogen, C1-C6 alkyl, C2-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally replaced by one or more R 4a replace;
[0017] Each R 4a are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NHS(=O)2R a 、-C(=O)R a 、-C(=O)C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d 、-C(=O)C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently substituted with one or more R;
[0018] or two R on the same atom4a Together they form an oxo group;
[0019] or two R on the same carbon 4a together form a cycloalkyl or heterocycloalkyl; each optionally substituted by one or more R;
[0020] or two R on different atoms 4a together form a cycloalkyl, heterocycloalkyl, aryl or heteroaryl; each optionally substituted with one or more R;
[0021] X is N or CR X ;
[0022] R X It is hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl;
[0023] R 5 It is hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl;
[0024] Each R 6 are independently halogen;
[0025] Each R a is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;
[0026] Each R bis independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene(cycloalkyl), C1-C6 alkylene(heterocycloalkyl), C1-C6 alkylene(aryl) or C1-C6 alkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted by one or more R; and
[0027] Each R c and R d R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted with one or more R;
[0028] or R c and R d together with the atoms to which they are attached form a heterocycloalkyl group which is optionally substituted with one or more R;
[0029] Each R is independently halogen, -CN, -OH, -OC1-C3 alkyl, -OC1-C3 haloalkyl, -SC1-C3 alkyl, -S(=O)C1-C3 alkyl, -S(=O)2C1-C3 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C3 alkyl, -S(=O)2N(C1-C3 alkyl)2, -NH2, -NHC1-C3 alkyl, -N(C1-C3 alkyl) -C(═O)C1-C3 alkyl, -C(═O)OH, -C(═O)OC1-C3 alkyl, -C(═O)NH2, -C(═O)NHC1-C3 alkyl, -C(═O)N(C1-C3 alkyl)2, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 deuterated alkyl, C1-C3 hydroxyalkyl, C1-C3 aminoalkyl, C1-C3 heteroalkyl or C3-C6 cycloalkyl;
[0030] Or two R's on the same atom form an oxo group.
[0031] In some embodiments of the compound of Formula (I), the compound has Formula (Ia):
[0032]
[0033] In some embodiments of the compound of Formula (I), the compound has Formula (Ib):
[0034]
[0035] Also disclosed herein is a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt, solvate or stereoisomer thereof and a pharmaceutically acceptable carrier.
[0036] Also disclosed herein is a method for treating a disease in a subject in need thereof, the method comprising administering a pharmaceutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, or a pharmaceutical composition disclosed herein. In some embodiments of the method for treating a disease, the disease is liver disease, metabolic disease, or cardiovascular disease. In some embodiments of the method for treating a disease, the disease is NAFLD. In some embodiments of the method for treating a disease, the disease is NASH. In some embodiments of the method for treating a disease, the disease is drug-induced liver injury (DILI). In some embodiments of the method for treating a disease, the disease is associated with HSD17B13. In some embodiments of the method for treating a disease, the disease is alcoholic liver disease. In some embodiments of the method for treating a disease, the disease is cirrhosis. In some embodiments of the method for treating a disease, the disease is decompensated portal hypertension. In some embodiments of the method for treating a disease, the disease is cholestatic liver disease.
[0037] Also disclosed herein is a method for selectively inhibiting HSD17B13, comprising administering a pharmaceutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. In some embodiments, the compound selectively inhibits HSD17B13 over HSD17B2, HSD17B14 or any combination thereof.
[0038] Incorporation by reference
[0039] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. DETAILED DESCRIPTION
[0040] definition
[0041] In the following description, certain specific details are set forth to provide a thorough understanding of the various embodiments. However, those skilled in the art will appreciate that the present invention can be practiced without these details. In other cases, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments. Unless the context otherwise requires, throughout the specification and the claims that follow, the word "comprise" and its variations such as "comprises" and "comprising" should be interpreted in an open, inclusive sense, that is, as "including but not limited to". In addition, the headings provided herein are for convenience only and do not explain the scope or meaning of the claimed invention.
[0042] References to "some embodiments" or "an embodiment" throughout this specification mean that a particular feature, structure, or characteristic described in association with the embodiment is included in at least one embodiment. Therefore, the phrase "in one embodiment" or "in one embodiment" appearing in various places throughout this specification may not all relate to the same embodiment. In addition, the particular features, structures, or characteristics may be combined in one or more embodiments in any suitable manner. In addition, unless the content clearly provides otherwise, as used in this specification and the appended claims, the singular forms "a / an" and "the" include plural referents. It should also be noted that unless the content clearly provides otherwise, the term "or" is generally adopted in its sense including "and / or".
[0043] Unless otherwise indicated, the following terms as used herein have the following meanings:
[0044] "Oxo" refers to =0.
[0045] "Carboxyl" refers to -COOH.
[0046] "Alkyl" refers to a straight or branched saturated hydrocarbon monovalent group having one to about ten carbon atoms, more preferably one to six carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl and hexyl, as well as longer alkyl groups such as heptyl, octyl, etc. Whenever it appears herein, a numerical range such as "C1-C6 alkyl" means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, but the definition also encompasses the occurrence of the term "alkyl" where no numerical range is specified. In some embodiments, the alkyl group is C1-C6. 10 Alkyl. In some embodiments, the alkyl group is a C1-C6 alkyl group. In some embodiments, the alkyl group is a C1-C5 alkyl group. In some embodiments, the alkyl group is a C1-C4 alkyl group. In some embodiments, the alkyl group is a C1-C3 alkyl group. Unless otherwise specifically stated in the specification, the alkyl group may be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkyl group is optionally substituted by oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2 or -NO2. In some embodiments, the alkyl group is optionally substituted by halogen, -CN, -OH or -OMe. In some embodiments, the alkyl group is optionally substituted by halogen.
[0047] "Alkenyl" refers to a straight or branched hydrocarbon monovalent group having one or more carbon-carbon double bonds and two to about ten carbon atoms, more preferably two to about six carbon atoms. The group may be in a cis or trans conformation about one or more double bonds, and should be understood to include two isomers. Examples include, but are not limited to, vinyl (-CH=CH2), 1-propenyl (-CH2CH=CH2), isopropenyl (-C(CH3)=CH2), butenyl, 1,3-butadienyl, etc. Whenever it appears in this article, a numerical range such as "C2-C6 alkenyl" means that the alkenyl group can be composed of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, but the definition also covers the occurrence of the term "alkenyl" in which no numerical range is specified. Unless specifically stated otherwise in the specification, alkenyl may be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkenyl is optionally substituted by oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH or -NO. In some embodiments, alkenyl is optionally substituted by halogen, -CN, -OH or -OMe. In some embodiments, alkenyl is optionally substituted by halogen.
[0048] "Alkynyl" refers to a straight or branched hydrocarbon monovalent group having one or more carbon-carbon triple bonds and two to about ten carbon atoms, more preferably two to about six carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl, etc. Whenever it appears in this article, a numerical range such as "C2-C6 alkynyl" means that the alkynyl group can be composed of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, but this definition also covers the appearance of the term "alkynyl" in which the numerical range is not specified. Unless otherwise specifically stated in the specification, the alkynyl group may be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkynyl group is optionally substituted by oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2 or -NO2. In some embodiments, alkynyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, alkynyl is optionally substituted with halogen.
[0049] "Alkylene" refers to a straight or branched divalent hydrocarbon chain. Unless specifically stated otherwise in the specification, alkylene may be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkylene is optionally substituted by oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2 or -NO2. In some embodiments, alkylene is optionally substituted by halogen, -CN, -OH or -OMe. In some embodiments, alkylene is optionally substituted by halogen.
[0050] "Alkoxy" refers to a group of formula -O alkyl, wherein alkyl is as defined above. Unless specifically stated otherwise in the specification, alkoxy may be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkoxy is optionally substituted by halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH or -NO. In some embodiments, alkoxy is optionally substituted by halogen, -CN, -OH or -OMe. In some embodiments, alkoxy is optionally substituted by halogen.
[0051] "Aryl" refers to a group derived from a hydrocarbon ring system containing 6 to 30 carbon atoms and at least one aromatic ring. The aryl group can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include a fused (when fused to a cycloalkyl or heterocycloalkyl ring, the aryl group is bonded through an aromatic ring atom) or a bridged ring system. In some embodiments, the aryl group is a 6- to 10-membered aryl group. In some embodiments, the aryl group is a 6-membered aryl (phenyl). Aryl groups include, but are not limited to, anthracene, naphthyl, phenanthrenyl, anthracene, azulene, benzene, Fluoranthene, fluorene, asymmetric indacene, symmetric indacene, indane, indene, naphthalene, phenanthene, phenanthrenes, pyrene and triphenylene hydrocarbon ring system derived aryl. Unless otherwise specifically stated in the specification, aryl can be optionally substituted, for example, by halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. Replaced. In some embodiments, aryl is optionally substituted by halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2 or -NO2. In some embodiments, aryl is optionally substituted by halogen, methyl, ethyl, -CN, -CF3, -OH or -OMe. In some embodiments, aryl is optionally substituted by halogen.
[0052] "Cycloalkyl" refers to a partially or fully saturated monocyclic or polycyclic carbocyclic ring, which may include a fused (when fused to an aryl or heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom) or bridged ring system. In some embodiments, the cycloalkyl is fully saturated. Representative cycloalkyls include, but are not limited to, cycloalkyls having three to fifteen carbon atoms (C3-C 15 Cycloalkyl or C3-C 15 cycloalkenyl), three to ten carbon atoms (C3-C 10 Cycloalkyl or C3-C 10 In some embodiments, the cycloalkyl group is a 3- to 10-membered cycloalkyl or a 3- to 10-membered cycloalkenyl group. In some embodiments, the cycloalkyl group is a 3- to 6-membered cycloalkyl or a 3- to 6-membered cycloalkenyl group. In some embodiments, the cycloalkyl group is a 5- to 6-membered cycloalkyl or a 5- to 6-membered cycloalkenyl group. Monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane and bicyclo[3.3.2]decane and 7,7-dimethyl-bicyclo[2.2.1]heptane. Partially saturated cycloalkyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. Unless otherwise specifically stated in the specification, cycloalkyls are optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2 or -NO2. In some embodiments, cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH or -OMe. In some embodiments, cycloalkyl is optionally substituted with halogen.
[0053] "Halo" or "halogen" refers to bromo, chloro, fluoro, or iodo. In some embodiments, halogen is fluoro or chloro. In some embodiments, halogen is fluoro.
[0054] "Haloalkyl" refers to an alkyl group as defined above substituted with one or more halo groups as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.
[0055] "Hydroxyalkyl" refers to an alkyl group as defined above that is substituted with one or more hydroxyl groups. In some embodiments, the alkyl group is substituted with one hydroxyl group. In some embodiments, the alkyl group is substituted with one, two or three hydroxyl groups. Hydroxyalkyl groups include, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl or hydroxypentyl. In some embodiments, aminoalkyl groups are hydroxymethyl groups.
[0056] "Aminoalkyl" refers to an alkyl group as defined above that is substituted with one or more amines. In some embodiments, the alkyl group is substituted with one amine. In some embodiments, the alkyl group is substituted with one, two or three amines. Aminoalkyl groups include, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl or aminopentyl. In some embodiments, the aminoalkyl group is aminomethyl.
[0057] "Deuterated alkyl" refers to an alkyl group as defined above that is substituted with one or more deuteriums. In some embodiments, the alkyl group is substituted with one deuterium. In some embodiments, the alkyl group is substituted with one, two or three deuteriums. In some embodiments, the alkyl group is substituted with one, two, three, four, five or six deuteriums. Deuterated alkyl groups include, for example, CD3, CH2D, CHD2, CH2CD3, CD2CD3, CHDCD3, CH2CH2D or CH2CHD2. In some embodiments, the deuterated alkyl group is CD3.
[0058] "Assorted alkyl" refers to an alkyl group, wherein one or more backbone atoms of the alkyl group are selected from atoms other than carbon, for example, oxygen, nitrogen, sulphur, phosphorus or a combination thereof. Assorted alkyl is connected to the remainder of the molecule at the carbon atom of the assorted alkyl group. On the one hand, assorted alkyl is a C1-C6 assorted alkyl group, wherein the assorted alkyl group is composed of 1 to 6 carbon atoms and one or more atoms other than carbon (for example, oxygen, nitrogen, sulphur, phosphorus or a combination thereof), wherein the assorted alkyl group is connected to the remainder of the molecule at the carbon atom of the assorted alkyl group. On the one hand, assorted alkyl is a C1-C6 assorted alkyl group, wherein the assorted alkyl group is composed of 1 to 6 carbon atoms and one or two atoms selected from oxygen, nitrogen and sulphur, wherein the assorted alkyl group is connected to the remainder of the molecule at the carbon atom of the assorted alkyl group. Examples of such heteroalkyl groups are, for example, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, -CH(CH3)OCH3, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2NHCH3 or -CH2CH2N(CH3)2. Unless otherwise specifically stated in the specification, heteroalkyl groups are optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, heteroalkyl groups are optionally substituted by oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2 or -NO2. In some embodiments, heteroalkyl groups are optionally substituted by oxo, halogen, methyl, ethyl, -CN, -CF3, -OH or -OMe. In some embodiments, heteroalkyl groups are optionally substituted by halogen.
[0059] "Heterocycloalkyl" refers to a 3 to 24-membered partially or fully saturated ring group containing 2 to 23 carbon atoms and 1 to 8 heteroatoms selected from nitrogen, oxygen, phosphorus and sulfur. In some embodiments, heterocycloalkyl is fully saturated. In some embodiments, heterocycloalkyl contains one to three heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, heterocycloalkyl contains one to three heteroatoms selected from nitrogen and oxygen. In some embodiments, heterocycloalkyl contains one to three nitrogens. In some embodiments, heterocycloalkyl contains one or two nitrogens. In some embodiments, heterocycloalkyl contains one nitrogen. In some embodiments, heterocycloalkyl contains one nitrogen and one oxygen. Unless otherwise specifically stated in the specification, heterocycloalkyl may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include a fused (when fused with an aryl or heteroaryl ring, the heterocycloalkyl is bonded by a non-aromatic ring atom) or a bridged ring system; and the nitrogen, carbon or sulfur atoms in the heterocycloalkyl may be optionally oxidized; the nitrogen atom may be optionally quaternized. Representative heterocycloalkyl groups include, but are not limited to, groups having two to fifteen carbon atoms (C2-C 15 Heterocycloalkyl or C2-C 15Heterocycloalkenyl), two to ten carbon atoms (C2-C 10 Heterocycloalkyl or C2-C 10In some embodiments, heterocycloalkyl is a 3 to 8-membered ring containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen or sulfur. In some embodiments, heterocycloalkyl is a 3 to 6-membered ring containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen or sulfur. In some embodiments, heterocycloalkyl is a 5 to 6-membered ring containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen or sulfur. Examples of such heterocycloalkyl groups include, but are not limited to, aziridine, azetidinyl, oxetanyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, Alkyl, pyrazolidinyl, quinuclidine, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-dioxol-4-yl and 2-oxo-1,3-dioxol-4-yl. The term heterocycloalkyl also includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides and oligosaccharides. Unless otherwise indicated, heterocycloalkyl has 2 to 10 carbons in the ring. It should be understood that when referring to the number of carbon atoms in heterocycloalkyl, the number of carbon atoms in heterocycloalkyl is not the same as the total number of atoms (including heteroatoms) (i.e., the skeleton atoms of the heterocycloalkyl ring) constituting heterocycloalkyl. In some embodiments, heterocycloalkyl is a 3 to 8 membered heterocycloalkyl. In some embodiments, heterocycloalkyl is a 3 to 7 membered heterocycloalkyl. In some embodiments, heterocycloalkyl is a 3 to 6 membered heterocycloalkyl. In some embodiments, heterocycloalkyl is a 4 to 6 membered heterocycloalkyl. In some embodiments, heterocycloalkyl is a 5 to 6 membered heterocycloalkyl. In some embodiments, heterocycloalkyl is a 3 to 8 membered heterocycloalkenyl. In some embodiments, heterocycloalkyl is a 3 to 7 membered heterocycloalkenyl. In some embodiments, heterocycloalkyl is a 3 to 6 membered heterocycloalkenyl. In some embodiments, heterocycloalkyl is a 4 to 6 membered heterocycloalkenyl. In some embodiments, heterocycloalkyl is a 5 to 6 membered heterocycloalkenyl.Unless specifically stated otherwise in the specification, heterocycloalkyl can be optionally substituted as described below, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. Replacement. In some embodiments, heterocycloalkyl is optionally substituted by oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2 or -NO2. In some embodiments, heterocycloalkyl is optionally substituted by halogen, methyl, ethyl, -CN, -CF3, -OH or -OMe. In some embodiments, heterocycloalkyl is optionally substituted by halogen.
[0060] "Heteroaryl" refers to a 5 to 14-membered ring system radical comprising one to thirteen carbon atoms, one to six heteroatoms selected from nitrogen, oxygen, phosphorus and sulfur, and at least one aromatic ring. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from nitrogen and oxygen. In some embodiments, the heteroaryl comprises one to three nitrogens. In some embodiments, the heteroaryl comprises one or two nitrogens. In some embodiments, the heteroaryl comprises one nitrogen. The heteroaryl may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include a fused (when fused to a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded by an aromatic ring atom) or a bridged ring system; and the nitrogen, carbon or sulfur atoms in the heteroaryl may be optionally oxidized; the nitrogen atom may be optionally quaternized. In some embodiments, the heteroaryl is a 5 to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5 to 6-membered heteroaryl. In some embodiments, heteroaryl is a 6-membered heteroaryl. In some embodiments, heteroaryl is a 5-membered heteroaryl. In some embodiments, heteroaryl is a 5- to 6-membered ring containing 1, 2, or 3 heteroatoms selected from oxygen, nitrogen, or sulfur. Examples include, but are not limited to, azepine, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyrone, benzofuranyl, benzofuranone, benzothienyl / benzothiophenyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanone, isothiazolyl , imidazolyl, indazolyl, indolyl, isoindolyl, indolinyl, isoindolyl, isoquinolinyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoaziridine, oxazolyl, oxirane, 1-pyridinyl oxide, 1-pyrimidinyl oxide, 1-pyrazinyl oxide, 1-pyridazinyl oxide, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidine, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise specifically in the specification, a heteroaryl group may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxy, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.In some embodiments, heteroaryl is optionally substituted by halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2 or -NO2. In some embodiments, heteroaryl is optionally substituted by halogen, methyl, ethyl, -CN, -CF3, -OH or -OMe. In some embodiments, heteroaryl is optionally substituted by halogen.
[0061] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs as well as instances where it does not occur. For example, "optionally substituted alkyl" means "alkyl" or "substituted alkyl" as defined above. In addition, an optionally substituted group may be unsubstituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), monosubstituted (e.g., -CH2CH2F), or substituted at any level between fully substituted and monosubstituted (e.g., -CH2CHF2, -CH2CF3, -CF2CH3, -CFHCHF2, etc.). With respect to any group containing one or more substituents, one skilled in the art will appreciate that such groups are not intended to introduce any substitution or substitution pattern that is sterically impractical and / or synthetically infeasible (e.g., substituted alkyl includes optionally substituted cycloalkyl, which in turn is defined to include optionally substituted alkyl, which may be endless). Thus, any substituent described will generally be understood to have a maximum molecular weight of about 1,000 Daltons, and more typically up to about 500 Daltons.
[0062] When referring to optional substituents, the term "one or more" means that the subject group is optionally substituted by one, two, three, four or more substituents. In some embodiments, the subject group is optionally substituted by one, two, three or four substituents. In some embodiments, the subject group is optionally substituted by one, two or three substituents. In some embodiments, the subject group is optionally substituted by one or two substituents. In some embodiments, the subject group is optionally substituted by a substituent. In some embodiments, the subject group is optionally substituted by two substituents.
[0063] "Effective amount" or "therapeutically effective amount" refers to an amount of a compound that is administered to a mammalian subject in a single dose or as part of a series of doses effective to produce the desired therapeutic effect.
[0064] "Treatment" of an individual (e.g., a mammal, such as a human) or a cell is any type of intervention used to attempt to alter the natural course of the individual or cell. In some embodiments, treatment includes administering a pharmaceutical composition after a pathological event begins or is contacted with a pathogen, and includes stabilizing the condition (e.g., the condition does not worsen) or alleviating the condition. In some embodiments, treatment also includes prophylactic treatment (e.g., administering a composition described herein when an individual is suspected of suffering from a liver disease such as NAFLD).
[0065] "Synergistic" or "synergistic" means that the effect of the combination is greater than the additive effect of each component alone at the same dose.
[0066] "HSD17B13" means hydroxysteroid 17-beta dehydrogenase 13, and refers to any nucleic acid of HSD17B13. For example, in some embodiments, HSD17B13 includes a DNA sequence encoding HSD17B13, an RNA sequence transcribed from a DNA encoding HSD17B13 (including genomic DNA comprising introns and exons). HSD17B13 may also refer to any amino acid sequence of HSD17B13 encoded by a DNA sequence and / or an RNA sequence (which may include a secondary or tertiary structure of a protein molecule). Targets may be referred to in uppercase or lowercase.
[0067] Compound
[0068] Described herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates or stereoisomers thereof that can be used to treat liver disease. In some embodiments, the liver disease is NAFLD. In some embodiments, the compounds disclosed herein are selective HSD17B13 inhibitors.
[0069] Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates or stereoisomers thereof:
[0070]
[0071] in:
[0072] Ring A is thiazolyl;
[0073] R 1 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl or C1-C6 aminoalkyl;
[0074] R 2 is hydrogen or C1-C6 alkyl;
[0075] R 3 It is C1-C 10 Alkyl, C1-C 10Halogenated alkyl, C1-C 10 Deuterated alkyl, C1-C 10 Hydroxyalkyl, C1-C 10 Aminoalkyl, C1-C 10 Heteroalkyl, C2-C 10 Alkenyl, C2-C 10 wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 3a replace;
[0076] Each R 3a are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NHS(=O)2R a 、-C(=O)R a 、-C(=O)C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d 、-C(=O)C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;
[0077] or two R on the same atom 3a Together they form an oxo group;
[0078] R 4 is deuterium, halogen, C1-C6 alkyl, C2-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally replaced by one or more R 4a replace;
[0079] Each R 4a are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NHS(=O)2R a 、-C(=O)R a 、-C(=O)C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d 、-C(=O)C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently substituted with one or more R;
[0080] or two R on the same atom 4a Together they form an oxo group;
[0081] or two R on the same carbon 4a together form a cycloalkyl or heterocycloalkyl; each optionally substituted by one or more R;
[0082] or two R on different atoms 4a together form a cycloalkyl, heterocycloalkyl, aryl or heteroaryl; each optionally substituted with one or more R;
[0083] X is N or CR X ;
[0084] R X It is hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl;
[0085] R 5 It is hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl;
[0086] Each R 6 are independently halogen;
[0087] Each R a is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;
[0088] Each R bis independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene(cycloalkyl), C1-C6 alkylene(heterocycloalkyl), C1-C6 alkylene(aryl) or C1-C6 alkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted by one or more R; and
[0089] Each R c and R d R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted with one or more R;
[0090] or R c and R d together with the atoms to which they are attached form a heterocycloalkyl group which is optionally substituted with one or more R;
[0091] Each R is independently halogen, -CN, -OH, -OC1-C3 alkyl, -OC1-C3 haloalkyl, -SC1-C3 alkyl, -S(=O)C1-C3 alkyl, -S(=O)2C1-C3 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C3 alkyl, -S(=O)2N(C1-C3 alkyl)2, -NH2, -NHC1-C3 alkyl, -N(C1-C3 alkyl) -C(═O)C1-C3 alkyl, -C(═O)OH, -C(═O)OC1-C3 alkyl, -C(═O)NH2, -C(═O)NHC1-C3 alkyl, -C(═O)N(C1-C3 alkyl)2, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 deuterated alkyl, C1-C3 hydroxyalkyl, C1-C3 aminoalkyl, C1-C3 heteroalkyl or C3-C6 cycloalkyl;
[0092] Or two R's on the same atom form an oxo group.
[0093] Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates or stereoisomers thereof:
[0094]
[0095] in:
[0096] Ring A is thiazolyl;
[0097] R 1 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl or C1-C6 aminoalkyl;
[0098] R 2 is hydrogen or C1-C6 alkyl;
[0099] R 3 It is C1-C 10 Alkyl, C1-C 10 Halogenated alkyl, C1-C 10 Deuterated alkyl, C1-C 10 Hydroxyalkyl, C1-C 10 Aminoalkyl, C1-C 10 Heteroalkyl, C2-C 10 Alkenyl, C2-C 10 wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 3a replace;
[0100] Each R 3a are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NHS(=O)2R a、-C(=O)R a 、-C(=O)C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d 、-C(=O)C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;
[0101] or two R on the same atom 3a Together they form an oxo group;
[0102] R 4 is deuterium, halogen, C1-C6 alkyl, C2-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally replaced by one or more R 4a replace;
[0103] Each R 4a are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NHS(=O)2R a 、-C(=O)R a 、-C(=O)C(=O)R a、-C(=O)OR b 、-C(=O)NR c R d 、C(=O)C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently substituted with one or more R;
[0104] or two R on the same atom 4a Together they form an oxo group;
[0105] or two R on the same carbon 4a together form a cycloalkyl or heterocycloalkyl; each optionally substituted by one or more R;
[0106] or two R on different atoms 4a together form a cycloalkyl, heterocycloalkyl, aryl or heteroaryl; each optionally substituted with one or more R;
[0107] X is N or CR X ;
[0108] R X It is hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl;
[0109] R 5 It is hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl;
[0110] Each R 6 are independently halogen;
[0111] Each R ais independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;
[0112] Each R b is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene(cycloalkyl), C1-C6 alkylene(heterocycloalkyl), C1-C6 alkylene(aryl) or C1-C6 alkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted by one or more R; and
[0113] Each R c and R d R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted with one or more R;
[0114] or R c and R d together with the atoms to which they are attached form a heterocycloalkyl group which is optionally substituted with one or more R;
[0115] Each R is independently halogen, -CN, -OH, -OC1-C3 alkyl, -OC1-C3 haloalkyl, -SC1-C3 alkyl, -S(=O)C1-C3 alkyl, -S(=O)2C1-C3 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C3 alkyl, -S(=O)2N(C1-C3 alkyl)2, -NH2, -NHC1-C3 alkyl, -N(C1-C3 alkyl) -C(═O)C1-C3 alkyl, -C(═O)OH, -C(═O)OC1-C3 alkyl, -C(═O)NH2, -C(═O)NHC1-C3 alkyl, -C(═O)N(C1-C3 alkyl)2, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 deuterated alkyl, C1-C3 hydroxyalkyl, C1-C3 aminoalkyl, C1-C3 heteroalkyl or C3-C6 cycloalkyl;
[0116] Or two R's on the same atom form an oxo group.
[0117] In some embodiments of the compound of Formula (I), the compound has Formula (Ia):
[0118]
[0119] In some embodiments of the compound of Formula (I), the compound has Formula (Ib):
[0120]
[0121] In some embodiments of compounds of Formula (I), (Ia) or (Ib), R 1 is hydrogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compound of formula (I), (Ia) or (Ib), R 1 is hydrogen or C1-C6 alkyl. In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 1 It's hydrogen.
[0122] In some embodiments of compounds of Formula (I), (Ia) or (Ib), R 2 is C1-C6 alkyl. In some embodiments of the compound of Formula (I), (Ia) or (Ib), R 2 It's hydrogen.
[0123] In some embodiments of compounds of Formula (I), (Ia) or (Ib), R 3 It is C1-C 10 Alkyl, C1-C 10 Halogenated alkyl, C1-C 10 Deuterated alkyl, C1-C 10 Hydroxyalkyl, C1-C10 Aminoalkyl, C1-C 10 C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein alkyl, alkylene, cycloalkyl, O-cycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 3a In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 3 It is C4-C 10 Alkyl, C1-C 10 Halogenated alkyl, C1-C 10 Deuterated alkyl, C1-C 10 Hydroxyalkyl, C1-C 10 Aminoalkyl, C1-C 10 C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 3a In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 3 It is C1-C 10 C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 3a In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 3 It is C4-C 10 C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 3a In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 3 It is C1-C 10 Alkyl or C1-C6 alkylene (aryl); wherein alkyl, alkylene and aryl are optionally and independently replaced by one or more R 3a In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 3 It is C4-C 10 Alkyl or C2-C6 alkylene (aryl); wherein alkyl, alkylene and aryl are optionally and independently replaced by one or more R 3aIn some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 3 is optionally and independently replaced by one or more R 3a Substituted C1-C 10 In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 3 is optionally and independently replaced by one or more R 3a Substituted C4-C 10 In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 3 It is C4-C 10 In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 3 is C1-C6 alkylene (aryl); wherein the alkylene and aryl are optionally and independently replaced by one or more R 3a In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 3 is C2-C6 alkylene(aryl); wherein alkylene and aryl are optionally and independently replaced by one or more R 3a In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 3 is C2-C6 alkylene (aryl); wherein the aryl group is optionally and independently replaced by one or more R 3a replace.
[0124] In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 3a are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl; or two R on the same atom 3a In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 3a are independently deuterium, halogen, -OH, -OR a , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl; or two R 3a In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 3aare independently halogen, -OR a or C1-C6 haloalkyl. In some embodiments of the compounds of Formula (I), (Ia) or (Ib), each R 3a are independently C1-C6 haloalkyl.
[0125] In some embodiments of compounds of Formula (I), (Ia) or (Ib), X is N. In some embodiments of compounds of Formula (I), (Ia) or (Ib), X is CR X .
[0126] In some embodiments of compounds of Formula (I), (Ia) or (Ib), R X is hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compound of Formula (I), (Ia) or (Ib), R X is hydrogen or C1-C6 alkyl. In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R X It's hydrogen.
[0127] In some embodiments of compounds of Formula (I), (Ia) or (Ib), R 5 is hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compound of Formula (I), (Ia) or (Ib), R 5 is hydrogen or C1-C6 alkyl. In some embodiments of the compounds of Formula (I), (Ia) or (Ib), R 5 It's hydrogen.
[0128] In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 6 In some embodiments of the compounds of Formula (I), (Ia) or (Ib), each R 6 In some embodiments of compounds of Formula (I), (Ia) or (Ib), one R 6 is a fluorine group and the other R 6 It's chlorine-based.
[0129] In some embodiments of compounds of Formula (I), (Ia) or (Ib), yes In some embodiments of compounds of Formula (I), (Ia) or (Ib), yes In some embodiments of compounds of Formula (I), (Ia) or (Ib), yes In some embodiments of compounds of Formula (I), (Ia) or (Ib), yes
[0130] In some embodiments of compounds of Formula (I), (Ia) or (Ib), R 4 is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally replaced by one or more R 4a replace.
[0131] In some embodiments of compounds of Formula (I), (Ia) or (Ib), R 4 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted by one or more R 4a replace.
[0132] In some embodiments of compounds of Formula (I), (Ia) or (Ib), R 4 is optionally replaced by one or more R 4a Substituted cycloalkyl.
[0133] In some embodiments of compounds of Formula (I), (Ia) or (Ib), R 4 is optionally replaced by one or more R 4a Substituted heterocycloalkyl.
[0134] In some embodiments of compounds of Formula (I), (Ia) or (Ib), R 4 is aryl or heteroaryl; wherein aryl and heteroaryl are optionally substituted by one or more R 4a replace.
[0135] In some embodiments of compounds of Formula (I), (Ia) or (Ib), R 4 is optionally replaced by one or more R 4a Substituted aryl.
[0136] In some embodiments of compounds of Formula (I), (Ia) or (Ib), R 4 is optionally replaced by one or more R 4a Substituted heteroaryl.
[0137] In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 4a are independently deuterium, halogen, -CN, -OH, -OR a 、-S(=O)R a 、-S(=O)2R a、-S(=O)2NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl; wherein the alkyl is optionally and independently substituted with one or more R; or two R on the same atom 4a Together they form an oxo group.
[0138] In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 4a are independently deuterium, halogen, -CN, -OH, -OR a 、-S(=O)R a 、-NR c R d , C1-C6 alkyl or C1-C6 haloalkyl; wherein the alkyl is optionally and independently substituted with one or more R; or two R on the same atom 4a Together they form an oxo group.
[0139] In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 4a is independently deuterium, halogen, -CN, -S(=O)R optionally and independently substituted with one or more R a or C1-C6 alkyl; or two R 4a Together they form an oxo group.
[0140] In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 4a are independently deuterium, halogen, -CN, -OH, -OR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl; or two R on the same atom 4a Together they form an oxo group.
[0141] In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 4a are independently deuterium, halogen, -CN, -OH, -OR a 、-S(=O)R a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, cycloalkyl or heterocycloalkyl; or two R on the same atom 4a Together they form an oxo group.
[0142] In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 4a are independently halogen, -CN, -OH, -OR a 、-S(=O)R a 、-NR c R d , C1-C6 alkyl or C1-C6 haloalkyl; or two R 4a Together they form an oxo group.
[0143] In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 4a are independently halogen, -S(=O)R a , C1-C6 alkyl or C1-C6 haloalkyl; or two R 4a Together they form an oxo group.
[0144] In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 4a are independently halogen, -S(=O)R a , C1-C6 alkyl or C1-C6 haloalkyl.
[0145] In some embodiments of compounds of Formula (I), (Ia) or (Ib), each R 4a are independently halogen.
[0146] In some embodiments of compounds of Formula (I), (Ia) or (Ib), two R 4a together form a cycloalkyl or heterocycloalkyl group; each optionally substituted with one or more R. In some embodiments of compounds of Formula (I), (Ia) or (Ib), two R on the same carbon4a Together they form a cycloalkyl group, which is optionally substituted with one or more R. In some embodiments of compounds of Formula (I), (Ia) or (Ib), two R on the same carbon 4a together form a heterocycloalkyl; each is optionally substituted by one or more R.
[0147] In some embodiments of compounds of Formula (I), (Ia) or (Ib), two R 4a Together they form a cycloalkyl group which is optionally substituted with one or more R. In some embodiments of compounds of Formula (I), (Ia) or (Ib), two R on different atoms 4a Together they form a heterocycloalkyl group, which is optionally substituted with one or more R. In some embodiments of compounds of Formula (I), (Ia) or (Ib), two R on different atoms 4a Together they form an aryl group, which is optionally substituted with one or more R. In some embodiments of compounds of Formula (I), (Ia) or (Ib), two R on different atoms 4a Together they form a heteroaryl group which is optionally substituted by one or more R.
[0148] In some embodiments of the compound of Formula (I), yes
[0149] In some embodiments of the compound of Formula (I), yes
[0150] In some embodiments of the compound of Formula (I), yes
[0151] In some embodiments of the compound of Formula (I), yes In some embodiments of the compound of Formula (I), yes In some embodiments of the compound of Formula (I), yes In some embodiments of the compound of Formula (I), yes In some embodiments of the compound of Formula (I), yes
[0152] In some embodiments of the compound of Formula (I), yes In some embodiments of the compound of Formula (I), yes In some embodiments of the compound of Formula (I), yes In some embodiments of the compound of Formula (I), yes In some embodiments of the compound of Formula (I), yes In some embodiments of the compound of Formula (I), yes In some embodiments of the compound of Formula (I), yes
[0153] Also disclosed herein is a compound of formula (II) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
[0154]
[0155] in:
[0156] R 1 It is a halogen;
[0157] R 2 It is a halogen;
[0158] X is N or CR X ;
[0159] R X It is hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl;
[0160] Y is N or CR Y ;
[0161] R Y It is hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl;
[0162] R 3 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl;
[0163] Ring A is pyrazole;
[0164] Each R 4 is independently deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R;
[0165] n is 0-2;
[0166] R 5 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl;
[0167] R 6 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally replaced by one or more R 6a replace;
[0168] Each R 6a are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)Ra 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 6b replace;
[0169] or two R on the same atom 6a Together they form an oxo group;
[0170] Each R 6b are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;
[0171] or two R on the same atom 6b Together they form an oxo group;
[0172] Each R ais independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;
[0173] Each R b R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted with one or more R;
[0174] Each R c and R d R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted with one or more R;
[0175] or R c and R d together with the atoms to which they are attached form a heterocycloalkyl group which is optionally substituted with one or more R;
[0176] Each R is independently deuterium, halogen, -CN, -OH, -OC1-C6 alkyl, -S(=O)C1-C6 alkyl, -S(=O)2C1-C6 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C6 alkyl, -S(=O)2N(C1-C6 alkyl)2, -NH2, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, -NHC(=O)OC C1-C6 alkyl, -C(=O)C1-C6 alkyl, -C(=O)OH, -C(=O)OC1-C6 alkyl, -C(=O)NH2, -C(=O)N(C1-C6 alkyl)2, -C(=O)NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl;
[0177] Or two R's on the same atom together form an oxo group.
[0178] In some embodiments of the compound of formula (II), the compound has formula (IIa), or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
[0179]
[0180] in:
[0181] R 4a is hydrogen or R 4 ;and
[0182] R 4b is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R.
[0183] In some embodiments of the compound of formula (II), the compound has formula (IIb), or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
[0184]
[0185] in:
[0186] R 4a is hydrogen or R 4 ;and
[0187] R 4bis hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R.
[0188] In some embodiments of the compound of formula (II), the compound has formula (IIc), or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
[0189]
[0190] in:
[0191] R 4a is hydrogen or R 4 ;and
[0192] R 4b is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R.
[0193] In some embodiments of the compound of formula (II), the compound has formula (IId), or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
[0194]
[0195] in:
[0196] R 4a is hydrogen or R 4 ;and
[0197] R 4b is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R.
[0198] In some embodiments of the compound of Formula (IIa)-(IId), R 4ais hydrogen, halogen or C1-C6 alkyl. In some embodiments of the compounds of formula (IIa)-(IId), R 4a It's hydrogen.
[0199] In some embodiments of the compound of Formula (II) or (IIa)-(IId), R 1 In some embodiments of the compounds of Formula (II) or (IIa)-(IId), R 1 It's chlorine-based.
[0200] In some embodiments of the compound of Formula (II) or (IIa)-(IId), R 2 In some embodiments of the compounds of Formula (II) or (IIa)-(IId), R 2 It's chlorine-based.
[0201] In some embodiments of the compounds of Formula (II) or (IIa)-(IId), X is CR X In some embodiments of the compound of Formula (II) or (IIa)-(IId), X is N.
[0202] In some embodiments of the compound of Formula (II) or (IIa)-(IId), R X is hydrogen, deuterium, halogen or C1-C6 alkyl. In some embodiments of the compound of formula (II) or (IIa)-(IId), R X is hydrogen or halogen. In some embodiments of the compounds of Formula (II) or (IIa)-(IId), R X It's hydrogen.
[0203] In some embodiments of the compounds of Formula (II) or (IIa)-(IId), Y is CR Y In some embodiments of the compound of Formula (II) or (IIa)-(IId), Y is N.
[0204] In some embodiments of the compound of Formula (II) or (IIa)-(IId), R Y is hydrogen, deuterium, halogen or C1-C6 alkyl. In some embodiments of the compound of formula (II) or (IIa)-(IId), R Y is hydrogen or halogen. In some embodiments of the compounds of Formula (II) or (IIa)-(IId), R Y It's hydrogen.
[0205] In some embodiments of the compound of Formula (II) or (IIa)-(IId), R 3 is hydrogen or C1-C6 alkyl. In some embodiments of the compound of formula (II) or (IIa)-(IId), R3 It's hydrogen.
[0206] In some embodiments of the compounds of Formula (II) or (IIa)-(IId), each R 4 is independently deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R 4 is independently deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R 4 is independently deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R 4 is independently C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl or aryl; wherein each alkyl, cycloalkyl and aryl is optionally and independently substituted with one or more R. In some embodiments of the compound of formula (II) or (IIa)-(IId), each R 4 is independently C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl or aryl. In some embodiments of the compound of formula (II) or (IIa)-(IId), each R 4 is independently C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compound of formula (II) or (IIa)-(IId), each R 4 are independently aryl.
[0207] In some embodiments of compounds of formula (II) or (IIa)-(IId), n is 0 or 1. In some embodiments of compounds of formula (II) or (IIa)-(IId), n is 0. In some embodiments of compounds of formula (II) or (IIa)-(IId), n is 1. In some embodiments of compounds of formula (II) or (IIa)-(IId), n is 2.
[0208] In some embodiments of the compound of Formula (IIa)-(IId), R 4b is C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of compounds of formula (IIa)-(IId), R 4b is C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of compounds of Formula (IIa)-(IId), R 4b is C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of compounds of formula (IIa)-(IId), R 4b is C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl or aryl; wherein each alkyl, cycloalkyl and aryl is optionally and independently substituted with one or more R. In some embodiments of the compounds of formula (IIa)-(IId), R 4b is C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl or aryl. In some embodiments of the compounds of formula (IIa)-(IId), R 4b is C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compounds of formula (IIa)-(IId), R 4b It is an aromatic group.
[0209] In some embodiments of the compound of Formula (II) or (IIa)-(IId), R 5 is hydrogen or C1-C6 alkyl. In some embodiments of the compound of formula (II) or (IIa)-(IId), R 5 It's hydrogen.
[0210] In some embodiments of the compound of Formula (II) or (IIa)-(IId), R 6is C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally replaced by one or more R 6a In some embodiments of the compounds of Formula (II) or (IIa)-(IId), R 6 is a C1-C6 alkyl group, the C1-C6 alkyl group is optionally substituted by one or more R 6a In some embodiments of the compounds of Formula (II) or (IIa)-(IId), R 6 is C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally replaced by one or more R 6a In some embodiments of the compounds of Formula (II) or (IIa)-(IId), R 6 is C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein alkylene, aryl and heteroaryl are optionally replaced by one or more R 6a In some embodiments of the compounds of Formula (II) or (IIa)-(IId), R 6 is C1-C6 alkylene (aryl); wherein the alkylene and aryl are optionally replaced by one or more R 6a replace.
[0211] In some embodiments of the compounds of Formula (II) or (IIa)-(IId), each R 6a are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 6b replace.
[0212] In some embodiments of the compounds of Formula (II) or (IIa)-(IId), each R 6aare independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl; wherein each alkyl is optionally and independently replaced by one or more R 6b In some embodiments of the compounds of Formula (II) or (IIa)-(IId), each R 6a Independently is -OR a , C1-C6 alkyl or C1-C6 haloalkyl.
[0213] In some embodiments of the compounds of Formula (II) or (IIa)-(IId), each R 6b are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compound of formula (II) or (IIa)-(IId), each R 6b are independently deuterium, halogen, C1-C6 alkyl or C1-C6 haloalkyl.
[0214] Also disclosed herein is a compound of formula (III), or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
[0215]
[0216] in:
[0217] Ring B is cycloalkyl, heterocycloalkyl, aryl or heteroaryl;
[0218] Each R 11 are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;
[0219] m is 1-5;
[0220] R 12 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl;
[0221] Each R 13 is independently deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R;
[0222] p is 0-3;
[0223] R 14 is C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 14a replace;
[0224] Each R 14a are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)Ra 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 14b replace;
[0225] or two R on the same atom 14a Together they form an oxo group;
[0226] Each R 14b are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;
[0227] or two R on the same atom 14b Together they form an oxo group;
[0228] Each R a is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;
[0229] Each R b R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted with one or more R;
[0230] Each R c and R d R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted with one or more R;
[0231] or R cand R d together with the atoms to which they are attached form a heterocycloalkyl group which is optionally substituted with one or more R;
[0232] Each R is independently deuterium, halogen, -CN, -OH, -OC1-C6 alkyl, -S(=O)C1-C6 alkyl, -S(=O)2C1-C6 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C6 alkyl, -S(=O)2N(C1-C6 alkyl)2, -NH2, -NHC1-C6 alkyl, -N(C1-C6 alkyl)2, -NHC(=O)OC C1-C6 alkyl, -C(=O)C1-C6 alkyl, -C(=O)OH, -C(=O)OC1-C6 alkyl, -C(=O)NH2, -C(=O)N(C1-C6 alkyl)2, -C(=O)NHC1-C6 alkyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl;
[0233] Or two R's on the same atom together form an oxo group.
[0234] In some embodiments of compounds of formula (II), ring B is aryl or heteroaryl. In some embodiments of compounds of formula (II), ring B is aryl. In some embodiments of compounds of formula (II), ring B is heteroaryl. In some embodiments of compounds of formula (II), ring B is 5 to 6 membered heteroaryl. In some embodiments of compounds of formula (II), ring B is phenyl or pyridinyl. In some embodiments of compounds of formula (II), ring B is phenyl. In some embodiments of compounds of formula (II), ring B is pyridinyl.
[0235] In some embodiments of the compound of formula (II), each R 11 are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl or C1-C6 haloalkyl.
[0236] In some embodiments of the compound of formula (II), each R 11 is independently halogen, -OH, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compound of formula (II), each R 11 are independently halogen or -OH.
[0237] In some embodiments of compounds of formula (III), m is 1-3. In some embodiments of compounds of formula (III), m is 2 or 3. In some embodiments of compounds of formula (III), m is 2. In some embodiments of compounds of formula (III), m is 3.
[0238] In some embodiments of the compound of formula (III), the compound has formula (IIIa), or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
[0239]
[0240] in:
[0241] R 15 It is a halogen;
[0242] R 16 It is a halogen;
[0243] W is N or CR W ;
[0244] R W It is hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl;
[0245] Z is N or CR Z ;
[0246] R Z It is hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl.
[0247] In some embodiments of the compound of Formula (IIIa), R 15 is fluoro or chloro. In some embodiments of the compound of formula (IIIa), R 15 It's chlorine-based.
[0248] In some embodiments of the compound of Formula (IIIa), R 16 is fluoro or chloro. In some embodiments of the compound of formula (IIIa), R 16 It's chlorine-based.
[0249] In some embodiments of the compound of Formula (IIIa), W is CR W In some embodiments of the compound of formula (IIIa), W is N.
[0250] In some embodiments of the compound of Formula (IIIa), R W is hydrogen, deuterium, halogen or C1-C6 alkyl. In some embodiments of the compound of formula (IIIa), R W is hydrogen or halogen. In some embodiments of the compound of formula (IIIa), R W It's hydrogen.
[0251] In some embodiments of the compound of formula (IIIa), Z is CR Z In some embodiments of the compound of Formula (IIIa), Z is N.
[0252] In some embodiments of the compound of Formula (IIIa), R Z is hydrogen, deuterium, halogen or C1-C6 alkyl. In some embodiments of the compound of formula (IIIa), R Z is hydrogen or halogen. In some embodiments of the compound of formula (IIIa), R Z It's hydrogen.
[0253] In some embodiments of the compound of Formula (III) or (IIIa), R 12 is hydrogen or C1-C6 alkyl. In some embodiments of the compound of formula (III) or (IIIa), R 12 It's hydrogen.
[0254] In some embodiments of the compound of Formula (III) or (IIIa), each R 13 is independently deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently substituted with one or more R. In some embodiments of the compound of formula (III) or (IIIa), each R 13 is independently halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compound of formula (III) or (IIIa), each R 13 is independently halogen or C1-C6 alkyl. In some embodiments of the compound of formula (III) or (IIIa), each R 13 In some embodiments of the compound of formula (III) or (IIIa), each R 13 are independently C1-C6 alkyl.
[0255] In some embodiments of compounds of formula (III) or (IIIa), p is 0-2. In some embodiments of compounds of formula (III) or (IIIa), p is 0 or 1. In some embodiments of compounds of formula (III) or (IIIa), p is 0. In some embodiments of compounds of formula (III) or (IIIa), p is 1. In some embodiments of compounds of formula (III) or (IIIa), p is 2.
[0256] In some embodiments of the compound of Formula (III) or (IIIa), R 14 is C1-C6 alkyl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is optionally and independently replaced by one or more R 14a In some embodiments of the compound of formula (III) or (IIIa), R 14 is a C1-C6 alkyl group, the C1-C6 alkyl group is optionally substituted by one or more R 14a In some embodiments of the compound of formula (III) or (IIIa), R 14 is C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkylene, aryl and heteroaryl is optionally and independently replaced by one or more R 14a In some embodiments of the compound of formula (III) or (IIIa), R 14 is C1-C6 alkylene (aryl); wherein each alkylene and aryl are optionally and independently replaced by one or more R 14a replace.
[0257] In some embodiments of the compound of Formula (III) or (IIIa), each R 14a are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 14b replace.
[0258] In some embodiments of the compound of Formula (III) or (IIIa), each R 14a are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl; wherein each alkyl is optionally and independently replaced by one or more R 14b replace.
[0259] In some embodiments of the compound of Formula (III) or (IIIa), each R 14a Independently is -OR a , C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compound of formula (III) or (IIIa), each R 14a are independently C1-C6 haloalkyl.
[0260] In some embodiments of the compound of Formula (III) or (IIIa), each R 14b are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compound of formula (III) or (IIIa), each R 14b are independently deuterium, halogen, C1-C6 alkyl or C1-C6 haloalkyl.
[0261] In some embodiments of the compounds disclosed herein, each R a is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, C1-C6 alkylene (cycloalkyl) or C1-C6 alkylene (heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R a is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R ais independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl; wherein each alkyl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R a R is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl. In some embodiments of the compounds disclosed herein, each R a is independently C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compounds disclosed herein, each R a are independently C1-C6 alkyl.
[0262] In some embodiments of the compounds disclosed herein, each R b R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, C1-C6 alkylene (cycloalkyl) or C1-C6 alkylene (heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R b R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R b R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl; wherein each alkyl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R b R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl. In some embodiments of the compounds disclosed herein, each R b R is independently hydrogen, C1-C6 alkyl or C1-C6 haloalkyl. b is independently hydrogen or C1-C6 alkyl. In some embodiments of the compounds disclosed herein, each R b In some embodiments of the compounds disclosed herein, each Rb are independently C1-C6 alkyl.
[0263] In some embodiments of the compounds disclosed herein, each R c and R d R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, C1-C6 alkylene (cycloalkyl) or C1-C6 alkylene (heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R c and R d R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R c and R d R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl; wherein each alkyl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R c and R d R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl. In some embodiments of the compounds disclosed herein, each R c and R d R is independently hydrogen, C1-C6 alkyl or C1-C6 haloalkyl. c and R d is independently hydrogen or C1-C6 alkyl. In some embodiments of the compounds disclosed herein, each R c and R d In some embodiments of the compounds disclosed herein, each R c and R d are independently C1-C6 alkyl.
[0264] In some embodiments of the compounds disclosed herein, R c and R dTogether with the atoms to which they are attached, they form a 5- to 6-membered heterocycloalkyl group, which is optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, R c and R d Together with the atoms to which they are attached, they form a 5-membered heterocycloalkyl group, which is optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, R c and R d Together with the atoms to which they are attached they form a 6-membered heterocycloalkyl group which is optionally substituted with one or more R groups.
[0265] In some embodiments of the compounds disclosed herein, each R is independently halogen, -CN, -OH, -OC1-C3 alkyl, -OC1-C3 haloalkyl, -NH2, -NHC1-C3 alkyl, -N(C1-C3 alkyl)2, -C(=O)C1-C3 alkyl, -C(=O)OH, -C(=O)OC1-C3 alkyl, -C(=O)NH2, -C(=O)NHC1-C3 alkyl, -C(=O)N(C1-C3 alkyl)2, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 deuterated alkyl, C1-C3 hydroxyalkyl, C1-C3 aminoalkyl, C1-C3 heteroalkyl, or C3-C6 cycloalkyl; or two R on the same atom form an oxo. In some embodiments of the compounds disclosed herein, each R is independently halogen, -CN, -OH, -OC1-C3 alkyl, -OC1-C3 haloalkyl, -NH2, -NHC1-C3 alkyl, -N(C1-C3 alkyl)2, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 deuterated alkyl, C1-C3 hydroxyalkyl, C1-C3 aminoalkyl, C1-C3 heteroalkyl, or C3-C6 cycloalkyl; or two R on the same atom form an oxo. In some embodiments of the compounds disclosed herein, each R is independently halogen, -CN, -OH, -OC1-C3 alkyl, -OC1-C3 haloalkyl, -NH2, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 deuterated alkyl, or C3-C6 cycloalkyl; or two R on the same atom form an oxo. In some embodiments of the compounds disclosed herein, each R is independently halogen, C1-C3 alkyl or C1-C3 haloalkyl; or two R on the same atom form an oxo. In some embodiments of the compounds disclosed herein, each R is independently halogen, C1-C3 alkyl or C1-C3 haloalkyl. In some embodiments of the compounds disclosed herein, each R is independently halogen or C1-C3 alkyl. In some embodiments of the compounds disclosed herein, each R is independently halogen.
[0266] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the art to provide stable moieties and compounds.
[0267] Described herein is a compound selected from the compounds in Table 1a, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
[0268] Table 1a
[0269]
[0270]
[0271]
[0272]
[0273]
[0274]
[0275]
[0276]
[0277]
[0278]
[0279]
[0280]
[0281]
[0282]
[0283]
[0284]
[0285]
[0286]
[0287]
[0288] Described herein is a compound selected from the compounds in Table 1b, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
[0289] Table 1b
[0290]
[0291] Other forms of the compounds disclosed herein
[0292] Isomers / stereoisomers
[0293] In some embodiments, the compounds described herein exist in the form of geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds provided herein include all cis (cis), trans (trans), syn (syn), anti (anti), entgegen (E) and zusammen (Z) isomers and their corresponding mixtures. In some cases, the compounds described herein have one or more chiral centers, and each center exists in the R configuration or S configuration. The compounds described herein include all diastereomeric forms, enantiomeric forms and epimeric forms and their corresponding mixtures. In additional embodiments of the compounds and methods provided herein, the mixture of enantiomers and / or diastereomers produced by a single preparation step, combination or mutual conversion can be used for the applications described herein. In some embodiments, the compounds described herein are prepared into their single stereoisomers by the following manner: reacting the racemic mixture of the compound with an optically active resolving agent to form a pair of diastereomeric compounds, separating diastereomers, and recovering optically pure enantiomers. In some embodiments, dissociable complexes are preferred. In some embodiments, diastereomers have different physical properties (e.g., melting points, boiling points, solubility, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, diastereomers are separated by chiral chromatography, or preferably, by separation / resolution techniques based on solubility differences. In some embodiments, the optically pure enantiomers and the resolving agent are then recovered by any practical means that do not result in racemization.
[0294] Labeled compounds
[0295] In some embodiments, the compounds described herein exist in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically labeled compounds in the form of pharmaceutical compositions. Therefore, in some embodiments, the compounds disclosed herein include isotopically labeled compounds that are identical to those described herein, with the exception that one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Examples of isotopes that can be incorporated into the compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2 H. 3 H. 13 C. 14 C. l5 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. Compounds described herein and pharmaceutically acceptable salts, solvates or stereoisomers thereof containing the above mentioned isotopes and / or other isotopes of other atoms are within the scope of the present invention. Certain isotopically labeled compounds, for example radioactive isotopes such as 3 H and 14 Those into which C is incorporated can be used in drug and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e. 14 C) isotopes are particularly preferred due to their ease of preparation and detectability. In addition, heavy isotopes such as deuterium (i.e. 2 H) may result in certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements.
[0296] In some embodiments, the compounds described herein are labeled by other means, including but not limited to the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
[0297] In some embodiments, labeled compounds described herein are used to measure the binding of unlabeled HSD17B13 inhibitors in vitro and in vivo.
[0298] Pharmaceutically acceptable salts
[0299] In some embodiments, the compounds described herein exist in the form of their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts in the form of pharmaceutical compositions.
[0300] In some embodiments, the compounds described herein have acidic or basic groups and therefore react with any of a number of inorganic or organic bases and inorganic and organic acids to form pharmaceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein or their solvates or stereoisomers, or by separately reacting the purified compound in its free form with a suitable acid or base and isolating the salt thus formed.
[0301] Examples of pharmaceutically acceptable salts include those prepared by reaction of the compounds described herein with mineral acids, organic acids or inorganic bases, such salts include acetates, acrylates, adipates, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyne-1,4-dioate, camphorate, camphorsulfonate, hexanoate, octanoate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogen phosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, formate, fumarate, gluconate heptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxybenzoate, gamma-hydroxybutyrate salt, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate, metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogenphosphate, 1-naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, toluenesulfonate, undecanoate and xylenesulfonate.
[0302] In addition, the compounds described herein can be prepared as pharmaceutically acceptable salts by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including but not limited to inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, Benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid and muconic acid. In some embodiments, other acids such as oxalic acid, while not pharmaceutically acceptable in themselves, are used to prepare salts that can be used as intermediates in obtaining the compounds disclosed herein, their solvates or stereoisomers, and their pharmaceutically acceptable acid addition salts.
[0303] In some embodiments, those compounds described herein that contain free acid groups are reacted with a suitable base, such as a pharmaceutically acceptable hydroxide, carbonate, bicarbonate, sulfate of a metal cation; with ammonia; or with a pharmaceutically acceptable organic primary, secondary, tertiary or quaternary amine. Representative salts include alkali metal or alkaline earth metal salts, such as lithium, sodium, potassium, calcium, and magnesium and aluminum salts, and the like. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N + (C 1-4 Alkyl)4, etc.
[0304] Representative organic amines that can be used to form base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It should be understood that the compounds described herein also include the quaternization of any basic nitrogen-containing groups they contain. In some embodiments, water- or oil-soluble or dispersible products are obtained by such quaternization.
[0305] Solvate
[0306] In some embodiments, the compounds described herein exist in the form of solvates. The present invention provides methods for treating diseases by administering such solvates. The present invention also provides methods for treating diseases by administering such solvates in the form of pharmaceutical compositions.
[0307] Solvates contain a stoichiometric or non-stoichiometric amount of solvent, and in some embodiments, the solvates are formed with pharmaceutically acceptable solvents such as water, ethanol, etc. When the solvent is water, a hydrate is formed, or when the solvent is an alcohol, an alcoholate is formed. Solvates of compounds described herein can be conveniently prepared or formed during the process described herein. By way of example only, hydrates of compounds described herein can be conveniently prepared by aqueous / organic solvent mixtures using organic solvents including but not limited to dioxane, tetrahydrofuran or methanol. In addition, compounds provided herein can exist in unsolvated forms as well as solvated forms. In general, for the purposes of compounds and methods provided herein, solvated forms are considered to be equivalent to unsolvated forms.
[0308] Tautomer
[0309] In some cases, compounds exist as tautomers. The compounds described herein include all possible tautomers within the structural formula described herein. Tautomers are compounds that can be interconverted by the migration of hydrogen atoms, which is accompanied by the conversion of single bonds and adjacent double bonds. In the bonding arrangement in which tautomerism is possible, there will be a chemical equilibrium of tautomers. All tautomeric forms of the compounds disclosed herein are considered. The exact ratio of tautomers depends on several factors, including temperature, solvent and pH.
[0310] Treatment
[0311] Provided herein is a method of inhibiting the expression or activity of HSD17B13, which can be used to treat, prevent or improve a disease associated with HSD17B13, such as NAFLD or NASH, in a subject in need thereof by administering a compound targeting HSD17B13 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
[0312] Provided herein is a method of inhibiting the expression or activity of HSD17B13 in a cell, the method comprising contacting the cell with a disclosed HSD17B13 inhibitor or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, thereby inhibiting the expression or activity of HSD17B13 in the cell. In some embodiments, the cell is a hepatocyte. In some embodiments, the cell is in the liver. In some embodiments, the cell is in the liver of a subject having a disease, disorder, condition, symptom or physiological marker associated with liver disease, metabolic disease or cardiovascular disease or a disorder or being at risk of having a disease, disorder, condition, symptom or physiological marker associated with liver disease, metabolic disease or cardiovascular disease or a disorder. In some embodiments, the cell is an adipocyte or monocyte from a subject having a disease or being at risk of having a disease. In some embodiments, the cell is a lymphocyte from a subject having a disease or being at risk of having a disease. In some embodiments, the liver disease, metabolic disease, or cardiovascular disease or condition is metabolic syndrome, fatty liver disease, chronic liver disease, cirrhosis, hepatic steatosis, steatohepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, non-alcoholic steatohepatitis (NASH), fulminant Wilson disease, rapidly fibrosing hepatitis C virus injury, and decompensated portal hypertension. In some embodiments, the liver disease, metabolic disease, or cardiovascular disease or condition is NASH. In some embodiments, the liver disease, metabolic disease, or cardiovascular disease or condition is cholestatic liver disease.
[0313] In some embodiments, the liver disease is primary biliary cirrhosis or primary sclerosing cholangitis.
[0314] Provided herein is a method for treating, preventing, delaying the onset of, slowing down the progression of, or improving the progression of, one or more diseases, disorders, conditions, symptoms, or physiological markers associated with HSD17B13, or one or more diseases, disorders, conditions, symptoms, or physiological markers associated with HSD17B13, comprising administering a compound disclosed herein or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof to a subject in need thereof. In some embodiments, a subject in need thereof is identified as having a disease, disorder, condition, symptom, or physiological marker, or is at risk of having a disease, disorder, condition, symptom, or physiological marker. In some embodiments, the liver disease, metabolic disease, or cardiovascular disease or disorder is metabolic syndrome, liver disease, fatty liver disease, chronic liver disease, cirrhosis, hepatic steatosis, steatohepatitis, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). In some embodiments, the liver disease, metabolic disease, or cardiovascular disease or disorder is NASH.
[0315] Provided herein is a method for reducing, improving or regulating liver steatosis, liver fibrosis, triglyceride synthesis, lipid levels, liver lipids, ALT levels, NAFLD activity score (NAS), cholesterol levels or triglyceride levels or a combination thereof in a subject in need, the method comprising administering a compound disclosed herein or a pharmaceutically acceptable salt thereof, a solvate or a stereoisomer thereof to the subject. In some embodiments, a compound disclosed herein or a pharmaceutically acceptable salt thereof, a solvate or a stereoisomer thereof is provided for reducing, improving or regulating liver steatosis of an individual. In some embodiments, a compound disclosed herein or a pharmaceutically acceptable salt thereof, a solvate or a stereoisomer thereof is provided for reducing, improving or regulating liver fibrosis of an individual. In some embodiments, a compound disclosed herein or a pharmaceutically acceptable salt thereof, a solvate or a stereoisomer thereof is provided for reducing, improving or regulating triglyceride synthesis in an individual. In some embodiments, a compound disclosed herein or a pharmaceutically acceptable salt thereof, a solvate or a stereoisomer thereof is provided for reducing, improving or regulating lipid levels in an individual. In some embodiments, compounds disclosed herein or its pharmaceutically acceptable salt, solvate or stereoisomer are provided for reducing, improving or regulating liver lipids in individual. In some embodiments, compounds disclosed herein or its pharmaceutically acceptable salt, solvate or stereoisomer are provided for reducing, improving or regulating ALT levels in individual. In some embodiments, compounds disclosed herein or its pharmaceutically acceptable salt, solvate or stereoisomer are provided for reducing, improving or regulating NAFLD activity score in individual. In some embodiments, compounds disclosed herein or its pharmaceutically acceptable salt, solvate or stereoisomer are provided for reducing, improving or regulating cholesterol levels in individual. In some embodiments, compounds disclosed herein or its pharmaceutically acceptable salt, solvate or stereoisomer are provided for reducing, improving or regulating triglyceride levels in individual. In some embodiments, the subject is identified as having a disease, disorder, condition, symptom or physiological marker associated with liver disease, metabolic disease or cardiovascular disease or disorder, or is at risk of having a disease, disorder, condition, symptom or physiological marker associated with liver disease, metabolic disease or cardiovascular disease or disorder. In some embodiments, liver disease, metabolic disease or cardiovascular disease or disorder is metabolic syndrome, liver disease, fatty liver disease, chronic liver disease, cirrhosis, hepatic steatosis, steatohepatitis, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In some embodiments, liver disease, metabolic disease or cardiovascular disease or disorder is NASH.
[0316] Provided herein is a method for treating, preventing, or delaying the onset of drug-induced liver injury (DILI) in a subject in need, comprising administering to the subject a compound disclosed herein or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, liver injury is fatty hepatitis. Also provided herein is a method for treating, preventing, or delaying the onset of drug-induced fatty hepatitis (DISH) in a subject in need. In some embodiments, the subject in need is receiving chemotherapy for the treatment of cancer. In some embodiments, the subject in need is receiving treatment for cardiovascular disease. In some embodiments, the subject in need is receiving treatment for mental illness / condition. In some embodiments, the subject in need is receiving treatment for pain. In some embodiments, the subject in need is receiving treatment for arthritis. In some embodiments, the chemotherapy is tamoxifen, toremifene, irinotecan, methotrexate, fluorouracil (5-FU), or any combination thereof. In some embodiments, the subject in need is receiving amiodarone, perhexiline, propranolol, or any combination thereof. In some embodiments, the subject in need is receiving amitriptyline, clozapine, or any combination thereof. In some embodiments, the subject in need is receiving methotrexate, pirprofen, or any combination thereof.
[0317] Cholestatic Disorders
[0318] Provided herein is a method of treating a cholestatic disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
[0319] In some embodiments, inhibition of HSD17B13 improves bile flow. In some embodiments, inhibition of HSD17B13 is used to treat cholestatic diseases. Cholestatic diseases include primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), Alagille syndrome, biliary atresia, liver damage in patients with cystic fibrosis, and progressive familial intrahepatic cholestasis (PFIC).
[0320] HSD17B13 protein is highly expressed in the liver and gallbladder. The gallbladder develops downstream of hepatocytes through the biliary tree. Inactivated HSD17B13 is associated with an increase in liver and plasma phosphatidylcholine. Phosphatidylcholine is essential for bile flow. Liver phosphatidylcholine is secreted into bile at a rate equivalent to the total liver level of phosphatidylcholine secreted with bile acids (BA) and cholesterol in one day. In some embodiments, inactivated HSD17B13 is associated with increased plasma levels of VLDL-cholesterol. This means that there is more cholesterol secreted in the liver instead of being broken down into bile acids and secreted into bile. In some embodiments, inhibiting HSD17B13 improves bile flow by increasing phosphatidylcholine. In some embodiments, HSD17B13 protects the biliary tree by preventing inflammation. In some embodiments, HSD17B13 protects the biliary tree by preventing cytotoxic bile acids from damaging the biliary tree.
[0321] In some embodiments, the cholestatic disease is primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), Alagille syndrome, biliary atresia, liver damage in patients with cystic fibrosis, progressive familial intrahepatic cholestasis (PFIC), intrahepatic cholestasis of pregnancy; drug-induced cholestasis, AIDS cholangiopathy, IG4-related cholangitis, bile duct stricture, or low phospholipid-related cholestasis.
[0322] In some embodiments, the cholestatic disease is primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), Alagille syndrome, biliary atresia, liver damage in patients with cystic fibrosis, or progressive familial intrahepatic cholestasis (PFIC).
[0323] In some embodiments, the cholestatic disease is primary sclerosing cholangitis (PSC).
[0324] In some embodiments, PSC is accompanied by inflammatory bowel disease (IBD). In some embodiments, PSC is accompanied by elevated levels of lipopolysaccharide (LPS) (endotoxinemia). In some embodiments, LPS levels are elevated in the blood. In some embodiments, LPS levels are elevated in the liver. In some embodiments, LPS levels are elevated in the biliary tree. In some embodiments, the cholestatic disease is primary biliary cholangitis (PBC). In some embodiments, the cholestatic disease is Alagille syndrome. In some embodiments, the cholestatic disease is biliary atresia. In some embodiments, the cholestatic disease is liver damage in patients with cystic fibrosis. In some embodiments, the cholestatic disease is progressive familial intrahepatic cholestasis (PFIC). In some embodiments, PFIC is PFIC-3 type. In some embodiments, PFIC-3 type is due to mutations in ABCB4, which requires phosphatidylcholine for bile acid transport.
[0325] In some embodiments, the cholestatic disease is treated by improving bile flow in a subject in need thereof. In some embodiments, the cholestatic disease is treated by improving cholesterol secretion in the liver of a subject in need thereof.
[0326] In some embodiments, inactivated HSD17B13 is associated with lower cytokine and inflammatory gene expression. In some embodiments, in hepatocytes with inactivated HSD17B13, the response of hepatocytes to LPS is improved. In some embodiments, inactivated HSD17B13 is associated with improved autophagy in response to LPS (see Figures 1A, 1B, and 1C). In some embodiments, an increase in LC3B-11 combined with an increase in p62 indicates accumulation of autophagosomes and autophagy defects.
[0327] Liver damage due to protein accumulation
[0328] Disclosed herein is a method for treating liver damage caused by protein accumulation in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. In some embodiments, the accumulated protein is α1-antitrypsin.
[0329] Alpha 1-antitrypsin is encoded by the gene SERPINA1. The normal allele is referred to as M, while the common SERPINA1 allele associated with liver disease has the amino acid changes Glu264Val, referred to as S, and Glu342Lys, referred to as Z. Individuals homozygous for the Z (designated PiZZ) allele have pulmonary manifestations of A1AT deficiency, which can be treated by supplementing the enzyme. However, individuals who are heterozygous for the Z allele with either the M (designated PiMZ) or with the S allele (designated PiSZ) have manifestations of liver disease. The protein produced by the translation of the Z and S alleles is a misfolded protein. Such misfolded proteins have been found to aggregate, and cell damage can result from the accumulation of misfolded and aggregated proteins. By increasing autophagy, protection from damage due to accumulated misfolded proteins has been observed.
[0330] In some embodiments, HSD17B13 plays a role in autophagy. In some embodiments, autophagy is important for eliminating misfolded proteins and has been implicated in liver damage caused by α1-antitrypsin deficiency. In some embodiments, inhibiting HSD17B13 improves autophagy, and thus improves the clearance of misfolded proteins, and thereby improves liver health. In some embodiments, liver diseases associated with α1-antitrypsin deficiency include inflammation and thrombocytopenia. In some embodiments, inactivated HSD17B13 is associated with lower inflammation, reduced inflammatory genes including NF-kB and TGF-β, and increased platelets.
[0331] In some embodiments, protein accumulation is cleared via autophagy. In some embodiments, the protein is a misfolded protein. In some embodiments, liver damage is caused by alpha 1-antitrypsin deficiency. In some embodiments, alpha 1-antitrypsin deficiency causes proteins to be unable to be fully processed and accumulate as misfolded proteins in the liver. In some embodiments, liver diseases associated with alpha 1-antitrypsin deficiency include inflammation. In some embodiments, liver diseases associated with alpha 1-antitrypsin deficiency include thrombocytopenia.
[0332] Treatment of virus-induced injuries
[0333] Disclosed herein is a method for treating viral infection-induced liver damage in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
[0334] Also disclosed herein is a method of reducing the severity of inflammation in a virally infected subject, the method comprising administering to the subject a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor.
[0335] Also disclosed herein is a method of reducing the severity of an acute immune response in a subject infected with a virus, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
[0336] Viral infection is often associated with a dysregulated liver inflammatory response. In some embodiments, inactivated HSD17B13 is associated with lower levels of activated genes for immune responses, including innate immune responses, cytokines. Inflammation is a key component of viral-driven damage. In some embodiments, inactivated HSD17B13 protects HCV patients from rapidly progressive fibrosis.
[0337] AAV-driven gene therapy is incorporated into hepatocytes via autophagy, so HSD17B13 inhibitors that improve autophagy and reduce inflammation may improve efficacy and reduce side effects.
[0338] In some embodiments, the viral infection is hepatitis A. In some embodiments, the viral infection is hepatitis B. In some embodiments, the viral infection is hepatitis C.
[0339] In some embodiments, the viral infection is SARS-Cov-2.
[0340] SARS-Cov-2
[0341] Liver injury and elevated liver transaminases are common features in patients with severe SARS-Cov-2 infection. There is no apparent increased risk associated with liver disease with COVID-19, therefore, 2-11% of COVID-19 patients have underlying liver comorbidities. In contrast, a greater proportion of patients (14-53%) had elevated liver transaminases. Patients suspected of having COVID-19 and testing positive for SARS-CoV-2 RNA had elevated ALT, AST, and decreased albumin compared to patients who tested negative for viral RNA consistent with liver injury. Among patients who died from COVID-19, 58% and 78% had elevated liver transaminases. Elevated liver transaminases were particularly pronounced in patients in the intensive care unit at 62%, compared to 25% of patients who did not require ICU care. Patients diagnosed with COVID-19 by CT scan in the subclinical stage had a lower incidence of elevated liver transaminases when compared to patients diagnosed after symptom onset. Although the virus may have a role in causing direct liver injury, as demonstrated by observations of SARS-CoV-2 RNA in the blood and feces and by 2–10% of patients developing diarrhea, liver injury may also result from secondary inflammatory events or from the use of many different medications during intensive care.
[0342] In addition to liver damage in patients with severe COVID-19, there is an increased incidence of cytokines or cytokine storms, which are a cause of multi-organ failure and death. Therefore, preventing or treating cytokine storms will be important for treating patients with the most severe disease. Analysis of the blood of COVID-19 patients showed that, overall, CD4 and CD8 cells were reduced, but Th17 cells were increased. Similarly, IL-6, IL-10, IL-2, and IFNγ were increased in the group of patients with severe disease. Overall, liver damage is seen in COVID-19 patients who are experiencing more extensive and severe disease, in which multiple organs other than the lungs are involved. One of the possible reasons for this may be that it is taken through the oral route and then through a more permeable intestinal barrier in patients with comorbidities such as diabetes. The liver is then exposed to the virus and as a key mediator of the inflammatory response, it can therefore mediate a alleviation of the inflammatory process, or mediate an acceleration of the inflammatory process, which leads to increased cytokine release and further organ damage.
[0343] Genetic evidence for the gene for the enzyme HSD17B13, which is associated with liver transaminase levels and liver disease, is rapidly increasing. At the time of this writing, the genetic evidence includes many studies with genetic and disease information from over 200,000 individuals. Deficiency in HSD17B13 activity has been shown to be protective against liver disease caused by overnutrition, excessive and chronic alcohol consumption, toxins such as copper, and viruses such as HCV. The highly reproducible association of HSD17B13 with multiple forms of liver disease, elevated liver transaminases, and liver damage has stimulated efforts to develop inhibitors of this enzyme to protect and reverse liver damage. The variety of toxicants and injuries protected by loss of HSD17B13 function makes it proposed here to prevent liver damage in severe COVID-19.
[0344] HSD17B13 activity has been shown to be involved in inflammation and inflammatory responses. Recently, loss of HSD17B13 function has been associated with reduced gene expression and protein levels of immune response genes involved in adverse outcomes including IL-6, IL-10, and IL-1β. In addition to lower ALT levels in patients with nonalcoholic fatty liver disease, polymorphisms in the enzymatic inactivation of HSD17B13 have been associated with lower severity of histopathological endpoints of inflammation.
[0345] In some embodiments, HSD17B13 inhibitors prevent and treat liver injury in patients with COVID-19, and reduce the severity of inflammation and acute immune responses in patients with COVID-19.
[0346] In some embodiments, viral infection is associated with dysregulated liver inflammatory response. In some embodiments, administration results in reduced levels of immune response activation genes. In some embodiments, administration results in reduced inflammation. In some embodiments, subjects in need have elevated alanine aminotransferase (ALT) levels. In some embodiments, subjects in need have elevated aspartate aminotransferase (AST) levels. In some embodiments, subjects in need have reduced albumin levels.
[0347] Malignant tumors
[0348] Disclosed herein is a method for treating a malignant tumor in a subject in need thereof, wherein the malignant tumor is selected from hepatocellular carcinoma (HCC), bile duct adenoma, cholangiocarcinoma, gallbladder adenocarcinoma and a malignant tumor of the bile duct, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
[0349] Inactive HSD17B13 is associated with a lower rate of HCC. However, HSD17B13 expression is low in tumor tissue but normal in the peritumoral space. High protein levels in the peritumoral space are associated with improved survival and tumor-free survival. This apparent paradox supports the use of small molecules to inhibit HSD17B13, but keeping this protein available to support autophagic activity. Autophagy is important for maintaining killer T cell responses and using the body's own immune system to fight tumors. By inhibiting HSD17B13, the surrounding tissues will be able to take on killer T cell responses due to efficient autophagy.
[0350] HSD17B13 is highly expressed in the normal gallbladder. Inactive HSD17B13 is associated with increased phosphatidylcholine, which is critical for sequestering cytotoxic bile acid excretion and bile flow. For these reasons and additionally improved killer T cell responses and reduced inflammation and fibrosis are mechanisms by which HSD17B13 inhibitors could be used to treat bile duct adenomas and gallbladder adenocarcinomas.
[0351] In some embodiments, the malignant tumor is hepatocellular carcinoma (HCC). In some embodiments, the malignant tumor is bile duct adenoma. In some embodiments, the malignant tumor is bile duct carcinoma. In some embodiments, the malignant tumor is gallbladder adenocarcinoma. In some embodiments, the HSD17B13 receptor is expressed in the peritumoral space.
[0352] Hemochromatosis
[0353] A method of treating hemochromatosis in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the hemochromatosis is primary hemochromatosis. In some embodiments, the hemochromatosis is secondary hemochromatosis. In some embodiments, the hemochromatosis is caused by liver disease. In some embodiments, the hemochromatosis is drug-induced hemochromatosis.
[0354] Lysosomal acid lipase deficiency (LAL-D)
[0355] Disclosed herein is a method for treating lysosomal acid lipase deficiency (LAL-D) in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, lysosomal acid lipase deficiency (LAL-D) is caused by a mutation in the LIPA gene. In some embodiments, lysosomal acid lipase deficiency (LAL-D) causes Wolman disease. In some embodiments, lysosomal acid lipase deficiency (LAL-D) causes cholesterol ester storage disease. In some embodiments, lysosomal acid lipase deficiency (LAL-D) is caused by a mutation in the LIPA gene. In some embodiments, lysosomal acid lipase deficiency (LAL-D) causes accumulation of fatty substances in cells and tissues in the body.
[0356] Bleeding disorders / clotting factor disorders
[0357] Disclosed herein is a method of treating a bleeding disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the bleeding disorder is hemophilia A or hemophilia B.
[0358] Disclosed herein is a method of treating a coagulation factor disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) inhibitor disclosed herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. In some embodiments, the coagulation factor disorder is von Willebrand disease.
[0359] In some embodiments, the following table lists diseases that are treated by inhibiting hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13).
[0360] AAV-induced liver injury Hepatic adenoma AAV injury Hepatic encephalopathy Alagille syndrome Hepatitis A Alcohol-related liver disease Hepatitis B Alpha-1 antitrypsin deficiency Hepatitis C Autoimmune hepatitis Hepatorenal syndrome Biliary atresia Intrahepatic cholestasis of pregnancy (ICP) Cholangiocarcinoma Liver cancer Covid 19 related LAL-D Crigler-Najjar syndrome Neonatal jaundice Cystic fibrosis related NAFLD Drug-induced liver injury PBC Galactosemia PSC Gallbladder cancer Progressive familial intrahepatic cholestasis Gilbert syndrome Reye syndrome HCC Glycogen storage disease type I Hemochromatosis Wilson disease
[0361] Also disclosed herein is a method for selectively inhibiting HSD17B13, the method comprising administering a pharmaceutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the compound selectively inhibits HSD17B13 over HSD17B2, HSD17B14, or any combination thereof. In some embodiments, the inhibition of HSD17B2 is associated with a disturbance in normal endocrine function in a variety of tissues. In some embodiments, the inhibition of HSD17B2 is associated with weight loss. In some embodiments, the inhibition of HSD17B2 is associated with muscle loss. In some embodiments, the inhibition of HSD17B14 is associated with a disturbance in normal endocrine function in a variety of tissues.
[0362] Drug administration
[0363] In certain embodiments, a composition containing one or more compounds described herein is administered for preventive and / or therapeutic treatment. In certain therapeutic applications, the composition is administered to a patient already suffering from the disease or condition in an amount sufficient to cure or at least partially arrest at least one symptom of the disease or condition. The amount effective for this purpose will depend on the severity and course of the disease or condition; previous therapy; the patient's health, weight, and response to the drug; and the judgment of the treating physician. The therapeutically effective amount is optionally determined by methods including, but not limited to, dose escalation and / or dose range clinical trials.
[0364] In preventive applications, compositions containing the compounds described herein are administered to patients susceptible to or otherwise at risk of a particular disease, disorder, or condition. Such an amount is defined as a "prophylactically effective amount or dose". In this use, the exact amount also depends on the patient's health status, weight, etc. When used in a patient, the effective amount for this use will depend on the severity and course of the disease, disorder, or condition; previous therapy; the patient's health status and response to drugs; and the judgment of the treating physician. In one aspect, preventive treatment includes administering a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof to a mammal that has previously experienced at least one symptom or risk factor of the disease being treated and is currently in remission to prevent the recurrence of symptoms of the disease or condition. In one aspect, preventive treatment includes administering a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof to a mammal having a patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism to prevent liver damage. A protein variant (I148M) in which isoleucine at 148 is changed to methionine in the potato protein-like phospholipase domain-containing protein 3 (PNPLA3), a protein expressed in the liver and involved in lipid metabolism, has recently been identified as a major determinant of liver fat content. Several studies have confirmed that the I148M variant confers susceptibility to the full range of liver damage associated with fatty liver: from simple steatosis to steatohepatitis and progressive fibrosis. In addition, the I148M variant represents a major determinant of the progression of alcohol-related steatohepatitis to cirrhosis, and represents a major determinant affecting fibrosis and related clinical outcomes in chronic hepatitis C virus hepatitis and possibly chronic hepatitis B virus hepatitis, hereditary hemochromatosis, and primary sclerosing cholangitis. In some embodiments, PNPLA3 polymorphisms are used to predict liver disease progression.
[0365] In certain embodiments where the patient's condition does not improve, at the discretion of the physician, administration of the compound is performed chronically, that is, for an extended period of time, including for the entire duration of the patient's life, to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.
[0366] Once the patient's condition has improved, a maintenance dose is administered if necessary. Subsequently, in specific embodiments, the dosage or frequency of administration, or both, is reduced to a level that maintains the improved disease, disorder, or condition, as varied by symptoms. However, in certain embodiments, after any recurrence of symptoms, the patient requires long-term intermittent or daily treatment.
[0367] The amount corresponding to such an amount for a given agent varies depending on factors such as the specific compound, the disease condition and its severity, the identity (e.g., weight, sex) of the subject or host in need of treatment, and is however determined according to the particular circumstances surrounding the case, including, for example, the specific agent administered, the route of administration, the condition being treated, and the subject or host being treated.
[0368] However, in general, dosages for adult treatment are generally in the range of 0.01 mg to 5000 mg per day. In one aspect, dosages for adult treatment are from about 1 mg to about 1000 mg per day. In one embodiment, the desired dosage is conveniently provided in a single dose or in divided doses, which are administered simultaneously or at appropriate intervals, for example, in two, three, four or more sub-doses per day.
[0369] In one embodiment, the daily dose suitable for the compounds described herein or their pharmaceutically acceptable salts is from about 0.01 to about 50 mg per kg of body weight. In some embodiments, the amount of active substance in the daily dose or dosage form is lower or higher than the range indicated herein based on many variables regarding a single treatment regimen. In various embodiments, the daily dose and unit dose are changed depending on many variables, including but not limited to the activity of the compound used, the disease or condition to be treated, the mode of administration, the needs of a single subject, the severity of the disease or condition to be treated, and the judgment of the practitioner.
[0370] The toxicity and therapeutic efficacy of such treatment regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including but not limited to determining the LD 10 and ED 90 The dose ratio between toxic and therapeutic effects is the therapeutic index, and it is expressed as LD 50 With ED 50 In certain embodiments, the data obtained from cell culture assays and animal studies are used to formulate therapeutically effective daily dosage ranges and / or therapeutically effective unit doses for use in mammals, including humans. In some embodiments, the daily dose of the compounds described herein is within the range of ED with minimal toxicity. 50 In certain embodiments, depending on the dosage form employed and the route of administration utilized, the daily dosage range and / or unit dosage varies within this range.
[0371] In any of the above-mentioned aspects are further embodiments wherein an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, is: (a) systemically administered to a mammal; and / or (b) orally administered to a mammal; and / or (c) intravenously administered to a mammal; and / or (d) administered to a mammal by injection; and / or (e) topically administered to a mammal; and / or (f) non-systemically or locally administered to a mammal.
[0372] Within any of the above-mentioned aspects are other embodiments comprising a single administration of an effective amount of the compound, including other embodiments wherein: (i) the compound is administered once a day; or (ii) the compound is administered to the mammal multiple times over the span of a day.
[0373] Route of administration
[0374] Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ocular, pulmonary, transmucosal, transdermal, vaginal, aural, nasal, and topical administration. In addition, parenteral delivery includes, by way of example only, intramuscular, subcutaneous, intravenous, intramedullary injection, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injection.
[0375] In certain embodiments, the compounds as described herein are administered in a local rather than systemic manner, for example, by direct injection of the compound into an organ, often in the form of a reservoir formulation or a sustained release formulation. In a specific embodiment, the long-acting formulation is administered by implantation (e.g., subcutaneous or intramuscular implantation) or by intramuscular injection. In addition, in other embodiments, the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with an organ-specific antibody. In such embodiments, the liposome is targeted to an organ and selectively absorbed by the organ. In other embodiments, the compounds as described herein are provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of a medium release formulation. In other embodiments, the compounds described herein are administered topically.
[0376] Pharmaceutical compositions / preparations
[0377] The compounds described herein are administered to a subject in need thereof, either alone or in combination with a pharmaceutically acceptable carrier, excipient or diluent in accordance with standard pharmaceutical practice, as a pharmaceutical composition. In one embodiment, the compounds of the invention may be administered to animals. The compounds may be administered orally or parenterally, including intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
[0378] In another aspect, provided herein is a pharmaceutical composition comprising a compound as described herein or a pharmaceutically acceptable salt, solvate or stereoisomer thereof and at least one pharmaceutically acceptable excipient. The pharmaceutical composition is formulated in a conventional manner using one or more pharmaceutically acceptable excipients that aid in processing the active compound into a pharmaceutically usable preparation. Appropriate formulations depend on the selected route of administration. An overview of the pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Edition (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H. A. and Lachman, L., eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Edition (Lippincott Williams & Wilkins 1999), which are incorporated herein by reference for such disclosure.
[0379] In some embodiments, the pharmaceutically acceptable excipient is selected from a carrier, a binder, a filler, a suspending agent, a flavoring agent, a sweetener, a disintegrant, a dispersant, a surfactant, a lubricant, a colorant, a diluent, a solubilizer, a wetting agent, a plasticizer, a stabilizer, a penetration enhancer, a wetting agent, a defoaming agent, an antioxidant, a preservative, and any combination thereof.
[0380] The pharmaceutical compositions described herein are administered to a subject by an appropriate route of administration, including, but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal routes of administration. Pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid oral dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, powders, dragees, effervescent formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, multi-particulate formulations, and mixed immediate and controlled release formulations.
[0381] Pharmaceutical compositions including a compound described herein, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, are manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
[0382] The pharmaceutical composition for oral use is obtained by mixing one or more solid excipients with one or more compounds described herein, optionally grinding the resulting mixture, and processing the mixture of particles after adding suitable auxiliary agents to obtain tablets or dragee cores when necessary. Suitable excipients include, for example, fillers, such as sugars, including lactose, sucrose, mannitol or sorbitol; cellulose preparations, such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose; or other excipients, such as polyvinyl pyrrolidone (PVP or povidone) or calcium phosphate. If necessary, disintegrants such as cross-linked sodium carboxymethyl cellulose, polyvinyl pyrrolidone, agar or alginic acid or its salt, such as sodium alginate, are added. In some embodiments, dyes or pigments are added to tablets or dragee coatings for marking or characterizing different combinations of active compound dosages.
[0383] Pharmaceutical compositions for oral administration include push-fit capsules made of gelatin and soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules contain the active ingredient in admixture with fillers such as lactose, binders such as starches and / or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compound is dissolved or suspended in a suitable liquid, such as a fatty oil, liquid paraffin, or liquid polyethylene glycol. In some embodiments, stabilizers are added.
[0384] The pharmaceutical composition for parenteral use is formulated into an infusion or injection. In some embodiments, the pharmaceutical composition suitable for injection or infusion includes a sterile aqueous solution or dispersion or sterile powder comprising a compound as described herein or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. In some embodiments, the pharmaceutical composition includes a liquid carrier. In some embodiments, the liquid carrier is a solvent or a liquid dispersion medium, including, for example, water, saline, ethanol, a polyol (such as glycerol, propylene glycol, liquid polyethylene glycol, etc.), a vegetable oil, a non-toxic glyceride and any combination thereof. In some embodiments, the pharmaceutical composition also includes a preservative to prevent microbial growth.
[0385] combination
[0386] Disclosed herein are methods of treating liver disease, metabolic disease, or cardiovascular disease using a combination of a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and an additional therapeutic agent.
[0387] In some embodiments, the additional therapeutic agent is used to treat diabetes or a diabetes-related disorder or condition.
[0388] In some cases, the additional therapeutic agent includes a statin, an insulin sensitizing drug, an insulin secretagogue, an alpha-glucosidase inhibitor, a GLP agonist, a GIP agonist, a THRβ agonist, a PDE inhibitor, a DPP-4 inhibitor (such as sitagliptin, vildagliptin, saxagliptin, linagliptin, anagliptin, teneligliptin, alogliptin, gemigliptin, or dutoglipitin), a catecholamine (such as epinephrine, norepinephrine, or In some cases, the statin is a thiazolidinedione (TZD) [such as pioglitazone, rosiglitazone, rivoglitazone or troglitazone], aleglitazar, farglitazar, muraglitazar or tesaglitazar), a peroxisome proliferator-activated receptor (PPAR)-alpha agonist, a peroxisome proliferator-activated receptor (PPAR)-delta agonist, a farnesoid X receptor (FXR) agonist (such as obeticholic acid), or a combination thereof. In some cases, the statin is an HMG-CoA reductase inhibitor. In other cases, additional therapeutic agents include fish oil, fibrate, vitamins such as nicotinic acid, retinoic acid (e.g., 9 cis-retinoic acid), nicotinamide riboside or its analogs, or combinations thereof. In other cases, additional therapeutic agents include ACC inhibitors, FGF19 and FGF21 mimetics, CCR2 / CCR5 antagonists, or combinations thereof.
[0389] In some embodiments, the additional therapeutic agent is vivitrol.
[0390] In some embodiments, the additional therapeutic agent is a statin such as an HMG-CoA reductase inhibitor, fish oil, fibrate, niacin, or a combination thereof. In other cases, the additional therapeutic agent is a dyslipidemia drug that blocks lipid absorption such as orlistat.
[0391] In some embodiments, the additional therapeutic agent is a vitamin such as retinoic acid or tocopheryl acetate that is used to treat diabetes and diabetes-related disorders or conditions, such as reducing increased body weight and / or reducing elevated blood sugar from food intake.
[0392] In some embodiments, the additional therapeutic agent is a glucose lowering agent. In some embodiments, the additional therapeutic agent is an anti-obesity agent. In some embodiments, the additional therapeutic agent is selected from peroxisome proliferator-activated receptor (PPAR) agonists (gamma, dual or pan), dipeptidyl peptidase (IV) inhibitors, glucagon-like peptide-1 (GLP-I) analogs, insulin or insulin analogs, insulin secretagogues, sodium glucose cotransporter 2 (SGLT2) inhibitors, glucophage, human amylin analogs, biguanides, alpha-glucosidase inhibitors, meglitinides, thiazolidinediones and sulfonylureas. In some embodiments, the additional therapeutic agent is metformin, sitagliptin, saxagliptin, repaglinide, nateglinide, exenatide, liraglutide, insulin lispro, insulin aspart, insulin glargine, insulin detemir, insulin isophane, and glucagon-like peptide 1, or any combination thereof. In some embodiments, the additional therapeutic agent is a lipid-lowering agent.
[0393] In some embodiments, the additional therapeutic agent is an antioxidant, a corticosteroid such as budesonide, an anti-tumor necrosis factor (TNF) agent, or a combination thereof.
[0394] In some embodiments, the additional therapeutic agent is administered simultaneously with the compounds disclosed herein. In some embodiments, the additional therapeutic agent and the compounds disclosed herein are administered sequentially. In some embodiments, the additional therapeutic agent is administered less frequently than the compounds disclosed herein. In some embodiments, the additional therapeutic agent is administered more frequently than the compounds disclosed herein. In some embodiments, the additional therapeutic agent is administered prior to the administration of the compounds disclosed herein. In some embodiments, the additional therapeutic agent is administered after the administration of the compounds disclosed herein.
[0395] Example
[0396] Example 1: Synthesis of 4,6-dichloro-5-hydroxy-N-(4-((2-(trifluoromethyl)benzyl)carbamoyl)-1H-pyrazol-3-yl)picolinamide
[0397]
[0398] Step 1: Synthesis of 3-amino-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide:
[0399] At 0 ° C, 2M trimethylaluminum (2.04 mL, 21.3 mmol) in toluene was added to a stirred solution of 3-amino-1H-pyrazole-4-formic acid methyl ester (0.6 g, 4.25 mmol) and 1-[2-(trifluoromethyl)phenyl]methylamine (0.745 g, 4.25 mmol) in toluene (3 mL). The resulting reaction mixture was stirred for 32 h at 100 ° C. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (10 mL), and extracted with ethyl acetate (15 x 2 mL). The combined organic phases were washed with saline solution (15 mL) and dried over anhydrous sodium sulfate, filtered and evaporated under vacuum to obtain a crude product. The crude product was purified by flash column chromatography to obtain 3-amino-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide (0.520 g, 43%) as a brown solid. LCMS (ES): m / z: Calcd. for C12H11F3N4O: 284.24; found: 285.1 (M+H).
[0400] Step 2: Synthesis of 4,6-dichloro-5-hydroxy-N-(4-((2-(trifluoromethyl)benzyl)carbamoyl)-1H-pyrazol-3-yl)picolinamide:
[0401] Phosphorus trichloride (0.164 mL, 1.76 mmol) was added to a stirred solution of 3-amino-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide (0.5 g, 1.76 mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.439 g, 2.11 mmol) in acetonitrile (5 mL, 76.6 mmol) at ambient temperature. The resulting reaction mixture was stirred at 100 ° C for 2 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (20 mL). The precipitated solid was filtered and dried under reduced pressure to obtain a crude solid. The resulting crude product was purified by reverse phase preparative HPLC to obtain 4,6-dichloro-5-hydroxy-N-(4-((2-(trifluoromethyl)benzyl)carbamoyl)-1H-pyrazol-3-yl)picolinamide (0.093 g, 11%) as an off-white solid. LCMS (ES): m / z: calculated for C18H12Cl2F3N5O3: 473.03; found: 472.1 (MH); 1H NMR (400 MHz, DMSO d6): δ11.71 (s, 1H), 8.83 (t, J=5.2 Hz, 1H), 8.21-8.16 (m, 1H), 8.10 (s, 1H), 7.75 (d, J=7.6 Hz, 1H), 7.70-7.66 (m, 1H), 7.55-7.48 (m, 2H), 4.73-4.63 (m, 2H).
[0402] Example 2: Synthesis of 4,6-dichloro-5-hydroxy-N-(1-methyl-4-((2-(trifluoromethyl)benzyl)carbamoyl)-1H-pyrazol-3-yl)picolinamide
[0403]
[0404] Step 1: Synthesis of 3-amino-1-methyl-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide:
[0405] At 0 ° C, 2M trimethylaluminum (2.47 mL, 25.8 mmol) in toluene was added to a stirred solution of 3-amino-1-methyl-1H-pyrazole-4-formic acid methyl ester (0.4 g, 2.58 mmol) and 1-[2-(trifluoromethyl)phenyl]methylamine (0.45 g, 2.58 mmol) in toluene (4 mL). The resulting reaction mixture was stirred at 100 ° C for 32 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (10 mL) and extracted with ethyl acetate (15 x 2 mL). The combined organic phases were washed with saline solution (15 mL) and dried over anhydrous sodium sulfate, filtered and evaporated under vacuum to obtain a crude product. The crude product was purified by flash column chromatography to obtain 3-amino-1-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide (0.5 g, 65.05%) as a brown solid. LCMS (ES): m / z: Calcd. for C13H13F3N4O: 298.27; found: 299.1 (M+H).
[0406] Step 2: Synthesis of 4,6-dichloro-5-hydroxy-N-(1-methyl-4-((2-(trifluoromethyl)benzyl)carbamoyl)-1H-pyrazol-3-yl)picolinamide
[0407] Phosphorus trichloride (0.157 mL, 1.68 mmol) was added to a stirred solution of 3-amino-1-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide (0.5 g, 1.68 mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.42 g, 2.01 mmol) in acetonitrile (5 mL) at ambient temperature. The resulting reaction mixture was stirred at 100 ° C for 2 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (20 mL). The precipitated solid was filtered and dried under reduced pressure to obtain a crude product. The resulting crude product was purified by reverse phase preparative HPLC to obtain 4,6-dichloro-5-hydroxy-N-[1-methyl-4-({[2-(trifluoromethyl)phenyl]methyl}carbamoyl)-1H-pyrazol-3-yl]pyridine-2-carboxamide (0.073 g, 9%) as a light yellow solid. LCMS (ES): m / z: calculated for C19H14Cl2F3N5O3: 487.04; found: 486.1 (MH); 1H NMR (400 MHz, DMSO-d6): δ11.47s, 1H), 8.77 (t, J=6.0Hz, 1H), 8.27 (s, 1H), 8.05 (s, 1H), 7.75 (d, J=8.0Hz, 1H), 7.95-7.68 (m, 1H), 7.54-7.47 (m, 2H), 4.68-4.58 (m, 2H), 3.86 (s, 3H).
[0408] Example 3: Synthesis of 3-(3,5-dichloro-4-hydroxybenzamido)-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide
[0409]
[0410] At room temperature, phosphorus trichloride (0.013mL, 0.158mmol) was added dropwise to a stirred solution of 3-amino-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide (0.15g, 0.528mmol) and 3,5-dichloro-4-hydroxybenzoic acid (0.12g, 0.580mmol) in acetonitrile (3mL). The resulting reaction mixture was heated to 100°C for 2h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (15mL), and the obtained solid was collected by filtration, washed with diethyl ether (5mL) and dried under reduced pressure vacuum to obtain a crude product as an off-white solid. The crude product was purified by preparative HPLC (column: XBridge C18 (250 mm x 4.6 mm x 5 μm); mobile phase (A): 0.1% TFA in water; mobile phase (B): acetonitrile; flow rate: 1.0 mL / min) to give 3-(3,5-dichloro-4-hydroxybenzamido)-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide (0.058 g, 23%) as a white solid. LCMS (ES) m / z: Calculated for C19H13Cl2F3N4O3 472.03; Found: 473.1 (M+H), 98.63%, at 254 nm. 1 H NMR (400 MHz, DMSO d6 at 90°C) δ 8.4 (bs, 1H), 8.13 (bs, 1H), 7.85 (s, 2H), 7.70 (d, J = 7.6 Hz, 1H), 7.62-7.57 (m, 2H), 7.49-7.47 (m, 1H), 4.63 (d, J = 24.8 Hz, 2H).
[0411] Example 4: Synthesis of 4,6-dichloro-5-hydroxy-N-(1-methyl-3-((2-(trifluoromethoxy)benzyl)carbamoyl)-1H-pyrazol-4-yl)picolinamide
[0412]
[0413] Step 1: Synthesis of methyl 1-methyl-4-nitro-1H-pyrazole-3-carboxylate
[0414] At 0 ° C, potassium carbonate (2.91g, 21mmol) was added to a stirred solution of 4-nitro-1H-pyrazole-3-formic acid methyl ester (3g, 17.5mmol) in anhydrous dimethylformamide (25mL), and then iodomethane (2.99g, 21mmol) was slowly added over a period of 15min. The resulting reaction mixture was stirred at room temperature for 2h. The reaction mixture was quenched with water (30mL) and extracted into ethyl acetate (20mL x 2 times). The combined organic layer was washed with water (30mL x 2 times), brine (20mL x 2 times), dried over sodium sulfate and evaporated under reduced pressure to produce a crude product. The crude product was purified by flash chromatography to obtain 1-methyl-4-nitro-1H-pyrazole-3-formic acid methyl ester (1.87g, 58%) and 1-methyl-4-nitro-1H-pyrazole-5-formic acid methyl ester (0.92g, 28%) as an off-white solid. LCMS (ES) m / z: calculated for C6H7N3O4, 185.04; found: 186.1 (M+H).
[0415] Step 2: Synthesis of methyl 4-amino-1-methyl-1H-pyrazole-3-carboxylate
[0416] To 1- methyl -4- nitro -1H- pyrazole -3- methyl formate (1.87g, 10.1mmol) in methanol (30mL) stirring solution, add Pd / C (0.45g, 2.11mmol) and then at room temperature under hydrogen atmosphere, stir for 3h.Reactant mixture is filtered through diatomaceous earth pad and washed with methanol (10mL).Filtrate is concentrated under reduced pressure to produce crude compound, which is ground with n-pentane (10mL), diethyl ether (10ml) to obtain 4- amino -1- methyl -1H- pyrazole -3- methyl formate (1.2g, 77%) in black solid.
[0417] Step 3: Synthesis of 4-amino-1-methyl-N-(2-(trifluoromethoxy)benzyl)-1H-pyrazole-3-carboxamide
[0418] At 0 ° C, 2M trimethylaluminum (0.46 mL, 4.83 mmol) in toluene was added to a stirred solution of 4-amino-1-methyl-1H-pyrazole-3-formic acid methyl ester (0.25 g, 1.61 mmol) and 1-[2-(trifluoromethoxy)phenyl]methylamine (0.30 g, 1.61 mmol) in toluene (5 mL). The resulting reaction mixture was stirred for 2 h at 100 ° C. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (10 mL) and extracted with ethyl acetate (15 x 2 mL). The combined organic phases were washed with saline solution (15 mL) and dried over anhydrous sodium sulfate, filtered and evaporated under vacuum to obtain a crude product. The crude product was purified by flash column chromatography to obtain 4-amino-1-methyl-N-(2-(trifluoromethoxy)benzyl)-1H-pyrazole-3-carboxamide (0.17 g, 35%) as a light yellow liquid. LCMS (ES) m / z: calcd. for C13H13F3N4O2, 314.10; found: 315.1 (M+H).
[0419] Step 4: Synthesis of 4,6-dichloro-5-hydroxy-N-(1-methyl-3-((2-(trifluoromethoxy)benzyl)carbamoyl)-1H-pyrazol-4-yl)picolinamide
[0420] At room temperature, phosphorus trichloride (0.011mL, 0.134mmol) was added dropwise to a stirred solution of 4-amino-1-methyl-N-(2-(trifluoromethoxy)benzyl)-1H-pyrazole-3-carboxamide (0.14g, 0.445mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.1g, 0.490mmol) in chlorobenzene (0.8mL). The resulting reaction mixture was heated to 100°C for 6h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (15mL), and the obtained solid was collected by filtration, washed with diethyl ether (5mL) and dried under reduced pressure to obtain a crude product as an off-white solid. The resulting crude product was purified by preparative HPLC to give 4,6-dichloro-5-hydroxy-N-(1-methyl-3-((2-(trifluoromethoxy)benzyl)carbamoyl)-1H-pyrazol-4-yl)picolinamide (0.067 g, 30%) as an off-white solid. LCMS (ES) m / z: Calculated for C19H14Cl2F3N5O4 503.04; Found: 504.1 (M+H). 1H NMR (400 MHz, DMSO d6) δ 11.13 (s, 1H), 8.98 (t, J = 6.0 Hz, 1H), 8.43 (s, 1H), 8.07 (s, 1H), 7.43-7.36 (m, 4H), 4.55 (d, J = 6.0 Hz, 2H), 3.96 (s, 3H).
[0421] Example 5: Synthesis of 4,6-dichloro-5-hydroxy-N-(1-methyl-5-((2-(trifluoromethoxy)benzyl)carbamoyl)-1H-pyrazol-4-yl)picolinamide
[0422] The title compound was synthesized as described above. LCMS (ES) m / z: Calculated for C19H14Cl2F3N5O4 is 503.04; found: 504.1 (M+H). 1H NMR (400 MHz, DMSO d6) δ 11.13 (s, 1H), 8.94 (t, J = 6.0 Hz, 1H), 8.43 (s, 1H), 8.07 (s, 1H), 7.43-7.36 (m, 4H) 4.55 (d, J = 6.0 Hz, 2H), 3.96 (s, 3H).
[0423] Example 6: Synthesis of 3-(3,5-dichloro-4-hydroxybenzamido)-1-methyl-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide
[0424]
[0425] Step 1: Synthesis of 3-(3,5-dichloro-4-methoxybenzamido)-1-methyl-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide
[0426] At 0 ° C, to 3,5-dichloro-4-methoxybenzoic acid (0.22g, 1.01mmol) in a stirred solution of pyridine (2mL), phosphoryl trichloride (0.094mL, 1.01mmol) was added and stirred at room temperature for 10 minutes. Then 3-amino-1-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide (0.3g, 1.01mmol) was added and stirred for 30 minutes. The process of reaction was monitored by TLC and LCMS. The reaction mixture was quenched with ice-cold water and extracted with ethyl acetate (3mL x 2). The combined organic layers were washed with water (2 mL x 2), brine (2 mL x 2), dried over sodium sulfate to give a crude compound, which was purified by flash column chromatography to give 3-(3,5-dichloro-4-methoxybenzamido)-1-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide (0.2 g, 40%) as a white solid. LCMS (ES) m / z: Calculated for C21H17Cl2F3N4O3: 500.06; Found: 501.1 (M+H).
[0427] Step 2: Synthesis of 3-(3,5-dichloro-4-hydroxybenzamido)-1-methyl-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide
[0428] At 0 ° C, to a stirred solution of 3-(3,5-dichloro-4-methoxybenzamido)-1-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide (0.110 g, 0.219 mmol) in dichloromethane (0.5 mL) was added tribromoborane (0.167 mL, 1.76 mmol) in dichloromethane and the reaction was stirred at room temperature for 1 hour. The progress of the reaction was monitored by TLC and LCMS. After the reaction was completed, the reaction mixture was quenched with ice-cold water and then extracted with DCM (3×5 mL). The combined organic layer was washed with water (3 mL x 2), brine (2 mL x 2), dried over sodium sulfate to obtain a crude compound, which was purified by flash column chromatography to obtain an off-white solid. The solid material was further purified by reverse phase preparative HPLC to give pure 3-(3,5-dichloro-4-hydroxybenzamido)-1-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide as a white solid. (31 mg, 29%). LCMS (ES) m / z: Calculated for C20H15Cl2F3N4O3: 486.05; Found: 487.1 (M+H), 1 H NMR (400MHz, DMSO-d6) δ10.98(s,1H),10.51(s,1H),8.51(t,J=5.6Hz,1H),8.22(s,1H),7.83(s,2H),7.70(d,J=7 .6Hz, 1H), 7.61 (t, J = 7.6Hz, 1H), 7.53 (d, J = 7.6Hz, 1H), 7.46 (t, J = 7.6Hz, 1H), 4.58 (d, J = 5.6Hz, 2H), 3.85 (s, 3H).
[0429] Example 7: Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-1-methyl-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide
[0430]
[0431] Step 1: Synthesis of 5-amino-1-methyl-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide
[0432] To a solution of 5-amino-1-methyl-1H-pyrazole-4-carboxylic acid methyl ester (0.4 g, 2.58 mmol) and 1-[2-(trifluoromethyl)phenyl]methylamine (0.358 mL, 2.58 mmol) in toluene (5 mL, 42.3 mmol) was added 2M trimethylaluminum in toluene (0.741 mL, 3 eq., 7.73 mmol) at 0°C. The reaction mixture was then stirred at 120°C for 12 h. The reaction mixture was cooled to ambient temperature and poured into cold water, the solid material obtained was filtered off and the filtrate was extracted with DCM (3 mL x 2). The combined organic phases were washed with water (2 mL x 2), brine (2 mL x 2), dried over sodium sulfate and evaporated under reduced pressure to give 5-amino-1-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide (0.77 g, quantitative). LCMS (ES) m / z: calcd. for C13H13F3N4O: 298.10; found: 299.1 (M+H).
[0433] Step 2: Synthesis of 5-(3,5-dichloro-4-methoxybenzamido)-1-methyl-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide
[0434] To a stirred solution of 3,5-dichloro-4-methoxybenzoic acid (0.0593 g, 0.268 mmol) in pyridine (1 mL) was added phosphoryl trichloride (0.025 mL, 0.268 mmol) at 0 ° C and stirred at room temperature for 10 minutes. To this stirred solution was added 5-amino-1-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide (0.08 g, 0.268 mmol) and stirred for another 30 minutes. The reaction mixture was quenched with ice-cold water and extracted with ethyl acetate (3 mL x 2). The combined organic layers were washed with water (2 mL x 2), brine (2 mL x 2), dried over sodium sulfate to give a crude compound, which was purified by flash column chromatography to give 5-(3,5-dichloro-4-methoxybenzamido)-1-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide (0.11 g, 82%) as a white solid. LCMS (ES) m / z: Calculated for C21H17Cl2F3N4O3: 500.06; Found: 501.0 (M+H).
[0435] Step 3: Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-1-methyl-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide
[0436] To a stirred solution of 5-(3,5-dichloro-4-methoxybenzamido)-1-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide (0.1 g, 0.199 mmol) in dichloromethane (0.556 mL) was added (0.151 mL, 1.6 mmol) at 0 °C and the reaction was stirred at room temperature for 1 h. The progress of the reaction was monitored by TLC and LCMS. After the reaction was complete, the reaction mixture was quenched with ice-cold water and extracted with DCM (3 × 5 mL). The combined organic layers were washed with water (3 mL x 2), brine (2 mL x 2), dried over sodium sulfate to give the crude compound, which was purified by flash column chromatography to give an off-white solid, which was further purified by reverse phase preparative HPLC to give 5-(3,5-dichloro-4-hydroxybenzamido)-1-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole-4-carboxamide (5 mg, 5%) as a white solid. LCMS (ES) m / z: Calculated for C20H15Cl2F3N4O3: 486.05; Found: 487.1 (M+H); 1 H NMR (400MHz, DMSO-d6) δ11.01(s,1H),10.31(bs,1H),8.55(t,J=5.6Hz,1H),8.00(d,J=6.4Hz,3H) ,7.70(d,J=8Hz,1H),7.61(t,J=7.6Hz,1H),7.52-7.43(m,2H),4.57(d,J=5.6Hz,2H),3.65(s,3H).
[0437] Example 8: Synthesis of 4,6-dichloro-5-hydroxy-N-(1-phenyl-4-((2-(trifluoromethyl)benzyl)carbamoyl)-1H-pyrazol-3-yl)picolinamide
[0438]
[0439] Step 1: Synthesis of methyl 3-amino-1-phenyl-1H-pyrazole-4-carboxylate
[0440] To a stirred solution of methyl 3-amino-1H-pyrazole-4-carboxylate (0.3 g, 2.13 mmol) in DMF (10 mL) was added iodobenzene (0.35 mL, 3.19 mmol), cesium carbonate (693 mg, 2.13 mmol) and cupric bromide (30.5 mg, 0.213 mmol) and the reaction mass was heated to 150 °C in MW for 45 min. After completion of the reaction, the reaction mass was quenched with water (20 mL) and extracted with ethyl acetate (20 mL), the organic layer was collected and washed with water (20 mL), brine solution (20 mL), the organic layer was dried over sodium sulphate and filtered and evaporated to get the crude product, which was purified by flash column chromatography to get pure methyl 3-amino-1-phenyl-1H-pyrazole-4-carboxylate (0.3 g, 65%) as off-white solid. LCMS (ES) m / z: calcd. for C11H11N3O2: 217; found: 218 (M+H).
[0441] Step 2: Synthesis of methyl 3-(4,6-dichloro-5-hydroxypicolinamido)-1-phenyl-1H-pyrazole-4-carboxylate
[0442] 4,6-dichloro-5-hydroxypicolinic acid (311mg, 1.5mmol), PCl3(158mg, 1.15mmol) were added to a stirred solution of 3-amino-1-phenyl-1H-pyrazole-4-formic acid methyl ester (250mg, 1.15mmol) in chlorobenzene (5mL) and the reaction mass was heated to 130°C for 4h. After the reaction was completed, the reaction mass was cooled to room temperature and quenched with ice water (10mL), and extracted with ethyl acetate (10mL), and the organic layer was collected and washed with water (10mL) and saline solution (10mL). The organic layer was dried over sodium sulfate and filtered and dried to obtain a crude product, which was purified by flash column chromatography to obtain the title product 3-(4,6-dichloro-5-hydroxypicolinamido)-1-phenyl-1H-pyrazole-4-formic acid methyl ester (250mg, 53%) as an off-white solid. LCMS (ES) m / z: calcd. for C17H12Cl2N4O4: 406; found: 407 (M+H).
[0443] Step 3: Synthesis of 4,6-dichloro-5-hydroxy-N-(1-phenyl-4-((2-(trifluoromethyl)benzyl)carbamoyl)-1H-pyrazol-3-yl)picolinamide
[0444] To a stirred solution of methyl 3-(4,6-dichloro-5-hydroxypicolinamido)-1-phenyl-1H-pyrazole-4-carboxylate (220 mg, 0.540 mmol) in toluene (5 mL) was added (2-(trifluoromethyl)phenyl)methanamine (0.076 mL, 0.540 mmol) and the reaction mass was cooled to 0°C and 2.0 M trimethylaluminum (0.81 mL, 1.62 mmol) in toluene was added and the reaction mass was heated to 100°C for 2 h. The progress of the reaction was monitored by TLC and LCMS, after completion of the reaction, the reaction mass was cooled to room temperature and quenched with ice water (10 mL) and extracted with ethyl acetate (20 mL) and dried over sodium sulphate to get the crude product, which was purified by flash column chromatography, the fractions were collected and dried to get the crude product, which was further purified by preparative HPLC. LCMS (ES) m / z: calcd. for C24H16Cl2F3N5O3: 549.0; found: 550 (M+H). 1 HNMR (400 MHz, DMSO-d 6): δ10.53(s,1H),8.70-8.62(m,1H),8.28(s,1H),7.91(s,1H),7.71(d,J=8.0Hz,1H),7.63-7 .60(m,1H),7.56-7.53(m,3H),7.49-7.45(m,3H),7.40-7.38(m,1H),4.60(d,J=5.2Hz,2H).
[0445] Example 9: Synthesis of 3-(3,5-dichloro-4-hydroxybenzamido)-1-phenyl-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide
[0446] The title compound was synthesized as described above. LCMS (ES): m / z: Calculated for C25H17Cl2F3N4O3: 548.0; found: 549 (M+H). 1 H NMR (400 MHz, DMSO-d 6): δ11.00(bs,1H),10.73(s,1H),9.01(s,1H),8.66(t,J=5.6Hz,1H),7.94(s,2H),7.87-7.80(m,2H),7.73-7.6 8(m,1H),7.64-7.62(m,2H),7.61-7.57(m,2H),7.50-7.47(m,1H),7.40-7.37(m,1H),4.63(d,J=5.2Hz,2H).
[0447] Example 10: Synthesis of 4,6-dichloro-5-hydroxy-N-(1-methyl-4-((2-(trifluoromethyl)benzyl)carbamoyl)-1H-pyrazol-5-yl)picolinamide
[0448]
[0449] Step 1: Synthesis of 5-amino-1-methyl-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide
[0450] At 0 ℃ under nitrogen, to 5-amino-1-methyl-1H-pyrazole-4-methyl-formiate (0.4g, 2.58mmol) and 1-[2-(trifluoromethyl) phenyl] methylamine (0.358mL, 2.58mmol) in toluene (5mL, 42.3mmol) solution in dropwise add trimethylaluminum (0.741mL, 3 equivalents, 7.73mmol) and stir for a while.Then the reaction mixture is stirred for 12h at 120 ℃.The process of reaction is monitored by TLC and LCMS.After the reaction is completed, the reaction mixture is quenched with ice cubes and the formed solid is filtered off.Water layer is extracted with DCM (3mL x 2). The combined organic layers were washed with water (2 mL x 2), brine (2 mL x 2), dried over sodium sulfate and evaporated under reduced pressure to give 5-amino-1-methyl-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide (0.77 g, 2.58 mmol). LCMS (ES) m / z: Calculated for C13H13F3N4O: 298.10; Found: 299.1 (M+H).
[0451] Step 2: Synthesis of 4,6-dichloro-5-hydroxy-N-(1-methyl-4-((2-(trifluoromethyl)benzyl)carbamoyl)-1H-pyrazol-5-yl)picolinamide
[0452] At 0 ° C, PCl3 (0.157 mL, 1.68 mmol) was added to a stirred solution of 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.174 g, 0.838 mmol) in pyridine (2 mL) and stirred at room temperature for 15 min. After 5-amino-1-methyl-N-(2-(trifluoromethyl)benzyl)-1H-pyrazole-4-carboxamide (0.25 g, 0.838 mmol) was added thereto and stirred for 30 min. The progress of the reaction was monitored by TLC and LCMS. After the reaction was completed, the reaction mass was quenched with ice-cold water and extracted with ethyl acetate (5 mL x 2). The combined organic layer was washed with water (3 mL x 2), brine (4 mL x 2), dried over sodium sulfate to obtain a crude compound, which was purified by Combi flash chromatography. The pure fractions were collected and concentrated to obtain the title compound, which was further purified by reverse phase preparative HPLC. The pure fractions were collected and concentrated to give pure 4,6-dichloro-5-hydroxy-N-(1-methyl-4-((2-(trifluoromethyl)benzyl)carbamoyl)-1H-pyrazol-5-yl)picolinamide (0.012 g, 0.0246 mmol) as a white solid. LCMS (ES) m / z: Calcd. for C19H14Cl2F3N5O3: 487.04; Found: 488.00 (M+H), 99.6% at 254 nm. 1 H NMR (400MHz, DMSO-d6) δ10.41 (s, 1H), 8.59-8.57 (m, 1H), 7.99 (d, J = 17.6Hz, 2H), 7.67 ( d,J=8Hz,1H),7.56-7.47(m,1H),7.48-7.42(m,2H),4.54(d,J=4.4Hz,2H),3.66(s,3H).
[0453] Example 11: Synthesis of 3,5-dichloro-4-hydroxy-N-(8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazine-5-yl)benzamide
[0454]
[0455] Step 1: Synthesis of 2-amino-6-bromo-3-methyl-N-(2-(trifluoromethyl)benzyl)benzamide
[0456] 1-[2-(trifluoromethyl)phenyl]methylamine (1.23mL, 8.69mmol), triethylamine (4.24mL, 30.4mmol), HATU (3.97g, 10.4mmol) and N,N-dimethylpyridine-4-amine (0.106g, 0.869mmol) were added to a stirred solution of 2-amino-6-bromo-3-trimethylbenzoic acid (2g, 8.69mmol) in N,N-dimethylformamide (10mL) and stirred at room temperature for 2h. The reaction was monitored by TLC. The reaction mixture was poured into water (40mL) and extracted with ethyl acetate (2x 75mL). The combined organic phases were washed with water, brine and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude material was purified by flash column chromatography to obtain 2-amino-6-bromo-3-methyl-N-(2-(trifluoromethyl)benzyl)benzamide (2g, 59%) as an off-white solid. LCMS (ES): m / z: Calculated for C16H14BrF3N2O: 386.02; found: 387.2.
[0457] Step 2: Synthesis of 5-bromo-8-methyl-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazin-4(3H)-one
[0458] At 0 ° C, sodium nitrite (2.89g, 41.8mmol) was added in batches to a stirred solution of 1M hydrogen chloride (72mL) and stirred for 20min, then 2-amino-6-bromo-3-methyl-N-(2-(trifluoromethyl)benzyl)benzamide (5.4g, 13.9mmol) was added in N,N-dimethylformamide (4mL) at 0 ° C and stirred for 1h. The reaction was monitored by TLC. After adjusting the pH to about 9 with concentrated ammonia, the reaction mixture was stirred for 20 minutes, and then the pH was adjusted to about 2 with concentrated hydrochloric acid, and stirring was continued for an additional 20min. The precipitated solid was filtered and washed with hexane (25mL), dried to obtain 5-bromo-8-methyl-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazine-4(3H)-one (3.4g, 61%) as an orange solid. LCMS (ES): m / z: Calculated for C16H11BrF3N3O: 397.18; found: 398.
[0459] Step 3: Synthesis of tert-butyl (8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazin-5-yl)carbamate
[0460] In a sealed tube, a suspension of 5-bromo-8-methyl-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazine-4(3H)-one (3.4 g, 8.54 mmol), tert-butyl carbamate (1.10 g, 9.39 mmol) and cesium carbonate (8.35 g, 25.6 mmol) in 1,4-dioxane (80 mL, 1.04 mmol) was degassed with nitrogen and Xanthphos (0.49 g, 0.854 mmol) and Pd(dba)2 (0.491 g, 0.854 mmol) were added at room temperature and stirred at 100 °C for 16 h. The progress of the reaction was monitored by LCMS and TLC. After completion, the reaction mixture was quenched with water and the compound was extracted with ethyl acetate. The organic layer was washed with brine solution, dried over anhydrous sodium sulfate, filtered and evaporated under vacuum to obtain a crude solid. The crude product was purified by flash column chromatography to give tert-butyl (8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazin-5-yl)carbamate (2.1 g, 56%) as an off-white solid. LCMS (ES): m / z: Calculated for C21H21F3N4O3: 434.42; Found: 435.1.
[0461] Step 4: Synthesis of 5-amino-8-methyl-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazin-4(3H)-one.
[0462] To a suspension of tert-butyl (8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazine-5-yl)carbamate (2 g, 4.76 mmol) in methanol (3.12 mL, 77.1 mmol) was added 4M HCl (0.826 mL, 23.8 mmol) in dioxane at room temperature. The resulting reaction mixture was stirred at ambient temperature for 16 h. The progress of the reaction was monitored by TLC. The reaction mixture was poured into water (40 mL) and extracted with ethyl acetate (3 x 50 mL). The organic phase was washed with water, brine and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give 5-amino-8-methyl-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazine-4(3H)-one (1.4 g, 92%) as a yellow solid. LCMS (ES): m / z: Calcd. for C16H13F3N4O: 334.30; found: 335.1.
[0463] Step 5: Synthesis of 3,5-dichloro-4-hydroxy-N-(8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazin-5-yl)benzamide
[0464] At ambient temperature, 3,5-dichloro-4-hydroxybenzoic acid (0.238 g, 1.15 mmol) and phosphorus trichloride (0.916 mL, 1.05 mmol) were added to a suspension of 5-amino-8-methyl-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazine-4(3H)-one (0.350 g, 1.05 mmol) in acetonitrile (5 mL). The resulting reaction mixture was heated to 130 ° C for 3 h. The reaction mixture was cooled to ambient temperature and then poured into ice-cold water (20 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phases were washed with water, brine and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by preparative HPLC to give 3,5-dichloro-4-hydroxy-N-(8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazin-5-yl)benzamide (0.010 g, 2%) as a white solid. LCMS (ES): m / z: Calculated for C23H15Cl2F3N4O3: 522.05; Found: 521.1 (MH); 1 H NMR (400MHz, DMSO-d6): δ12.29(s,1H),11.15(bs,1H),8.86(d,J=8.4Hz,1H),8.00(d,J=8.4 Hz, 1H), 7.84-7.80 (m, 3H), 7.62-7.52 (m, 2H), 7.31 (d, J = 8Hz, 1H), 5.78 (s, 2H), 2.72 (s, 3H).
[0465] Example 12: Synthesis of 4,6-dichloro-5-hydroxy-N-(8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazine-5-yl)picolinamide
[0466]
[0467] At ambient temperature, 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.240 g, 1.15 mmol) and phosphorus trichloride (0.09 mL, 1.05 mmol) were added to a suspension of 5-amino-8-methyl-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazine-4(3H)-one (0.35 g, 1.05 mmol) in acetonitrile (5 mL). The resulting reaction mixture was heated to 130 ° C for 3 h. The reaction mixture was cooled to ambient temperature and then poured into ice-cold water (20 mL) and extracted with ethyl acetate (10 mL x3). The combined organic phases were washed with water, brine and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude product was purified by preparative HPLC to give 4,6-dichloro-5-hydroxy-N-(8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazin-5-yl)picolinamide (0.006 g, 1.8%) as a white solid. LCMS (ES): m / z: Calculated for C22H14Cl2F3N5O3: 523.04; Found: 524.1 (M+H); 1 H NMR (400MHz, DMSO-d6): δ13.05(s,1H),9.0(d,J=8.4Hz,1H),8.09(s,1H),7.97(d,J=8.8Hz, 1H),7.82(t,J=7.6Hz,1H),7.61-7.51(m,2H),7.30(d,J=8Hz,1H),5.76(s,2H),2.71(s,3H).
[0468] Example 13: Synthesis of 4,6-dichloro-N-(8-fluoro-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazine-5-yl)-5-hydroxypicolinamide
[0469]
[0470] Step 1: Synthesis of 2-amino-6-bromo-3-fluoro-N-(2-(trifluoromethyl)benzyl)benzamide
[0471] 1-[2-(trifluoromethyl)phenyl]methylamine (0.604mL, 4.27mmol), triethylamine (2.08mL, 15mmol), HATU (1.95g, 5.13mmol), N,N-dimethylpyridine-4-amine (0.052g, 0.427mmol) were added to a stirred solution of 2-amino-6-bromo-3-fluorobenzoic acid (1g, 4.27mmol) in DMF (15mL) and stirred at room temperature for 16h. The reaction was monitored by TLC. The reaction mixture was poured into water (40mL) and extracted with ethyl acetate (150mL). The organic phase was washed with water, brine and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude material was purified by flash column chromatography to obtain 2-amino-6-bromo-3-fluoro-N-(2-(trifluoromethyl)benzyl)benzamide (1.5g, 89.74%) as an off-white solid. LCMS (ES): m / z: Calcd. for C15H11BrF4N2O: 390.0; found: 391.0.
[0472] Step 2: Synthesis of 5-bromo-8-fluoro-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazin-4(3H)-one
[0473] At 0 ° C, 1M HCL solution (25mL) was added dropwise to a stirred solution of sodium nitrite (1.06g, 15.3mmol) and stirred for 20min, then 2-amino-6-bromo-3-fluoro-N-{[2-(trifluoromethyl)phenyl]methyl}benzamide (2g, 5.11mmol) dissolved in DMF (10mL) was added and stirred for 1h at 0 ° C. The reaction was monitored by TLC. The pH was then adjusted to about 9 with concentrated ammonia, stirred for 20 minutes and then adjusted to about 2 with concentrated hydrochloric acid, and continued to stir for 20 minutes. After completing the reaction, suction filtration was performed, the filter cake was washed with a small amount of hexane, and dried to obtain 5-bromo-8-fluoro-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazine-4(3H)-one (0.6g, 29%) as an orange solid. LCMS (ES): m / z: Calculated for C15H8BrF4N3O: 400.98; found: 402.0.
[0474] Step 3: Preparation of tert-butyl (8-fluoro-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazin-5-yl)carbamate
[0475] In a sealed tube, a suspension of 5-bromo-8-fluoro-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazine-4(3H)-one (0.2 g, 0.497 mmol), tert-butyl carbamate (0.117 g, 0.995 mmol) and cesium carbonate (0.486 g, 1.49 mmol) in 1,4-dioxane (5.15 mL, 60.4 mmol) was degassed with nitrogen and Xantphos (0.0288 g, 0.0497 mmol), Pd(dba)2 (0.0286 g, 0.0497 mmol) were added at room temperature and stirred at 100 °C for 16 h. The progress of the reaction was monitored by LCMS and TLC. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with water (10 mL), brine (3 ml) and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude material was purified by flash column chromatography to give tert-butyl (8-fluoro-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazin-5-yl)carbamate (0.130 g, 59.6%) as a colorless liquid. LCMS (ES): m / z: Calculated for C20H18F4N4O3: 438.34; Found: 439.1.
[0476] Step 4: Synthesis of 5-amino-8-fluoro-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazine-4(3H)-one
[0477] To a suspension of tert-butyl (8-fluoro-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazine-5-yl)carbamate (0.130 g, 0.297 mmol) in methanol (5 ml) was added 4M HCl in dioxane (0.0515 mL, 1.48 mmol) and stirred at room temperature for 16 h. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with water (10 mL), brine (5 ml) and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude material was purified by flash column chromatography to give 5-amino-8-fluoro-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazine-4(3H)-one (0.095 g, 94%). LCMS (ES): m / z: Calcd. for C15H10F4N4O: 338.27; found: 339.1.
[0478] Step 5: Synthesis of 4,6-dichloro-5-hydroxy-N-(8-methyl-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazin-5-yl)picolinamide
[0479] 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.0879 g, 0.423 mmol) and phosphorus trichloride (33.6 μL, 0.384 mmol) were added to a suspension of 5-amino-8-fluoro-3-(2-(trifluoromethyl)benzyl)benzo[d][1,2,3]triazine-4(3H)-one (0.130 g, 0.384 mmol) in acetonitrile (5 ml) and stirred at 120 ° C for 3 h. The reaction was monitored by TLC. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (10 mL x 3). The organic phase was washed with water (10 mL), brine (5 ml) and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude material was purified by preparative HPLC. The pure fractions were collected and concentrated to give 4,6-dichloro-N-(8-fluoro-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazin-5-yl)-5-hydroxypicolinamide (0.007 g, 3.45%) as a white solid. 1 H NMR (400 MHz, DMSO-d 6): δ12.90 (s, 1H), 9.14-9.10 (m, 1H), 8.10-8.04 (m, 2H), 7.86 (d, J = 7.6 Hz, 1H), 7.64-7.54 (m, 2H), 7.38 (d, J = 8 Hz, 1H), 5.80 (s, 2H). LCMS (ES) m / z: calculated for C21H11Cl2F4N5O3: 527.02; found: 528.1 (M+H).
[0480] Example 14: Synthesis of 3,5-dichloro-N-(8-fluoro-4-oxo-3-(2-(trifluoromethyl)benzyl)-3,4-dihydrobenzo[d][1,2,3]triazine-5-yl)-4-hydroxybenzamide
[0481] The title compound was synthesized as described above. LCMS (ES) m / z: Calcd. for C22H12Cl2F4N4O3: 526.02; Found: 527.0 (M+H); 1H NMR (400MHz, DMSO-d6) δ12.03(s,1H),11.22(s,1H),8.90(d,J=9.2Hz,1H),8.07(t,J =9.6Hz,1H),7.85-7.81(m,3H),7.61-7.51(m,2H),7.36(d,J=8Hz,1H),5.78(s,2H).
[0482] Example 15: Synthesis of 4,6-dichloro-N-(8-fluoro-2-methyl-4-oxo-3-((1S,2R)-2-phenylcyclobutyl)-3,4-dihydroquinazolin-5-yl)-5-hydroxypicolinamide
[0483]
[0484] Step 1: Synthesis of 2-amino-6-bromo-3-fluoro-N-((1S,2R)-2-phenylcyclobutyl)benzamide
[0485] At room temperature, triethylamine (0.89mL, 6.41mmol), HATU (0.75g, 3.2mmol) and (1S, 2R)-2-phenylcyclobutyl-1-amine (315mg, 2.14mmol) were added to a stirred solution of 2-amino-6-bromo-3-fluorobenzoic acid (0.5g, 2.14mmol) in tetrahydrofuran (5mL). The resulting reaction mixture was stirred at room temperature for 2h. The reaction mixture was poured into water (25mL) and extracted into ethyl acetate (2x 50mL). The combined organic matter was washed with water (10mL) and brine solution (10mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude product, which was purified by flash column chromatography to obtain 2-amino-6-bromo-3-fluoro-N-((1S, 2R)-2-phenylcyclobutyl) benzamide (0.62g, 80%) as an off-white solid. LCMS (ES) m / z: calcd for C17H16BrFN2O: 362.04; found: 363.0 (M+2H).
[0486] Step 2: Synthesis of 5-bromo-8-fluoro-2-methyl-3-((1S,2R)-2-phenylcyclobutyl)quinazolin-4(3H)-one
[0487] At room temperature, p-TSA (58.7 mg, 0.341 mmol) and pentane-2,4-dione (0.192 mL, 1.87 mmol) were added to a stirred solution of 2-amino-6-bromo-3-fluoro-N-[(1S, 2R)-2-phenylcyclobutyl]benzamide (619 mg, 1.7 mmol) in toluene (6 mL). The resulting reaction mixture was heated to 120 ° C in a sealed tube for 16 hours. After completion, the reaction mixture was quenched with water (25 mL) and extracted into ethyl acetate (2 x 50 mL). The combined organics were washed with water (20 mL) and brine solution (20 mL), dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure vacuum to give a crude product 5-bromo-8-fluoro-2-methyl-3-((1S, 2R)-2-phenylcyclobutyl)quinazoline-4(3H)-one (0.62 g, 94%) as a brown solid. LCMS (ES) m / z: calcd for C19H16BrFN2O: 387.05; found: 389.1 (M+2H).
[0488] Step 3: Synthesis of tert-butyl (8-fluoro-2-methyl-4-oxo-3-((1S,2R)-2-phenylcyclobutyl)-3,4-dihydroquinazolin-5-yl)carbamate
[0489] To a stirred solution of 5-bromo-8-fluoro-2-methyl-3-[(1S,2R)-2-phenylcyclobutyl]-3,4-dihydroquinazolin-4-one (0.5 g, 1.29 mmol) in 1,4-dioxane (3 mL) was added tert-butyl carbamate (454 mg, 3.87 mmol) and cesium carbonate (1.26 g, 3.87 mmol). The mixture was purged with N2 for 10 min, then Xanthphos (0.15 g, 0.258 mmol) and Pd(dba)2 (74.2 mg, 0.129 mmol) were added and heated to 100°C for 16 hours. The reaction mixture was filtered through a pad of celite, washed with ethyl acetate (30 mL), and the filtrate was evaporated to give a crude product, which was purified by flash column chromatography to give tert-butyl (8-fluoro-2-methyl-4-oxo-3-((1S,2R)-2-phenylcyclobutyl)-3,4-dihydroquinazolin-5-yl)carbamate (0.33 g, 60%) as an off-white solid. LCMS (ES) m / z: Calculated for C24H26FN3O3: 423.20; Found: 424.2 (M+H).
[0490] Step 4: Synthesis of 5-amino-8-fluoro-2-methyl-3-((1S,2R)-2-phenylcyclobutyl)quinazolin-4(3H)-one
[0491] 4M HCl (1.95 mL) in dioxane was added to solid N-{8-fluoro-2-methyl-4-oxo-3-[(1S, 2R)-2-phenylcyclobutyl]-3,4-dihydroquinazolin-5-yl}carbamic acid tert-butyl ester (0.33 g, 0.779 mmol) at 0 ° C under nitrogen atmosphere. The reaction mixture was heated to 80 ° C for 2 hours. After completion, the reaction mixture was evaporated to dryness under reduced pressure to give a solid, which was further ground with n-pentane (20 mL) and dried to give 5-amino-8-fluoro-2-methyl-3-((1S, 2R)-2-phenylcyclobutyl)quinazolin-4(3H)-one (0.2 g, 79%) as a white solid. LCMS (ES) m / z: calculated for C19H18FN3O: 323.14; found: 324.1 (M+H).
[0492] Step 5: Synthesis of 4,6-dichloro-N-(8-fluoro-2-methyl-4-oxo-3-((1S,2R)-2-phenylcyclobutyl)-3,4-dihydroquinazolin-5-yl)-5-hydroxypicolinamide
[0493] To a stirred solution of hydroxypyridine 5-amino-8-fluoro-2-methyl-3-[(1S, 2R)-2-phenylcyclobutyl]-3,4-dihydroquinazoline-4-one (150 mg, 0.464 mmol) in acetonitrile (2 mL) was added 4,6-dichloro-5--2-carboxylic acid (0.092 g, 0.18 mmol) and phosphorus trichloride (0.041 mL, 0.464 mmol). In a sealed tube, the resulting reaction mixture was heated at 100 ° C for 3 hours. After completion, the reaction mixture was quenched with ice-cold water (15 mL) and stirred for 5 minutes, and the obtained solid was collected by filtration. The solid material was washed with n-pentane (10 mL) and acetonitrile (10 mL), dried under reduced pressure to give 4,6-dichloro-N-(8-fluoro-2-methyl-4-oxo-3-((1S,2R)-2-phenylcyclobutyl)-3,4-dihydroquinazolin-5-yl)-5-hydroxypicolinamide (0.092 g, 39%) as an off-white solid. LCMS (ES) m / z: Calculated for C25H19Cl2FN4O3: 512.08; Found: 513.1 (M+H). HNMR(400MHz,DMSO-d6)δ13.54(s,1H),8.72-8.68(m,2H),8.12(s,1H),7.70-7.65(m,1H),7.35-7.28(m,4H) ,7.22-7.19(m,1H),4.95-4.90(m,1H),4.81-4.76(m,1H),2.40(s,3H),2.36-2.25(m,2H),2.01-1.96(m,2H).
[0494] Example 16: Synthesis of 3,5-dichloro-N-(8-fluoro-2-methyl-4-oxo-3-((1S,2R)-2-phenylcyclobutyl)-3,4-dihydroquinazolin-5-yl)-4-hydroxybenzamide
[0495]
[0496] Phosphorus trichloride (0.024mL, 0.278mmol) was added to a stirred solution of 5-amino-8-fluoro-2-methyl-3-[(1S, 2R)-2-phenylcyclobutyl]-3,4-dihydroquinazoline-4-one (90mg, 0.278mmol) and 3,5-dichloro-4-hydroxybenzoic acid (69.1mg, 0.334mmol) in chlorobenzene (3.0mL) at 0°C under a nitrogen atmosphere. The resulting reaction mass was heated to 130°C for 12 hours. The reaction mixture was quenched with ice-cold water (10mL) and stirred for 5 minutes, and the obtained solid was collected by filtration. The solid was washed with n-pentane (10ml) and dried under reduced pressure vacuum to obtain a crude product as a light yellow solid. The crude material was purified by preparative HPLC to give 3,5-dichloro-N-(8-fluoro-2-methyl-4-oxo-3-((1S,2R)-2-phenylcyclobutyl)-3,4-dihydroquinazolin-5-yl)-4-hydroxybenzamide (0.030 g, 21%) as an off-white solid. LCMS (ES) m / z: Calculated for C26H20Cl2FN3O3: 511.09; Found: 512.1 (M+H). HNMR(400MHz,DMSO-d6)δ12.73(s,1H),11.17(s,1H),8.56-8.53(m,1H),7.93(s,2H),7.70-7.65(m,1H),7.34-7.18 (m,5H),4.97-4.93(m,1H),4.76-4.69(m,1H),3.25-3.15(m,2H),2.42(s,3H),2.38-2.25(m,2H),1.99-1.94(m,1H).
[0497] Example 17: Preparation of 3,5-dichloro-N-(2,8-dimethyl-4-oxo-3-(2-(2-(trifluoromethyl)phenyl)cyclobutyl)-3,4-dihydroquinazolin-5-yl)-4-hydroxybenzamide
[0498]
[0499] Step 1: Preparation of 1-(cyclopropylidenemethyl)-2-(trifluoromethyl)benzene
[0500] To a stirred solution of 2-(trifluoromethyl)benzaldehyde (10 g, 57.4 mmol) (1) in tetrahydrofuran (150 mL) was added (3-bromopropyl)triphenylphosphonium bromide (29.3 g, 63.2 mmol), followed by potassium tert-butoxide (19.3 g, 172 mmol) and then stirred at 70 °C for 2 h. The reaction mixture was cooled to ambient temperature and poured into cold water (50 mL) and extracted with ethyl acetate (3 x 45 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated to give a crude product. The crude product was purified by flash column chromatography to give 1-(cyclopropylidenemethyl)-2-(trifluoromethyl)benzene (2.5 g, 22%) as a slightly yellow oil. 1HNMR (400MHz, CDCl3): δ7.96 (d, J=8.0Hz, 1H), 7.63 (d, J=8.0Hz, 1H), 7.48 (t, J=7.6Hz, 1H), 7.32-7.25 (m, 1H), 7.12 (s, 1H), 1.2-1.5 (m, 4H).
[0501] Step 2: Synthesis of 2-(2-(trifluoromethyl)phenyl)cyclobutan-1-one
[0502] At 0 ° C, m-CPBA (1.25 g, 7.27 mmol) was added to a stirred solution of 1- (cyclopropylidene methyl) -2- (trifluoromethyl) benzene (1.2 g, 6.05 mmol) in dichloromethane (10 mL). After completion of the addition, the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with cold water (25 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic layer was washed with saturated sodium bicarbonate aqueous solution (25 mL), dried over sodium sulfate, filtered and concentrated to give a crude product. The crude product was purified by flash column chromatography to obtain 2- (2- (trifluoromethyl) phenyl) cyclobutane-1-one (0.5 g, yield: 39%) as a slightly yellow oil. 1H NMR (400MHz, CDCl3): δ7.67(d,J=8.0Hz,1H),7.43-7.58(m,2H),7.38(t,J=7.6Hz,1H),4.9 0(t,J=8.8Hz,1H),3.25-3.4(m,1H),3.12-3.18(m,1H),2.6-2.7(m,1H),2.08-2.2(m,1H).
[0503] Step 3: Synthesis of 2-(2-(trifluoromethyl)phenyl)cyclobutan-1-one oxime
[0504] To a stirred solution of 2-(2-(trifluoromethyl)phenyl)cyclobutan-1-one (4) (0.365 g, 1.7 mmol) in ethanol (10 mL) was added hydroxylamine hydrochloride (0.355 g, 5.11 mmol) and potassium carbonate (0.707 g, 5.11 mmol). The resulting reaction mixture was stirred at room temperature for 16 h. The reaction mixture was quenched with cold water (30 mL) and extracted with ethyl acetate (3 x 25 mL), the combined organic layers were dried over sodium sulfate, filtered and concentrated to give 2-(2-(trifluoromethyl)phenyl)cyclobutan-1-one oxime (0.4 g, yield: 102%) as a crude yellow solid. LCMS (ES) m / z: Calculated for C11H10F3NO: 229.07; Found: 230.1 (M+H);
[0505] Step 4: Synthesis of 2-(2-(trifluoromethyl)phenyl)cyclobutane-1-amine
[0506] To a stirred solution of 2-(2-(trifluoromethyl)phenyl)cyclobutan-1-one oxime (0.4 g, 1.75 mmol) in THF:MeOH (4:1) (12 mL) at 0°C under inert atmosphere was added nickel chloride hexahydrate (0.083 mg, 0.349 mmol) followed by sodium borohydride (0.330 mg, 8.73 mmol) in portions and after complete addition the reaction was stirred at ambient temperature for 1 h. The reaction mixture was quenched with cold water (30 mL) and extracted with ethyl acetate (3 x 25 mL), the combined organic layers were dried over sodium sulfate, filtered and concentrated to give 2-(2-(trifluoromethyl)phenyl)cyclobutan-1-amine (6) (0.215 g, 57%) as a yellow sticky solid. LCMS (ES) m / z: Calculated for C11H12F3N: 215.09; Found: 216.1 (M+H).
[0507] Step 5: Synthesis of 2-amino-6-bromo-3-methyl-N-(2-(2-(trifluoromethyl)phenyl)cyclobutyl)benzamide
[0508] To a stirred solution of 2-amino-6-bromo-3-trimethylbenzoic acid (7) (0.2 g, 0.869 mmol) in N,N-dimethylformamide (5 mL) was added triethylamine (0.422 mL, 3.04 mmol) followed by HATU (0.661 g, 1.74 mmol) at 0°C under inert atmosphere and stirred for 5 min, then to this solution was added 2-(2-(trifluoromethyl)phenyl)cyclobutan-1-amine (6) (0.187 g, 0.869 mmol) and then stirred at room temperature for 16 h. The reaction mixture was quenched with cold water (30 mL) and extracted with ethyl acetate (3 x 25 mL), the combined organic layers were dried over sodium sulfate, filtered and concentrated to give the crude product. The crude product was purified by flash column chromatography to give 2-amino-6-bromo-3-methyl-N-(2-(2-(trifluoromethyl)phenyl)cyclobutyl)benzamide (0.1 g, 26.92%) as a yellow sticky solid. LCMS (ES) m / z: Calcd. for C19H18BrF3N2O: 426.06; Found: 427.0 (M+H).
[0509] Step 6: Synthesis of 5-bromo-2,8-dimethyl-3-(2-(2-(trifluoromethyl)phenyl)cyclobutyl)quinazolin-4(3H)-one
[0510] To a stirred solution of 2-amino-6-bromo-3-methyl-N-(2-(2-(trifluoromethyl)phenyl)cyclobutyl)benzamide (0.090 g, 0.211 mmol) in toluene (1 mL) was added pentane-2,4-dione (0.031 g, 0.316 mmol) and p-TSA (0.008 g, 0.042 mmol). The resulting reaction mixture was stirred at 100 ° C for 1 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was dissolved in ethyl acetate (25 mL) and washed with saturated sodium bicarbonate solution (15 mL), water (15 mL), and the organic layer was then dried over sodium sulfate, filtered and concentrated to give a crude product 5-bromo-2,8-dimethyl-3-(2-(2-(trifluoromethyl)phenyl)cyclobutyl)quinazoline-4(3H)-one (0.090 g, yield: 95%) as a yellow sticky solid. LCMS (ES) m / z: calcd. for C21H18BrF3N2O: 450.06; found: 451.1 (M+H).
[0511] Step 7: Preparation of 3,5-dichloro-N-(2,8-dimethyl-4-oxo-3-(2-(2-(trifluoromethyl)phenyl)cyclobutyl)-3,4-dihydroquinazolin-5-yl)-4-hydroxybenzamide
[0512] To a stirred solution of 5-bromo-2,8-dimethyl-3-(2-(2-(trifluoromethyl)phenyl)cyclobutyl)quinazolin-4(3H)-one (9) (0.075 g, 0.166 mmol) in 1,4-dioxane (7.5 mL) was added 3,5-dichloro-4-hydroxybenzamide (10) (0.034 mg, 0.166 mmol) and potassium tert-butoxide (0.056 g, 0.499 mmol), the reaction mixture was degassed using argon for 10 min, then to this solution was added Xantphos (0.0192 g, 0.033 mmol) and bis(dibenzylideneacetone)palladium(0) (0.0191 g, 0.033 mmol) at room temperature. The resulting reaction mixture was heated to 100°C for 1 h, the reaction mixture was cooled to room temperature and ice-cold water (15 mL) was added thereto and extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated to give the crude product. The crude product was purified by flash column chromatography to give 3,5-dichloro-N-(2,8-dimethyl-4-oxo-3-(2-(2-(trifluoromethyl)phenyl)cyclobutyl)-3,4-dihydroquinazolin-5-yl)-4-hydroxybenzamide (0.008 g, 8%) as an off-white solid. LCMS (ES) m / z: Calculated for C28H22Cl2F3N3O3: 575.10; Found: 576.2 (M+H); 1H NMR(400MHz,DMSO-d6)δ12.41(s,1H),11.1(s,1H),8.36(d,J=8.4Hz,1H),7.65- 7.8(m,2H),7.53(dJ=8.4Hz,1H),7.37(d,J=8.0Hz,2H),7.26(t,J=7.2Hz,1H),7 .16(t,J=7.6Hz,1H),5.41-5.45(m,1H),4.60-4.64(m,1H),3.0-3.10(m,1H),2. 65-2.8(m,1H),2.57(s,3H),2.37(s,3H),1.2-1.3(m,1H),1.15(t,J=7.2Hz,1H).
[0513] Example 18: Synthesis of 4,6-dichloro-N-(1-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazolin-5-yl)-5-hydroxypicolinamide
[0514]
[0515] Step 1: Synthesis of 5-bromo-3-{[2-(trifluoromethyl)phenyl]methyl}-1,2,3,4-tetrahydroquinazoline-2,4-dione
[0516] To a solution of 5-bromo-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (5 g, 20.7 mmol) in THF (40 mL) was added (2-(trifluoromethyl)phenyl)methanamine (3.62 g, 20.7 mmol) and triethylamine (6.7 mL, 2.5 eq., 51.6 mmol) at ambient temperature. The resulting reaction mixture was heated to 80 °C for 1 h, cooled to room temperature and diluted with ethyl acetate (50 mL) and water (30 mL) and extracted into ethyl acetate. The organic layer was dried over Na2SO4 and concentrated to obtain a brown oil. The viscous compound was dissolved in THF (10 mL) cooled to 0 °C and triphosgene (3.07 g, 0.5 eq., 10.3 mmol) was then added and stirred at ambient temperature for 30 min, then triethylamine was added to the stirred solution and stirring was continued for additional 2 h, the solid material was removed from the reaction mixture by filtration. The filtrate was concentrated and dried to give a brown solid, which was triturated with diethyl ether (10 mL) to give 5-bromo-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione (5 g, 60% yield) as an off-white solid. LCMS (ES) m / z: Calculated for C16H10BrF3N2O2: 397.99; Found: 399.0. Step 2: Synthesis of 5-bromo-1-ethyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione
[0517] Potassium carbonate (0.26 g, 1.88 mmol), potassium iodide (0.05 g, 0.301 mmol) and bromoethane (0.13 g, 1.25 mmol) were added to a solution of 5-bromo-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione (0.5 g, 1.25 mmol) in 5 mL of dimethylformamide. The resulting reaction mixture was heated at 120 ° C for 16 h, cooled to room temperature and diluted with ethyl acetate (30 mL) and water (20 mL) and extracted into ethyl acetate (2 x 20 mL). The organic layer was dried over Na2SO4 and concentrated to obtain a residue, which was triturated with diethyl ether (20 mL) to obtain pure 5-bromo-1-ethyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione (0.5 g, 93%) as an off-white solid. LCMS (ES) m / z: Calcd. for C18H14BrF3N2O2: 426.0; found: 427.0.
[0518] Step 3: Synthesis of tert-butyl (1-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazolin-5-yl)carbamate
[0519] A stirred solution of 5-bromo-1-ethyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione (1 g, 2.34 mmol) and tert-butyl carbamate (0.27 g, 2.34 mmol) in 1,4-dioxane (5 mL) and cesium carbonate (1.53 g, 4.68 mmol) was degassed with nitrogen for 10 min, and then Pd(dba)2 (0.067 g, 0.117 mmol) and Xanthphos (0.13 g, 0.234 mmol) were added. The resulting reaction mixture was stirred at 100 ° C for 5 h. The progress of the reaction was monitored by LCMS. After the reaction was completed, the reaction mixture was filtered through celite and the filtrate was diluted with ethyl acetate (50 mL), washed with water (30 mL) and the organic layer was dried over Na2SO4 and concentrated to give a residue, which was triturated with diethyl ether (20 mL) to give pure tert-butyl (1-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazolin-5-yl)carbamate (0.6 g, 55%). LCMS (ES) m / z: Calculated for C23H24F3N3O4: 463.17; Found: 364.1 (M-Boc).
[0520] Step 4: Synthesis of 5-amino-1-ethyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione
[0521] A stirred solution of tert-butyl (1-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazoline-5-yl)carbamate (0.6 g, 1.29 mmol) in dichloromethane (5 mL) was cooled to 0 ° C and HCl (5 mL) in dioxane was added, and the reaction was stirred at ambient temperature for 2 h. The progress of the reaction was monitored by TLC / LCMS. After the reaction was complete, the reaction mixture was concentrated and triturated with diethyl ether (10 mL) to give pure 5-amino-1-ethyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione (450 mg, 95% yield) as an off-white solid. LCMS (ES) m / z: Calculated for C18H16F3N3O2: 363.2; Found: 364.1 (M+H).
[0522] Step 5: Synthesis of 4,6-dichloro-N-(1-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazolin-5-yl)-5-hydroxypicolinamide
[0523] To 5-amino-1-ethyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione (0.2g, 0.55mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.11g, 0.55mmol) in chlorobenzene (2mL) solution, add PCl3(0.075g, 0.550mmol). The reaction mixture is heated at 120°C for 3h. The progress of the reaction is monitored by TLC / LCMS. After the reaction is complete, the reaction mixture is diluted with ethyl acetate (10mL) and washed with water (10mL x 2), aqueous bicarbonate solution (10mL) and the combined organic layer is concentrated to obtain residue, which is purified by reverse phase preparative HPLC. The pure fractions were collected and concentrated to give 4,6-dichloro-N-(1-ethyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazolin-5-yl)-5-hydroxypicolinamide (54 mg, 18% yield) as a white solid. LCMS (ES) m / z: Calculated for C24H17Cl2F3N4O4: 553.36; Found: 553.1 (M+H). 1 H NMR (400MHz, DMSO-d6) δ13.54(s,1H),8.64(d,J=8Hz,1H),8.08(s,1H),7.82-7.7.5(m,2H),7.53(t,J=7.6Hz,1H),7. 45(t,J=8Hz,1H),7.30-7.22(m,1H),7.21(d,J=9.2Hz,1H),5.33(s,2H),4.17(q,J=6.8Hz,2H),1.23(t,J=6.8Hz,3H).
[0524] Example 19: Synthesis of 4,6-dichloro-N-(8-fluoro-1-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazolin-5-yl)-5-hydroxypicolinamide
[0525]
[0526] Step 1: Synthesis of 5-bromo-8-fluoro-2H-benzo[d][1,3]oxazine-2,4(1H)-dione
[0527] To a stirred solution of 2-amino-6-bromo-3-fluorobenzoic acid (0.5 g, 2.14 mmol) in THF (6 mL) was added triphosgene (0.63 g, 2.14 mmol) over 30 min at -10 °C, then stirred at -10 to -5 °C for 1 h, then stirred at room temperature for 16 h. Upon completion, the reaction mixture was evaporated under reduced pressure vacuum to give a residue, to which diethyl ether (3 x 50 mL) was added and stirred for 5 min, the obtained solid was collected by filtration, the solid was triturated with diethyl ether (25 mL) and evaporated to dryness to give 5-bromo-8-fluoro-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (0.4 g, 72%) as a light yellow solid. LCMS (ES) m / z: Calculated for CHBrFNO: 258.93; Found: 259.9 (M+H).
[0528] Step 2: Synthesis of 5-bromo-8-fluoro-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione
[0529] 1-[2-(trifluoromethyl)phenyl]methylamine (0.21mL, 1.54mmol) and triethylamine (0.24mL) were added dropwise to a solution of 5-bromo-8-fluoro-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (0.4g, 1.54mmol) in tetrahydrofuran (10mL). The reaction mixture was heated at 80°C for 2h. After completion, the reaction mixture was cooled to room temperature and quenched with water (50mL) and extracted into ethyl acetate (3x50 mL). The combined organic matter was washed with water (10mL) and brine solution (10mL), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a brown oil. The oil was dissolved in tetrahydrofuran (10mL) cooled to 0°C, and triphosgene (0.22g, 0.76mmol) was then added. The reaction mixture was stirred at room temperature for 30min, and triethylamine (0.24mL) was then added. The reaction mixture was stirred at room temperature for 2 h and filtered. The filtrate was concentrated and dried to give 5-bromo-8-fluoro-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione (0.6 g, 93.5%) as a yellow solid. LCMS (ES) m / z: calculated for C16H9BrF4N2O2: 415.98; found: 417.0 (M+H).
[0530] Step 3: Synthesis of 5-bromo-8-fluoro-1-methyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione
[0531] To a stirred solution of 5-bromo-8-fluoro-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione (0.7g, 1.68mmol) in N,N-dimethylformamide (7mL), potassium carbonate (0.69g, 5.03mmol) was added and stirred at room temperature for 15min. Then iodomethane (0.15mL, 2.52mmol) was added to the reaction mixture and stirred at room temperature for 1h. After completion, water (25mL) was added and extracted with ethyl acetate (3x 25mL). The combined organic matter was washed with saline solution (15mL) and dried over anhydrous sodium sulfate, filtered and dried under reduced pressure vacuum to obtain 5-bromo-8-fluoro-1-methyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione 5 (0.5g, 69.1%) as an off-white solid. LCMS (ES) m / z: calcd. for C17H11BrF4N2O2: 431.2; found: 432.0 (M+H).
[0532] Step 4: Synthesis of tert-butyl (8-fluoro-1-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazolin-5-yl)carbamate
[0533] To a stirred solution of 5-bromo-8-fluoro-1-methyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione (0.2 g, 0.464 mmol) and tert-butyl carbamate (0.16 g, 1.39 mmol) in 1,4-dioxane (3 mL) was added cesium carbonate (0.45 g, 1.39 mmol). The reaction mixture was degassed with nitrogen and Xantphos (0.053 g, 0.92 mmol) and Pd(dba)2 (0.026 g, 0.46 mmol) were added. The reaction mixture was heated to 100 °C for 12 h. The reaction mixture was filtered through a pad of celite, washed with ethyl acetate (2 x 50 mL), and the filtrate was evaporated under reduced pressure to give tert-butyl (8-fluoro-1-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazolin-5-yl)carbamate (0.5 g, 92%) as an off-white solid. LCMS (ES) m / z: Calculated for C22H21F4N3O4: 467.15; Found: 368.1 (M-BocH).
[0534] Step 5: Synthesis of 5-amino-8-fluoro-1-methyl-3-(2(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione
[0535] To a stirred solution of tert-butyl (8-fluoro-1-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazolin-5-yl)carbamate (0.5 g, 1.07 mmol) in 1,4-dioxane was added 4M HCl (5 mL) in 1,4-dioxane and then stirred at the same temperature for 16 h at room temperature. After the reaction was complete, the reaction mixture was evaporated under reduced pressure to give a yellow solid, which was triturated with diethyl ether (25 mL) and evaporated to dryness to give 5-amino-8-fluoro-1-methyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione (0.3 g, 76%) as a light yellow solid. LCMS (ES) m / z: calcd. for C17H13F4N3O2: 367.09; found: 368.1 (M+H).
[0536] Step 6: Synthesis of 4,6-dichloro-N-(8-fluoro-1-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazolin-5-yl)-5-hydroxypicolinamide
[0537] At 0 ° C under nitrogen atmosphere, to 5-amino-8-fluoro-1-methyl-3-(2-(trifluoromethyl)benzyl)quinazoline-2,4(1H,3H)-dione (0.15g, 0.408mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.084mg, 0.40mmol) in a stirred solution of chlorobenzene (2mL) trichlorophosphine (0.025mL, 0.286mmol) was added and heated to 130 ° C for 3h. After completion, the reaction mass was quenched with ice-cold water (15mL) and stirred for 5min, and the obtained solid was collected by filtration, washed with diethyl ether (2x15 mL) and dried under reduced pressure vacuum to obtain a crude product as a yellow solid. The crude solid material was purified by preparative purification. The collected fractions were lyophilized to give 4,6-dichloro-N-(8-fluoro-1-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazolin-5-yl)-5-hydroxypicolinamide (0.045 g, 20%) as an off-white solid. LCMS (ES) m / z: calculated for C23H14Cl2F4N4O4: 556.03; found: 555.1 (MH); 1H NMR (400 MHz, DMSO-d6) δ13.42 (s, 1H), 8.65-8.61 (m, 1H), 8.07 (s, 1H), 7.77-7.72 (m, 2H), 7.56-7.52 (m, 1H), 7.48-7.44 (m, 1H), 7.31-7.29 (m, 1H), 5.31 (s, 2H), 3.68 (d, J=9.2 Hz, 3H).
[0538] Example 20: Synthesis of 4,6-dichloro-5-hydroxy-N-(1-methyl-2,4-dioxo-3-(2-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroquinazolin-5-yl)picolinamide
[0539] The title compound was synthesized as described above. LCMS (ES) m / z: Calcd. for C23H15Cl2F3N4O4: 538.04; found: 539.1 (M+H). 1 H NMR (400MHz, DMSO-d6) δ13.52 (s, 1H), 8.65 (d, J = 8.4Hz, 1H), 8.08 (s, 1H), 7.83 -7.75(m,2H),7.55-7.40(m,2H),7.25-7.22(m,2H),5.33(s,2H),3.54(s,3H).
[0540] Example 21: Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-2-methyl-N-(2-(trifluoromethoxy)benzyl)thiazole-4-carboxamide
[0541]
[0542] Step 1: Synthesis of 5-amino-2-methyl-N-(2-(trifluoromethoxy)benzyl)thiazole-4-carboxamide
[0543] At ambient temperature, HATU (2.4 g, 6.32 mmol), triethylamine (2.2 mL, 15.8 mmol) and (2- (trifluoromethoxy) phenyl) methylamine (0.6 g, 3.16 mmol) were added to a stirred solution of 5-amino-2-methylthiazole-4-carboxylic acid (0.5 g, 3.16 mmol) in tetrahydrofuran (5 mL). The resulting reaction mixture was stirred for 16 h at ambient temperature. The progress of the reaction was monitored by TLC / LCMS. After the reaction was complete, the reaction mixture was quenched with ice-cold water (20 mL) and extracted with ethyl acetate (3x10 ml). The combined organic layer was washed with water (10 mL), brine (10 mL), dried over sodium sulfate and evaporated under reduced pressure to produce a crude compound, which was purified by flash column chromatography to obtain 5-amino-2-methyl-N-(2- (trifluoromethoxy) benzyl) thiazole-4-carboxamide (0.88 g, 84%) as a yellow liquid. LCMS (ES) m / z: Calcd. for C13H12F3N3O2S: 331.0; found: 332.1 (M+1).
[0544] Step 2: Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-2-methyl-N-(2-(trifluoromethoxy)benzyl)thiazole-4-carboxamide
[0545] Phosphorus trichloride (52.8 μL, 0.604mmol) and 3,5-dichloro-4-hydroxybenzoic acid (275mg, 1.33mmol) were added to a stirred solution of 5-amino-2-methyl-N-(2-(trifluoromethoxy)benzyl)thiazole-4-carboxamide (0.4g, 1.21mmol) in chlorobenzene (5mL) and stirred for 2h at 130°C. The progress of the reaction was monitored by TLC / LCMS. After the reaction was completed, the reaction mixture was quenched with ice-cold water (20mL) and filtered to produce a crude compound, which was purified by flash column chromatography to obtain an off-white solid. The solid was further ground with hot methanol (10mL) to obtain 5-(3,5-dichloro-4-hydroxybenzamido)-2-methyl-N-(2-(trifluoromethoxy)benzyl)thiazole-4-carboxamide (0.05g, 8%) as a white solid. LCMS (ES) m / z: calculated for C20H14Cl2F3N3O4S: 519.0; found: 520.1 (M+1). 1H NMR (400 MHz, DMSO d6) δ 12.31 (s, 1H), 11.32 (s, 1H), 9.11 (t, J = 8.0 Hz, 1H), 7.82 (s, 2H), 7.45–7.35 (m, 4H), 4.59 (d, J = 4.0 Hz, 2H), 2.65 (s, 3H).
[0546] Example 22: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-methyl-N-(2-(trifluoromethoxy)benzyl)thiazole-4-carboxamide
[0547]
[0548] Phosphorus trichloride (52.8 μL, 0.604mmol) and 4,6-dichloro-5-hydroxypicolinic acid (0.27g, 1.33mmol) were added to a stirred solution of 5-amino-2-methyl-N-(2-(trifluoromethoxy)benzyl)thiazole-4-carboxamide (0.4g, 1.21mmol) in chlorobenzene (5mL) at ambient temperature. The resulting reaction mixture was heated to 130 ° C for 2h. The progress of the reaction was monitored by TLC / LCMS. After the reaction was completed, the reaction mixture was quenched with ice water (20mL). The precipitated solid was filtered and evaporated to obtain an off-white solid. The solid material was purified by flash column chromatography to obtain 5-(4,6-dichloro-5-hydroxypicolinamido)-2-methyl-N-(2-(trifluoromethoxy)benzyl)thiazole-4-carboxamide (0.051g, 8%) as a white solid. LCMS (ES) m / z: calculated for C19H13Cl2F3N4O4S: 520.00; found: 521.1 (M+1); 1HNMR (400 MHz, DMSO d6) δ12.64 (s, 1H), 9.0 (t, J=4 Hz, 1H), 8.09 (s, 1H), 7.40–7.32 (m, 4H), 4.55 (d, J=8.0 Hz, 2H), 2.62 (s, 3H).
[0549] Example 23: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-phenyl-N-(2(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0550]
[0551] Step 1: Synthesis of ethyl 2-amino-2-cyanoacetate
[0552] At ambient temperature, zinc (11.5 g, 5 equivalents, 176 mmol) was added in batches to a stirred solution of (E)-(ethyl cyano(oxime)formate) (5 g, 35.2 mmol) in acetic acid (50 mL). The reaction mixture was stirred for 30 minutes at ambient temperature. The reaction process was monitored by TLC. After the reaction was complete, the mixture was filtered through diatomaceous earth and washed with dichloromethane (200 mL). The filtrate was evaporated under reduced pressure to obtain ethyl 2-amino-2-cyanoacetate (4 g) as an orange sticky solid. The crude compound was used for the next step without purification.
[0553] Step 2: Synthesis of ethyl 2-cyano-2-(phenylformamido)acetate
[0554] Benzoyl chloride (4.83 g, 34 mmol) and triethylamine (7.9 g, 78 mmol) were added to a stirred solution of ethyl 2-amino-2-cyanoacetate (4 g, 31.2 mmol) in dichloromethane (50 mL) at 0 ° C. The reaction was stirred for 2 h at ambient temperature. The reaction progress was monitored by TLC. After the reaction was completed, the mixture was diluted with dichloromethane (50 mL), washed with water (100 mL) and saline solution (100 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and evaporated to obtain a crude product. 2-cyano-2-(phenylformamido)ethyl acetate (1 g, 13% yield) was obtained as a yellow solid by flash chromatography purification. LCMS (ES) m / z: calculated for C12H12N2O3: 232.08; found: 233.1.
[0555] Step 3: Synthesis of 5-amino-2-phenyl-1,3-thiazole-4-carboxylic acid ethyl ester
[0556] To a stirred solution of ethyl 2-cyano-2-(phenylformamido)acetate (1 g, 4.31 mmol) in toluene (20 mL) was added Lawesson reagent (5.22 g, 3 equivalents, 12.9 mmol). The resulting reaction mixture was heated to reflux for 18 hours. The reaction progress was monitored by TLC and LCMS. After completion, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated sodium bicarbonate solution (3 x 50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and evaporated to obtain a residue. It was purified by flash chromatography to obtain ethyl 5-amino-2-phenyl-1,3-thiazole-4-carboxylate (400 mg, 37%) as a yellow solid. LCMS (ES) m / z: calculated for C12H12N2O2S: 248.06; found: 249.1.
[0557] Step 5: Synthesis of 5-amino-2-phenyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1,3-thiazole-4-carboxamide
[0558] 2M trimethylaluminum (2mL, 4mmol) in toluene is added to a stirred solution of 5-amino-2-phenyl-1,3-thiazole-4-carboxylic acid ethyl ester (0.25g, 1.01mmol) and 1-[2-(trifluoromethyl)phenyl]methylamine (0.21g, 1.21mmol) in toluene (1mL). The reaction mixture is heated at 100°C for 1h. The reaction mixture is cooled to ambient temperature and quenched with ice-cold water (15mL) and extracted with ethyl acetate (25x 2mL). The combined organic phases are washed with saline solution (15mL) and dried over anhydrous sodium sulfate, filtered and evaporated under vacuum to obtain a crude brown solid, which is ground with diethyl ether (10mL) to obtain 5-amino-2-phenyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1,3-thiazole-4-carboxamide (0.2g, 52% yield). LCMS (ES) m / z: calcd. for C18H14F3N3OS: 377.3; found: 378.1.
[0559] Step 6: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-phenyl-N-(2(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0560] Phosphorus trichloride (72.8 mg, 0.53 mmol) was added to a stirred solution of 5-amino-2-phenyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1,3-thiazole-4-carboxamide (0.2 g, 0.53 mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (110 mg, 0.53 mmol) in chlorobenzene (2 mL) at ambient temperature. The resulting reaction mixture was heated at 120 ° C for 3 h. The progress of the reaction was monitored by LCMS. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate (25 mL) and washed with water (10 mLx2), aqueous bicarbonate solution (10 mL). The organic phase was dried over Na2SO4, concentrated under reduced pressure to give a crude residue, which was purified by reverse phase preparative HPLC to give 4,6-dichloro-5-hydroxy-N-[2-phenyl-4-({[2-(trifluoromethyl)phenyl]methyl}carbamoyl)-1,3-thiazol-5-yl]pyridine-2-carboxamide (0.07 g, 22% yield) as a light yellow solid. LCMS (ES) m / z: Calculated for C24H15Cl2F3N4O3S: 566.02; Found: 565.1 (MH). 1H NMR (400MHz, DMSO d6) δ12.73(s,1H),9.25(d,J=6Hz,1H),8.13(s,1H),8.04(d,J=7.2Hz,2H),7. 74(d,J=8Hz,1H),7.66–6.63(m,1H),7.54-7.47(m,5H),4.75(d,J=4.8Hz,2H).
[0561] Example 24: 5-(4,6-dichloro-5-hydroxypicolinamido)-N-(1-(2-(trifluoromethyl)phenyl)cyclopropyl)thiazole-4-carboxamide
[0562]
[0563] Step 1: Synthesis of 1-(2-(trifluoromethyl)phenyl)cyclopropan-1-amine
[0564] At -78 ° C under nitrogen atmosphere, to a stirred solution of 2-(trifluoromethyl)benzonitrile (5g, 29.2mmol) and tetraisopropoxytitanium (13.3mL, 43.8mmol) in diethyl ether (50mL, 481mmol) was added 1M ethylmagnesium bromide (73mL, 73mmol) in diethyl ether, and then the reaction mixture was slowly raised to 0 ° C for 1 h. At 0 ° C, boron trifluoride diethyl ether (9.02mL, 73mmol) was added dropwise to the reaction mixture. The reaction mixture was stirred at ambient temperature for 1 hour. The reaction mixture was then cooled to 0 ° C, 4N HCl (50mL) was added and stirred at ambient temperature for an additional 1 hour. The reaction mixture was then cooled to 0 ° C, diluted with diethyl ether (100mL) and 20% NaOH aqueous solution (80mL) was added. The reaction mixture was stirred at ambient temperature for 1 hour. The layers were separated and the organic layer was washed with cold 4N HCl (2X25mL). The aqueous layer was basified by using 20% aqueous NaOH solution (pH = 10) and extracted with diethyl ether (2X100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure at ambient temperature to give 1-[2-(trifluoromethyl)phenyl]cyclopropane-1-amine (3 g, 14.9 mmol) as a yellow liquid. LCMS (ES) m / z: calculated for C10H10F3N: 201.08; found: 202.1 (M+H).
[0565] Step 2: Synthesis of 5-amino-N-(1-(2-(trifluoromethyl)phenyl)cyclopropyl)thiazole-4-carboxamide
[0566] HATU (633mg, 1.66mmol) is added to a stirred solution of 5-amino-1,3-thiazole-4-carboxylic acid (0.2g, 1.39mmol) and 1-[2-(trifluoromethyl)phenyl]cyclopropyl-1-amine (279mg, 1.39mmol) and triethylamine (0.5mL 4.16mmol) in tetrahydrofuran (4mL). The reaction mixture is stirred for 3h at ambient temperature. After completion, the reaction mixture is diluted with ethyl acetate (50mL), washed with water (2x20 mL) and saline solution (20mL). The organic phase is dried over anhydrous sodium sulfate, filtered and evaporated to obtain a crude product. It is purified by flash column chromatography, the collected fractions are judged by TLC, the pure fractions are merged and evaporated under reduced pressure to obtain 5-amino-N-{1-[2-(trifluoromethyl)phenyl]cyclopropyl}-1,3-thiazole-4-carboxamide (0.3g) as an off-white solid. LCMS (ES) m / z: calcd. for C14H12F3N3OS: 327.07; found: 328.1 (M+H).
[0567] Step 3: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-N-(1-(2-(trifluoromethyl)phenyl)cyclopropyl)thiazole-4-carboxamide
[0568] Phosphorus trichloride (42 mg, 0.306 mmol) was added to a stirred suspension of 5-amino-N-{1-[2-(trifluoromethyl)phenyl]cyclopropyl}-1,3-thiazole-4-carboxamide (0.1 g, 0.306 mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (95.3 mg, 1.5 equivalents, 0.458 mmol) in acetonitrile (5 mL) at 0 ° C under a nitrogen atmosphere. The reaction mixture was heated to 100 ° C for 16 hours. After completion, the reaction mixture was diluted with ethyl acetate (50 mL), washed with saturated sodium bicarbonate solution (20 mL), water (20 mL) and brine solution (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and evaporated to give a crude product. Purification by preparative HPLC gave 4,6-dichloro-5-hydroxy-N-[4-({1-[2-(trifluoromethyl)phenyl]cyclopropyl}carbamoyl)-1,3-thiazol-5-yl]pyridine-2-carboxamide (0.05 g, 31%) as a white solid. LCMS (ES) m / z: calculated for C20H13Cl2F3N4O3S: 516.00; found: 515.1 (MH); 1H NMR (400 MHz, DMSO-d6) δ12.49 (s, 1H), 8.67 (s, 1H), 8.34 (s, 1H), 8.12 (s, 1H), 8.05 (d, J=7.6 Hz, 1H), 7.71-7.67 (m, 2H), 7.53-7.49 (m, 1H), 1.45 (m, 2H), 1.33 (m, 2H).
[0569] Example 25: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-N-methyl-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0570]
[0571] Step 1: Synthesis of tert-butyl (2-(trifluoromethyl)benzyl)carbamate
[0572] Methylamine (3.19mL, 28.7mmol) was added to a stirred solution of 2-(trifluoromethyl)benzaldehyde (1g, 5.74mmol) in methanol (10mL, 247mmol) and stirred at room temperature for 30min. After 30 minutes, the reaction mass was cooled to 0°C and sodium borohydride (0.43g, 11.5mmol) was added in batches and stirred at room temperature for 2 hours. Triethylamine (2.4mL, 17.2mmol), N,N-dimethylpyridine-4-amine (0.14g, 1.15mmol) and di-tert-butyl dicarbonate (1.98mL, 8.61mmol) were added to the reaction mixture and stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure to remove methanol. The residue was quenched with water (50mL) and extracted into ethyl acetate (20mL x 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate and evaporated under reduced pressure to give crude tert-butyl (2-(trifluoromethyl)benzyl)carbamate (0.8 g, 48%) as a gummy solid. LCMS (ES) m / z: Calcd. for C13H16F3NO2 275.11; Found: 275.1 (M+H).
[0573] Step 2: Synthesis of N-methyl-1-(2-(trifluoromethyl)phenyl)methanamine
[0574] A stirred solution of tert-butyl (2-(trifluoromethyl)benzyl)carbamate (0.8 g, 2.77 mmol) in 4M HCl / 1,4-dioxane (1.01 g, 10 equiv., 27.7 mmol) was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure and the residue was washed with diethyl ether (10 mL) to give N-methyl-1-(2-(trifluoromethyl)phenyl)methanamine (0.6 g, 92%) as an off-white solid. LCMS (ES) m / z: Calcd. for C9H11ClF3N 225.05; Found: 190.1 (M+H).
[0575] Step 3: Synthesis of 5-amino-N-methyl-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0576] To a stirred solution of 5-amino-1,3-thiazole-4-carboxylic acid methyl ester (0.25 g, 1.58 mmol), methyl({[2-(trifluoromethyl)phenyl]methyl})amine hydrochloride (0.428 g, 1.9 mmol) and triethylamine (0.22 mL, 1.58 mmol) in toluene (2 mL, 16.9 mmol). The mixture was cooled to 0 °C and trimethylaluminum (0.455 mL, 4.74 mmol) was added. The resulting reaction mixture was heated to 100 °C for 2 h. The reaction mixture was cooled to ambient temperature and quenched with water (15 mL) and extracted into ethyl acetate (2 x 30 mL). The combined organics were washed with brine solution (2 x 10 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure to give the crude product. The crude product was purified by Combi flash chromatography to give 5-amino-N-methyl-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.24 g, 48%) as an off-white solid. LCMS (ES) m / z: Calcd. for C13H12F3N3OS 315.07; Found: 316.1 (M+H).
[0577] Step 4: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-N-methyl-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0578] At room temperature, trichlorophosphine (0.018mL, 0.209mmol) was added dropwise to the stirred solution of 5-amino-N-methyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1,3-thiazole-4-carboxamide (0.220g, 0.698mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.16g, 0.767mmol) in chlorobenzene (4mL) to the reaction mixture. The reaction was then stirred at 130°C for 2 hours. The reaction mixture was cooled to ambient temperature and quenched into ice-cold water (10mL), and the resulting mixture was extracted into ethyl acetate (5mL x 2). The combined organic layer was washed with brine (3mL x2), dried over sodium sulfate and evaporated under reduced pressure to produce a crude product. The resulting crude product was purified by preparative HPLC to give 5-(4,6-dichloro-5-hydroxypicolinamido)-N-methyl-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.048 g, 13%) as a white solid. LCMS (ES) m / z: Calculated for C19H13Cl2F3N4O3S 504.00; Found: 505.1 (M+H). 1H NMR (400 MHz, DMSO d6, at 90°C) δ 12.78 (bs, 1H), 8.61 (s, 1H), 8.09 (s, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.66 (t, J = 7.6 Hz, 1H), 7.52-7.46 (m, 3H), 5.34 (bs, 2H), 3.05 (s, 3H).
[0579] The following compounds were synthesized as described above.
[0580]
[0581]
[0582]
[0583]
[0584] Example 59: Synthesis of 2-cyclopropyl-5-(4,6-dichloro-5-hydroxypicolinamido)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0585]
[0586] Step 1: Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-cyclopropylthiazole-4-carboxylate
[0587] To 5-bromo-2-cyclopropylthiazole-4-formic acid methyl esters (0.5g, 1.91mmol) and tert-butyl carbamate (0.223g, 1.91mmol) in 1,4-dioxane (10mL) stirring solution, add cesium carbonate (1.24g, 3.82mmol) and degas with nitrogen for 10min, then add Pd (dba) 2 (0.054g, 0.095mmol), Xanthphos (0.11g, 0.19mmol) and stir at 100 ℃ for 16h. Monitor the progress of reaction by TLC and LCMS. After the reaction is completed, reaction mixture is filtered through diatomaceous earth pad, filtrate is diluted with ethyl acetate (50mL), washed with water (25x 2mL), saline solution and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to obtain crude product. The crude product was purified by flash column chromatography to give methyl 5-((tert-butoxycarbonyl)amino)-2-cyclopropylthiazole-4-carboxylate (0.3 g, 52% yield). LCMS (ES) m / z: Calculated for C13H18N2O4S: 298.10; Found: 243.1. (M- t bu).
[0588] Step 2: Synthesis of tert-butyl (2-cyclopropyl-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate
[0589] To a solution of methyl 5-{[(tert-butoxy)carbonyl]amino}-2-cyclopropyl-1,3-thiazole-4-carboxylate (0.2 g, 0.670 mmol) and 1-[2-(trifluoromethyl)phenyl]methanamine (0.141 g, 0.804 mmol) in toluene (4 mL) was added 2M trimethylaluminum (2 mL, 2 mmol) in toluene at 0°C. The reaction mixture was heated at 100°C for 1 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (15 mL) and extracted with ethyl acetate (25 x 2 mL). The combined organic phases were washed with brine solution (15 mL) and dried over anhydrous sodium sulfate, filtered and evaporated under vacuum to afford a crude brown solid, which was triturated with diethyl ether (10 mL) to give tert-butyl (2-cyclopropyl-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.120 g, 40% yield). LCMS (ES) m / z: Calculated for C20H22F3N3O3S: 441.13; Found: 342.1 (M-Boc).
[0590] Step 3: Synthesis of 5-amino-2-cyclopropyl-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0591] A stirred solution of tert-butyl N-[2-cyclopropyl-4-({[2-(trifluoromethyl)phenyl]methyl}carbamoyl)-1,3-thiazol-5-yl]carbamate (0.120 g, 0.272 mmol) in dichloromethane (2 mL) was cooled to 0 °C and then 4M HCl (2 mL) in 1,4 dioxane was added. The resulting reaction mixture was stirred at ambient temperature for 2 h. The reaction mixture was concentrated under reduced pressure and the obtained residue was triturated with diethyl ether (10 mL) to give 5-amino-2-cyclopropyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1,3-thiazole-4-carboxamide (0.090 g, 97% yield). LCMS (ES) m / z: Calculated for C15H14F3N3OS: 341.08; Found: 342.1 (M+H).
[0592] Step 4: Synthesis of 2-cyclopropyl-5-(4,6-dichloro-5-hydroxypicolinamido)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0593] Phosphorus trichloride (0.032 g, 0.234 mmol) was added to a solution of 5-amino-2-cyclopropyl-N-{[2-(trifluoromethyl)phenyl]methyl}-1,3-thiazole-4-carboxamide (0.080 g, 0.234 mmol) and 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.048 g, 0.234 mmol) in chlorobenzene (1 mL). The resulting reaction mixture was heated at 120 ° C for 1 h. The progress of the reaction was monitored by LCMS. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate (25 mL), and washed with water (10 mLx2), saline solution (10 mL). The organic phase was dried over Na2SO4 and concentrated under reduced pressure to give a crude residue, which was purified by flash column chromatography to give 4,6-dichloro-N-[2-cyclopropyl-4-({[2-(trifluoromethyl)phenyl]methyl}carbamoyl)-1,3-thiazol-5-yl]-5-hydroxypyridine-2-carboxamide (0.032 g, 25% yield) as an off-white solid. LCMS (ES): m / z: Calculated for C21H15Cl2F3N4O3S: 530.0; Found: 531.1 (M+H); 1 H NMR (400 MHz, DMSO-d 6): δ12.60(s,1H),8.95(t,J=6Hz,1H),8.10(s,1H),7.75(d,J=7.6 1H),7.66(t,J=7.2Hz,1H)7.50-7.46(m,2H),4.71(d,J=6Hz,2H),2.38-2.33(m,1H),1.20-1.14(m,4H).
[0594] Example 60: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0595]
[0596] Step 1: Preparation of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate
[0597] At ambient temperature, to 5-amino-2-bromothiazole-4-methyl-formiate (1g, 4.22mmol) in tetrahydrofuran (20mL, 246mmol) stirring solution, add di-tert-butyl dicarbonate (1.45mL, 6.33mmol), DIPEA (2.2mL, 12.7mmol) and DMAP (0.520g, 4.22mmol) and then stir extra 2h at the same temperature.Reaction mixture is poured into water (40mL) and extracted with ethyl acetate (50mL x 3).The organic phase merged is washed with water, brine and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to obtain crude product.Crude material is purified by flash column chromatography to obtain 2-bromo-5-((tert-butoxycarbonyl) amino) thiazole-4-methyl-formiate (0.9g, 63%) as white solid. LCMS (ES): m / z: Calculated for C10H13BrN2O4S: 335.98; found: 337.0.
[0598] Step 2: Preparation of methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluorophenyl)thiazole-4-carboxylate
[0599] To 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-formic acid methyl ester (0.460g, 1.36mmol) and (2-fluorophenyl)boric acid (0.382g, 2.73mmol) in 1,4-dioxane: water 8:2 (6mL) in a stirred solution and potassium carbonate (0.566g, 4.09mmol) and degassed with nitrogen for 10min, then bis(tri-tert-butylphosphine)palladium (0.0697g, 0.136mmol) was added and stirred at 100°C for 16h. The progress of the reaction was monitored by TLC / LCMS. After the reaction was completed, the reaction mixture was filtered through a diatomaceous earth pad, the filtrate was diluted with ethyl acetate (50mL), washed with water (25x 2mL), a saline solution and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to obtain a crude product. The crude product was purified by flash column chromatography to give methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluorophenyl)thiazole-4-carboxylate (0.350 g, 73%) as a brown solid. LCMS (ES): m / z: Calcd. for C16H17FN2O4S: 352.09; Found: 353.1.
[0600] Step 3: Preparation of tert-butyl (2-(2-fluorophenyl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate
[0601] At 0 ℃, to 5-((tert-butoxycarbonyl)amino)-2-(2-fluorophenyl)thiazole-4-formic acid methyl ester (0.3g, 0.851mmol) in toluene (5mL) stirring solution, add 1-[2-(trifluoromethyl)phenyl]methylamine (0.119mL, 0.851mmol) and 2M trimethylaluminum (0.245mL, 2.55mmol) in toluene. The resulting reaction mixture was stirred at 100 ℃ for 16 hours. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (25mL), and extracted with ethyl acetate (25x2mL). The organic phase merged was washed with saline solution (15mL) and dried over anhydrous sodium sulfate, filtered and evaporated under vacuum to obtain a crude product. The crude material was purified by flash column chromatography to give tert-butyl (2-(2-fluorophenyl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.3 g, 71%) as an off-white solid. LCMS (ES): m / z: Calcd. for C23H21F4N3O3S: 495.1; Found: 496.1.
[0602] Step 4: Preparation of 5-amino-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0603] To a suspension of tert-butyl (2-(2-fluorophenyl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.250 g, 0.505 mmol) in methanol (1 mL) at 0°C was added 4M HCl in dioxane (5 mL, 144 mmol) and then stirred at room temperature for 2 h. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with water (10 ml), brine (5 ml) and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give 5-amino-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.170 mg, 85%) as a white solid. LCMS (ES): m / z: Calculated for C18H13F4N3OS: 395.07; Found: 396.1.
[0604] Step 5: Preparation of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0605] 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.101 g, 0.487 mmol) and phosphorus trichloride (0.0387 mL, 0.443 mmol) were added to a suspension of 5-amino-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.175 g, 0.443 mmol) in chlorobenzene (5 mL). The resulting reaction mixture was added at 120 ° C for 3 h. The progress of the reaction was monitored by LCMS. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate (25 mL), and washed with water (10 mL x 2), brine solution (10 mL). The organic phase was dried over Na2SO4, concentrated under reduced pressure to give a crude residue, which was purified by flash column chromatography Na2SO4 to give 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.015 g, 6%) as a white solid. LCMS (ES): m / z: Calculated for C24H14Cl2F4N4O3S: 584.0; Found: 585.1 (MH); 1 H NMR (400 MHz, DMSO-d 6): δ12.74(s,1H),9.37(t,J=6Hz,1H),8.51-8.47(m,1H),8.15(s,1H),7.78(d, J=7.6Hz,1H),7.68(t,J=7.6Hz,1H),7.58-7.39(m,5H),4.81(d,J=6Hz,2H).
[0606] The following compounds have been synthesized using the above procedure.
[0607]
[0608]
[0609] Example 78: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(1,1-dioxythiomorpholino)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0610]
[0611] Step 1: Synthesis of methyl 5-amino-2-bromothiazole-4-carboxylate
[0612] At 0 ° C, to a stirred solution of 5-aminothiazole-4-carboxylic acid methyl ester (0.7 g, 4.43 mmol) in tetrahydrofuran (7 mL, 86 mmol) was added N-bromosuccinimide (0.86 g, 4.87 mmol) and the reaction mixture was then stirred at ambient temperature for 1 h. The reaction mixture was quenched with ice water (30 ml) and extracted with ethyl acetate (3 x 20 mL). The combined organic layer was washed with water (20 mL), brine (20 mL), dried over sodium sulfate and evaporated under reduced pressure to produce a crude product, which was purified by flash chromatography to give 5-amino-2-bromothiazole-4-carboxylic acid methyl ester (0.960 g, 92%) as a brown solid. LCMS (ES) m / z: calculated for C5H5BrN2O2S: 235.93; found: 237.0 (M+H).
[0613] Step 2: Synthesis of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate
[0614] At ambient temperature, di-tert-butyl dicarbonate (1.4mL, 6.07mmol), N,N-diisopropylethylamine (2.12mL, 12.1mmol) and 4-(dimethylamino)pyridine (0.5g, 4.05mmol) were added to a stirred solution of 5-amino-2-bromothiazole-4-formic acid methyl esters (0.96g, 4.05mmol) in tetrahydrofuran (15mL, 184mmol). The resulting reaction mixture was stirred for additional 2h at the same temperature. The progress of the reaction was monitored by TLC. The reaction mixture was quenched with ice water (50ml) and extracted with ethyl acetate (3x 20mL). The combined organic layer was washed with water (10mL), brine (10mL), dried over sodium sulfate and evaporated under reduced pressure to produce a crude product, which was purified by flash column chromatography to obtain 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-formic acid methyl esters (1.1g, 81%) as a white solid. LCMS (ES) m / z: calcd. for C10H13BrN2O4S: 335.98; found: 337.0 (M+H).
[0615] Step 3: Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-(1,1-dioxythiomorpholino)thiazole-4-carboxylate
[0616] To a stirred solution of 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-formic acid methyl ester (0.7g, 2.08mmol) and thiomorpholine 1,1-dioxide (421mg, 3.11mmol) in 1,4-dioxane (8mL), cesium carbonate (2.03g, 6.23mmol) was added and degassed with nitrogen for 10min, then Pd(dba)2 (0.095g, 0.155mmol), Xanthphos (0.18g, 0.311mmol) were added and stirred at 100°C for 12h. The progress of the reaction was monitored by TLC and LCMS. After the reaction was completed, the reaction mixture was filtered through a diatomaceous earth pad, the filtrate was diluted with ethyl acetate (50mL), washed with water (25x 2mL), a saline solution and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to obtain a crude product. The crude product was purified by flash column chromatography to give methyl 5-((tert-butoxycarbonyl)amino)-2-(1,1-dioxidothiomorpholino)thiazole-4-carboxylate (0.70 g, 87%) as an off-white solid. LCMS (ES) m / z: Calculated for C14H21N3O6S2: 391.09; Found: 392.0 (M+H).
[0617] Step 4: Synthesis of tert-butyl (2-(1,1-dioxidothiomorpholino)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate
[0618] To a suspension of methyl 5-((tert-butoxycarbonyl)amino)-2-(1,1-dioxidothiomorpholino)thiazole-4-carboxylate (0.7 g, 1.79 mmol) and (2-(trifluoromethyl)phenyl)methylamine (345 mg, 1.97 mmol) in toluene (7 mL) was added 2M trimethylaluminum (1.32 mL, 2.68 mmol) in toluene at 0 ° C. The reaction mixture was heated at 100 ° C for 16 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (15 mL) and extracted with ethyl acetate (25 x 2 mL). The combined organic phases were washed with saline solution (15 mL) and dried over anhydrous sodium sulfate, filtered and evaporated under vacuum to obtain a crude product. The crude material was purified by flash column chromatography to give tert-butyl (2-(1,1-dioxidothiomorpholino)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.680 g, 71%) as a yellow solid. LCMS (ES) m / z: Calculated for C21H25F3N4O5S2: 534.1; Found: 535.1 (M+H).
[0619] Step 5: Synthesis of 5-amino-2-(1,1-dioxythiomorpholino)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0620] To a stirred solution of tert-butyl (2-(1,1-dioxidothiomorpholino)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (680 mg, 1.27 mmol) in methanol (2 mL) was added 4M HCl (15 mL, 60 mmol) in dioxane at 0°C and stirred for 2 h at room temperature. The progress of the reaction was monitored by TLC and LCMS. After the reaction was complete, the reaction mixture was evaporated under reduced pressure and the obtained residue was triturated with diethyl ether to give 5-amino-2-(1,1-dioxidothiomorpholino)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.68 g, 58%) as a brown solid. LCMS (ES) m / z: Calculated for C16H17F3N4O3S2: 434.07; Found: 435.0 (M+H).
[0621] Step 6: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(1,1-dioxythiomorpholino)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0622] Under nitrogen atmosphere, phosphorus trichloride (0.063 mL, 0.725 mmol) was added dropwise to a suspension of 5-amino-2-(1,1-dioxidothiomorpholino)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (630 mg, 1.45 mmol) and 4,6-dichloro-5-hydroxypicolinic acid (332 mg, 1.6 mmol) in chlorobenzene (5 mL) under nitrogen atmosphere. The resulting reaction mixture was heated to 130 ° C for 2 h. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was poured into ice-cold water (20 ml), the precipitated solid was filtered and purified by flash column chromatography to give a brown solid, which was further purified by preparative HPLC to give 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(1,1-dioxidothiomorpholino)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.153 g, 17%) as a yellow solid. LCMS (ES) m / z: Calculated for C22H18Cl2F3N5O5S2: 623.01; Found: 622.1 (M-1); 1 H NMR (400MHz, DMSO-d6) δ12.45(s,1H),8.93(t,J=6.0Hz,1H),8.09(s,1H),7.80(d,J =4.0Hz,1H),7.67(t,J=4.0Hz,1H),7.51–7.42(m,2H),4.7(d,J=8.0Hz,2H),4.02(br s,4H),3.31(br s,4H).
[0623] Example 79: Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-2-(1,1-dioxythiomorpholino)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0624]
[0625] Under nitrogen atmosphere, phosphorus trichloride (0.050mL, 0.575mmol) was added dropwise to a suspension of 5-amino-2-(1,1-dioxidothiomorpholino)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.5g, 1.15mmol) and 3,5-dichloro-4-hydroxybenzoic acid (262mg, 1.27mmol) in chlorobenzene (5mL). The reaction mass was heated to 130°C for 2h. The progress of the reaction was monitored by TLC and LCMS. After the reaction was completed, the reaction mixture was quenched with ice water (20ml) and extracted with ethyl acetate (3x 10ml). The combined organic layer was washed with water (10mL), brine (10mL), dried over sodium sulfate and evaporated under reduced pressure to produce a crude product, which was purified by flash chromatography. The column purified compound was further purified by preparative HPLC to give 5-(3,5-dichloro-4-hydroxybenzamido)-2-(1,1-dioxidothiomorpholino)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.057 g, 8%) as a yellow solid. LCMS (ES) m / z: Calculated for C23H19Cl2F3N4O5S2: 622.0; Found: 621.1 (MH); 1 H NMR(400MHz,DMSO-d6)δ12.0(s,1H),11.28(br s,1H),9.01(t,J=8.0Hz,1H),7.79(s,2H),7.75(d,J=8.0Hz,1H),7.67(t,J=8.0Hz,1H),7.48(t,J=8.0Hz,2H),4.70(d,J=4.0Hz,2H),4.02(br s,4H),3.28(brs,4H).
[0626] Example 80: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-morpholino-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0627]
[0628] Step 1: Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-morpholinothiazole-4-carboxylate
[0629] To a stirred solution of 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-formic acid methyl ester (1.65 g, 4.89 mmol) and morpholine (0.633 mL, 7.34 mmol) in 1,4-dioxane (8 mL) was added cesium carbonate (4.78 g, 14.7 mmol) and degassed with nitrogen for 10 min, then Pd(dba)2 (0.14 g, 0.244 mmol), Xanthphos (0.27 g, 0.48 mmol) were added and stirred at 100 ° C for 12 h. The progress of the reaction was monitored by TLC / LCMS. After the reaction was completed, the reaction mixture was filtered through a celite pad, the filtrate was diluted with ethyl acetate (50 mL), washed with water (25 x 2 mL), a saline solution and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to obtain a crude product. The crude product was purified by flash column chromatography to give methyl 5-((tert-butoxycarbonyl)amino)-2-morpholinothiazole-4-carboxylate (740 mg, 44%) as a yellow solid. LCMS (ES) m / z: Calcd. for C14H21N3O5S: 343.12; Found: 344.2 (M+H).
[0630] Step 2: Synthesis of tert-butyl (2-morpholino-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate
[0631] At 0 ° C, 2M trimethylaluminum (1.53 mL, 3.06 mmol) in toluene was added to a suspension of 5-((tert-butoxycarbonyl)amino)-2-morpholinothiazole-4-carboxylic acid methyl ester (0.7 g, 2.04 mmol) and (2-(trifluoromethyl)phenyl)methylamine (428 mg, 2.45 mmol) in toluene (7 mL). The reaction mixture was heated at 100 ° C for 16 h. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (15 mL) and extracted with ethyl acetate (25 x 2 mL). The combined organic phases were washed with saline solution (15 mL) and dried over anhydrous sodium sulfate, filtered and evaporated under vacuum to obtain a crude product. The crude material was purified by flash column chromatography using 50% ethyl acetate in n-hexane to give tert-butyl (2-morpholino-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (430 mg, 43%) as a yellow solid. LCMS (ES) m / z: Calculated for C21H25F3N4O4S: 486.1; Found: 487.1 (M+1).
[0632] Step 3: Synthesis of 5-amino-2-morpholino-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0633] To a stirred solution of tert-butyl (2-morpholino-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (430 mg, 0.884 mmol) in methanol (2 mL) was added HCl (15 mL, 60 mmol) in dioxane at 0 ° C. and stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC and LCMS. After the reaction was completed, the reaction mixture was evaporated under reduced pressure and washed with diethyl ether to give 5-amino-2-morpholino-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (300 mg, 26%) as a brown solid. LCMS (ES) m / z: Calculated value for C16H17F3N4O2S 386.10; Found: 387.0 (M+1).
[0634] Step 4: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-morpholino-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0635] Under nitrogen atmosphere, phosphorus trichloride (0.034mL, 0.388mmol) was added dropwise to a suspension of 5-amino-2-morpholino-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.3g, 0.776mmol) and 4,6-dichloro-5-hydroxypicolinic acid (178mg, 0.854mmol) in chlorobenzene (4mL). The reaction mass was heated to 130 ° C for 2h. The process of the reaction was monitored by TLC and LCMS. After the reaction was completed, the reaction mixture was quenched with ice water (20mL) and extracted with ethyl acetate (3x10ml). The combined organic layers were washed with water (10 mL), brine (10 mL), dried over sodium sulfate and evaporated under reduced pressure to give a crude product, which was purified by flash column chromatography to give 5-(4,6-dichloro-5-hydroxypicolinamido)-2-morpholino-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (14 mg, 3%) as a yellow solid. LCMS (ES) m / z: Calculated for C22H18Cl2F3N5O4S: 575.04; Found: 576.1 (M+1); 1 H NMR (400MHz, DMSO-d6) δ12.25(s,1H),8.69(t,J=8.0Hz,1H),7.94(s,1H),7.75(d,J=8.0Hz,1H),7.67( t,J=8.0Hz,1H),7.49-7.48(m,2H),4.7(d,J=8.0Hz,2H),3.73(t,J=4.0Hz,4H),3.45(t,J=4.0Hz,4H).
[0636] Example 81: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(tetrahydro-2H-pyran-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0637]
[0638] Step 1: Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-(3,6-dihydro-2H-pyran-4-yl)thiazole-4-carboxylate
[0639] To a stirred solution of methyl 2-bromo-5-{[(tert-butoxy)carbonyl]amino}-1,3-thiazole-4-carboxylate (1 g, 2.97 mmol) and 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.93 g, 4.45 mmol) in 1,4-dioxane:water (10 mL:1 mL) was added potassium carbonate (1.23 g, 8.9 mmol) and degassed with nitrogen for 10 min, then 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) chloride.DCM complex (110 mg, 0.148 mmol) was added and stirred at 100° C. for 2 h. The progress of the reaction was monitored by TLC and LCMS. After the reaction was completed, the reaction mixture was filtered through a celite pad, the filtrate was diluted with ethyl acetate (50 mL), washed with water (25 x 2 mL), brine solution and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give a crude product. The crude product was purified by flash column chromatography to give methyl 5-{[(tert-butoxy)carbonyl]amino}-2-(3,6-dihydro-2H-pyran-4-yl)-1,3-thiazole-4-carboxylate (0.9 g, 89%) as a white solid. LCMS (ES) m / z: Calculated for C15H20N2O5S: 340.11; Found: 341.2 (M+1).
[0640] Step 2: Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)thiazole-4-carboxylate
[0641] Palladium / carbon 10% w / w (0.1 g) was added to a stirred solution of 5-{[(tert-butoxy)carbonyl]amino}-2-(3,6-dihydro-2H-pyran-4-yl)-1,3-thiazole-4-formic acid methyl ester (0.9 g, 2.64 mmol) in methanol (5 mL) and tetrahydrofuran (5 mL). The resulting reaction mixture was stirred for 16 h under a hydrogen atmosphere at ambient temperature. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was filtered through a diatomaceous earth pad, and the filtrate was concentrated under reduced pressure to obtain 5-{[(tert-butoxy)carbonyl]amino}-2-(oxacyclohexane-4-yl)-1,3-thiazole-4-formic acid methyl ester (0.9 g, 99% yield) as a white solid, which was used for the next step without any column purification. LCMS (ES) m / z: calculated for C15H22N2O5S: 342.12; found: 343.0 (M+1). Step 3: Synthesis of tert-butyl (2-(tetrahydro-2H-pyran-4-yl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate
[0642] Under nitrogen atmosphere at 0 ° C, to 5-{[(tert-butoxy)carbonyl]amino}-2-(oxacyclohexane-4-yl)-1,3-thiazole-4-carboxylic acid methyl ester (0.9g, 2.63mmol) and 1-[2-(trifluoromethyl)phenyl]methylamine (5) (0.691g, 3.94mmol) in toluene (10mL) in a suspension dropwise addition of 2M trimethylaluminum in toluene (1.97mL, 3.94mmol). The resulting reaction mixture was heated to 100 ° C for 1h. The progress of the reaction was monitored by TLC and LCMS. After the reaction was completed, the reaction mixture was quenched with ice water (50mL) and extracted with ethyl acetate (2x 50mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over sodium sulfate and evaporated under reduced pressure to give a crude product, which was purified by flash column chromatography to give tert-butyl (2-(tetrahydro-2H-pyran-4-yl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.65 g, 51%) as a white solid. LCMS (ES) m / z: Calculated for C22H26F3N3O4S: 485.16.; Found: 486.0 (M+1).
[0643] Step 4: Synthesis of 5-amino-2-(tetrahydro-2H-pyran-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0644] To a suspension of tert-butyl N-[-(oxan-4-yl)-4-({[2-(trifluoromethyl)phenyl]methyl}carbamoyl)-1,3-thiazol-5-yl]carbamate (0.650 g, 1.34 mmol) in dichloromethane (5 mL) at 0°C was added 4M HCl (5 mL) in dioxane and then stirred at ambient temperature for 16 h. The reaction mixture was concentrated under reduced pressure to give 5-amino-2-(tetrahydro-2H-pyran-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.4 g, 77%) as an off-white solid. LCMS (ES) m / z: Calculated for C17H18F3N3O2S: 385.1; Found: 386.0 (M+1).
[0645] Step 5: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(tetrahydro-2H-pyran-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0646] Under nitrogen atmosphere, phosphorus trichloride (0.071g, 0.519mmol) was added dropwise to a suspension of 5-amino-2-(tetrahydro-2H-pyran-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.2g, 0.519mmol) and 4,6-dichloro-5-hydroxypicolinic acid (0.108g, 0.519mmol) in chlorobenzene (4mL). The reaction mixture was heated to 120°C for 3h. The progress of the reaction was monitored by TLC and LCMS. After the reaction was complete, the reaction mixture was quenched with ice water (20mL) and extracted with ethyl acetate (3x 20ml). The combined organic layers were washed with water (10 mL), brine (10 mL), dried over sodium sulfate and evaporated under reduced pressure to give a crude residue, which was triturated with diethyl ether (10 mL) and filtered, and the solid was dried under vacuum to give 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(tetrahydro-2H-pyran-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.101 g, 33%) as a light brown solid. LCMS (ES) m / z: Calculated for C23H19Cl2F3N4O4S: 574.05; Found: 575.2 (M+1); 1H NMR (400MHz, DMSO-d6) δ12.23(s,1H),8.81(t,J=6.4Hz,1H),7.81-7.74(m,2H),7.71-7.65(m,1H),7.51-7.46(m,2H) 4.72(d,J=5.6Hz,2H),4.00-3.93(m,2H),3.49-3.44(m,2H),3.25-3.17(m,1H),2.09-1.99(m,2H),1.85-1.75(m,2H).
[0647] Example 82: Synthesis of 5-(3,5-dichloro-4-hydroxybenzamido)-2-(tetrahydro-2H-pyran-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0648]
[0649] Under nitrogen atmosphere, phosphorus trichloride (71.3mg, 0.519mmol) was added dropwise to a suspension of 5-amino-2-(tetrahydro-2H-pyran-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.2g, 0.519mmol) and 3,5-dichloro-4-hydroxybenzoic acid (0.107g, 0.519mmol) in chlorobenzene (4mL). The reaction mixture was heated to 120°C for 3h. The progress of the reaction was monitored by TLC and LCMS. After the reaction was complete, the reaction mixture was quenched with ice water (20mL) and extracted with ethyl acetate (3x 10ml). The combined organic layers were washed with water (10 mL), brine (10 mL), dried over sodium sulfate and evaporated under reduced pressure to give a crude product, which was purified by flash column chromatography to give 5-(3,5-dichloro-4-hydroxybenzamido)-2-(tetrahydro-2H-pyran-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.104 g, 34% yield) as a white solid. LCMS (ES) m / z: Calculated for C24H20Cl2F3N3O4S: 573.05; Found: 572.2 (M-1). 1H NMR(400MHz,DMSO-d6)δ12.24(s,1H),11.32(br s,1H),9.12(t,J=6.4Hz,1H),7.82(s,2H),7.77-7.74(m,1H),7.67(t,J=7.6Hz,1H),7.52-7.47(m,2H),4.72( d,J=6Hz,2H),3.97-3.94(m,2H),3.50-3.41(m,2H),3.28-3.23(m,1H),2.03-1.99(m,2H),1.86-1.76(m,2H).
[0650] The following compounds have been synthesized as per the above procedure.
[0651]
[0652] Example 85: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0653]
[0654] Step 1: Preparation of methyl 5-((tert-butoxycarbonyl)amino)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)thiazole-4-carboxylate
[0655] 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine (0.483g, 2.16mmol) and potassium carbonate (0.898g, 6.49mmol) were added to a stirred solution of 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-formic acid methyl ester (0.730g, 2.16mmol) in 1,4-dioxane (10ml), water (1.5ml). The reaction mixture was purged with nitrogen for 15 minutes, and then [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (0.177g, 0.216mmol) was added and stirred at 100°C for 16h. The reaction mixture was monitored by TLC. The reaction mixture was poured into water (40mL) and extracted with ethyl acetate (50mL x 3). The organic phase was washed with water (10 ml), brine (5 mL) and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude material was purified by flash column chromatography to give methyl 5-((tert-butoxycarbonyl)amino)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)thiazole-4-carboxylate (0.7 g, 91%) as a brown solid. LCMS (ES): m / z: Calculated for C16H23N3O4S: 353.14; Found: 354.1.
[0656] Step 2: Preparation of tert-butyl (2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate
[0657] Under nitrogen atmosphere at 0 ° C, to 5- ((tert-butoxycarbonyl) amino) -2- (1- methyl -1,2,3,6- tetrahydropyridine -4- bases) thiazole -4- carboxylic acid methyl esters (0.3g, 0.849mmol) in toluene (5mL) in a stirred solution dropwise added 1- [2- (trifluoromethyl) phenyl] methylamine (0.149g, 0.849mmol) and 2M trimethylaluminum in toluene (0.229mL, 2.55mmol). The resulting reaction mixture is heated to 100 ° C, continued for 16h. The progress of the reaction is monitored by TLC and LCMS. After the reaction is completed, the reaction mixture is quenched with ice-cold water (50mL) and extracted with ethyl acetate (2x 50mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over sodium sulfate and evaporated under reduced pressure to give a crude product, which was purified by flash column chromatography to give tert-butyl (2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.3 g, 71%) as an off-white solid. LCMS (ES): m / z: Calculated for C23H27F3N4O3S: 496.18; Found: 497.2. Step 3: Preparation of 5-amino-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0658] To a suspension of tert-butyl N-[2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4-({[2-(trifluoromethyl)phenyl]methyl}carbamoyl)-1,3-thiazol-5-yl]carbamate (0.280 g, 0.564 mmol) in methanol (5 mL) was added 4M HCl (7 mL) in dioxane at ambient temperature. And stirred for an additional 1 h. The reaction mixture was concentrated under reduced pressure to give 5-amino-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-{[2-(trifluoromethyl)phenyl]methyl}-1,3-thiazole-4-carboxamide (0.18 g, 80%) as a white solid. LCMS (ES): m / z: Calculated for C18H19F3N4OS: 396.16; Found: 397.1.
[0659] Step 4: Preparation of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0660] At ambient temperature, 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.0866g, 0.416mmol) and phosphorus trichloride (0.0331mL, 0.378mmol) were added to a suspension of 5-amino-2-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-N-{[2-(trifluoromethyl)phenyl]methyl}-1,3-thiazole-4-carboxamide (0.150mg, 0.378mmol) in chlorobenzene (5mL), and the resulting reaction mixture was stirred at 130°C for 3h. The reaction was monitored by TLC. The reaction mixture was poured into water (20mL) and extracted with ethyl acetate (20mL x 3). The organic phase was washed with water (10mL), brine (3mL) and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude material was purified by preparative HPLC to give 4,6-dichloro-5-hydroxy-N-[2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4-({[2-(trifluoromethyl)phenyl]methyl}carbamoyl)-1,3-thiazol-5-yl]pyridine-2-carboxamide TFA salt (0.006 g, 3%) as a white solid. LCMS (ES) m / z: Calculated for C24H20Cl2F3N5O3S: 585.06; Found: 584.2 (MH); 1 H NMR (400 MHz, DMSO-d 6): δ12.63(s,1H),9.80(br s,1H),9.04(t,J=6Hz,1H),8.04(s,1H),7.78(d,J=7.6Hz,1H),7.67(t,J=8Hz,1H),7.50(t,J=7.6Hz,2H),6.63(s,1H),4.75(br s,2H),4.05-3.88(m,1H),3.76-3.64(m,1H),3.36(br s,2H),2.92(s,3H),2.68-2.67-2.87(m,2H).
[0661] Example 86: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(1-methylpiperidin-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0662]
[0663] Step 1: Synthesis of methyl 5-((tert-butoxycarbonyl)amino)-2-(1-methylpiperidin-4-yl)thiazole-4-carboxylate
[0664] To a stirred solution of 5-{[(tert-butoxy)carbonyl]amino}-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-thiazole-4-carboxylate (0.250 g, 0.707 mmol) in MeOH:THF (4:1) (6 mL) was added Pd / carbon 10% (0.150 g) and stirred at room temperature for 3 h under H2 atmosphere. The progress of the reaction was monitored by LCMS. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated under reduced pressure to give methyl 5-((tert-butoxycarbonyl)amino)-2-(1-methylpiperidin-4-yl)thiazole-4-carboxylate (0.250 g, 99%) as a brown solid. LCMS (ES) m / z: Calculated for C16H25N3O4S: 355.16; Found: 356.2 (M+H).
[0665] Step 2: Synthesis of tert-butyl (2-(1-methylpiperidin-4-yl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate.
[0666] To a stirred solution of 5-((tert-butoxycarbonyl)amino)-2-(1-methylpiperidin-4-yl)thiazole-4-carboxylic acid methyl ester (0.250 g, 0.703 mmol) in toluene (10.0 mL) at 0°C, 1-[2-(trifluoromethyl)phenyl]methylamine (0.123 g, 0.703 mmol) and trimethylaluminum (2.0 M in toluene) (0.101 g, 1.41 mmol) were added dropwise. The resulting reaction mixture was stirred at 100°C for 3 h. The reaction mixture was cooled to ambient temperature and poured into ice-cold water (25 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated to give a crude product. The crude product was purified using flash chromatography to give tert-butyl (2-(1-methylpiperidin-4-yl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.150 g, 43%) as an off-white solid. LCMS (ES) m / z: Calcd. for C23H29F3N4O3S: 498.19; Found: 499.2 (M+H).
[0667] Step 3: Synthesis of 5-amino-2-(1-methylpiperidin-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide.
[0668] To a stirred solution of tert-butyl (2-(1-methylpiperidin-4-yl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.150 g, 0.301 mmol) in DCM (3.0 mL) was added hydrogen chloride (4M in 1,4-dioxane) (0.054 g, 1.5 mmol) and stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure to give a crude residue, which was triturated with diethyl ether (15 mL) and n-pentane (15 mL) to give 5-amino-2-(1-methylpiperidin-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.1 g, 83%) as a brown solid. LCMS (ES) m / z: Calculated for C18H21F3N4OS: 398.14; Found: 399.2 (M+H). Step 4: Synthesis of 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(1-methylpiperidin-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide.
[0669] To a stirred solution of 5-amino-2-(1-methylpiperidin-4-yl)-N-{[2-(trifluoromethyl)phenyl]methyl}-1,3-thiazole-4-carboxamide (0.1 g, 0.251 mmol) in acetonitrile (10 mL, 191 mmol) was added 4,6-dichloro-5-hydroxypyridine-2-carboxylic acid (0.052 g, 0.251 mmol) and phosphorus trichloride (0.027 g, 0.201 mmol) at ambient temperature. The resulting reaction mixture was heated to 130 ° C for 1 h. The reaction was cooled to room temperature and then ice-cold water (15 mL) was added thereto, and the precipitated solid was filtered to obtain a crude solid. The crude compound was purified by preparative HPLC to give 5-(4,6-dichloro-5-hydroxypicolinamido)-2-(1-methylpiperidin-4-yl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide formate (0.0227 g, 15.3%) as an off-white solid. LCMS (ES) m / z: Calculated for C24H22Cl2F3N5O3S: 587.08; Found: 588.2 (M+H); 1 H NMR (400 MHz, DMSO-d 6): δ12.25(s,1H),9.30(s,1H),8.77(s,1H),7.75-7.77(m,1H),7.6-7.70(m,1H),7.47-7.52(m,2H),4.73(d,J=5.6Hz,2H),3.46(br s,4H),3.08(br s,2H),2.8(s,3H),2.3-2.4(br s,1H),1.8-2.1(br s,2H).
[0670] The following compounds have been synthesized as described above.
[0671]
[0672]
[0673] Example 105: Synthesis of 5-(3-chloro-5-fluoro-4-hydroxybenzamido)-2-(2-fluoro-5-(pyrrolidin-1-ylmethyl)phenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0674]
[0675] Step 1: Preparation of methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluoro-5-formylphenyl)thiazole-4-carboxylate
[0676] To a solution of 2-bromo-5-{[(tert-butoxy)carbonyl]amino}-1,3-thiazole-4-carboxylic acid methyl ester (0.9 g, 2.67 mmol) and (2-fluoro-5-formylphenyl)boronic acid (0.538 g, 3.2 mmol) dissolved in 1,4-dioxane (10 mL) was added potassium carbonate (1.11 g, 8.01 mmol) and water (1 mL). The reaction mixture was purged with nitrogen for 15 minutes and then Pd(dppf)Cl2.DCM complex (0.218 g, 0.26 mmol) was added at room temperature. The resulting reaction mixture was heated to 100 ° C for 2 h. The progress of the reaction was monitored by TLC. The reaction mixture was filtered through a pad of celite, the pad was washed with ethyl acetate (25 mL), the filtrate was washed with water (2 x 50 ml), brine solution (25 mL) and dried over Na2SO4, concentrated and dried to give the crude product as a brown solid (0.85 g, 83.7% yield). LCMS (ES): m / z: Calculated for C17H17FN2O5S: 380.08; Found: 381.0 (M+H).
[0677] Step 2: Preparation of methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluoro-5-(pyrrolidin-1-ylmethyl)phenyl)thiazole-4-carboxylate
[0678] At room temperature, to 5-{[(tert-butoxy)carbonyl]amino}-2-(2-fluoro-5-formylphenyl)-1,3-thiazole-4-formic acid methyl ester (0.6g, 1.58mmol) in methanol (6mL, 148mmol) stirring solution, add pyrrolidine (1.12g, 15.8mmol) and titanium isopropoxide (4.78mL, 15.8mmol) and stir 12h under argon atmosphere.At room temperature, add NaBH4(298mg, 7.89mmol) thereto.Gained reaction mixture is stirred at room temperature for additional 2h.The process of reaction is monitored by TLC.After completion, reaction mixture is quenched with water (20mL) and gained residue is filtered through celite pad and washed with DCM (25mL x 2). The combined organic phases were washed with water (15), dried over sodium sulfate and evaporated under reduced pressure to give the crude compound, which was triturated with 10% ethyl acetate: hexane (10 ml x 2) and diethyl ether (10 mL x 2) to give methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluoro-5-(pyrrolidin-1-ylmethyl)phenyl)thiazole-4-carboxylate (0.205 g, 29.84%) as an off-white solid. LCMS (ES): m / z: Calculated for C21H26FN3O4S: 435.16; Found: 436.1 (M+H).
[0679] Step 3: Preparation of tert-butyl (2-(2-fluoro-5-(pyrrolidin-1-ylmethyl)phenyl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate
[0680] To 5-{[(tert-butoxy)carbonyl]amino}-2-{2-fluoro-4-[(pyrrolidin-1-yl)methyl]phenyl}-1,3-thiazole-4-formic acid methyl ester (0.205g, 0.471mmol) in a stirred solution in toluene (2mL, 16.9mmol) 1-[2-(trifluoromethyl)phenyl]methylamine (0.066mL, 0.471mmol) was added and cooled to 0°C. 1M trimethylaluminum (0.136mL, 1.41mmol) in toluene was added thereto. The resulting reaction mixture was heated to 100°C for 16h. The progress of the reaction was monitored by TLC. After the reaction was complete, the reaction mixture was quenched with cold water (25mL) and extracted into EtOAc (25mL x 3). The combined organic layer was dried over sodium sulfate and evaporated under reduced pressure to obtain a crude product. The crude product was purified by Combi flash chromatography using 3% methanol: dichloromethane as eluent to give tert-butyl (2-(2-fluoro-5-(pyrrolidin-1-ylmethyl)phenyl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.4 g, 77%) as an off-white solid. LCMS (ES): m / z: Calcd. for C28H30F4N4O3S: 578.20; Found: 579.0 (M+H).
[0681] Step 4: Preparation of 5-amino-2-(2-fluoro-5-(pyrrolidin-1-ylmethyl)phenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0682] At 0 ° C, to N- (2- {2- fluoro-4- [(pyrrolidin-1-yl) methyl] phenyl} -4- ({ [2- (trifluoromethyl) phenyl] methyl} carbamoyl) -1,3-thiazole -5- bases) tert-butyl carbamate (0.4g, 0.691mmol) in methanol (4mL) solution was added in dioxane 4M HCl (0.86mL) and stirred at room temperature for 16h under argon atmosphere. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was alkalized with sodium bicarbonate (10mL) and extracted into ethyl acetate (25mL x2). The combined organic layers were washed with water (10 mL), brine solution (10 ml), dried over sodium sulfate and evaporated under reduced pressure to give 5-amino-2-(2-fluoro-5-(pyrrolidin-1-ylmethyl)phenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (95 mg, 29%) as a pale yellow solid.
[0683] LCMS (ES): m / z: calcd. for C23H22F4N4OS: 478.15; found: 479.0 (M+H).
[0684] Step-5: Preparation of 5-(3-chloro-5-fluoro-4-hydroxybenzamido)-2-(2-fluoro-5-(pyrrolidin-1-ylmethyl)phenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0685] At room temperature, 3-chloro-5-fluoro-4-hydroxybenzoic acid (41.6 mg, 0.218 mmol) and phosphorus trichloride (0.017 mL, 0.199 mmol) were added to a suspension of 5-amino-2-{2-fluoro-5-[(pyrrolidin-1-yl)methyl]phenyl}-N-{[2-(trifluoromethyl)phenyl]methyl}-1,3-thiazole-4-carboxamide (0.095 g, 0.199 mmol) in acetonitrile (1 mL) and then stirred for 2 h at 130 ° C. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was poured into ice-cold water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with water (10 mL), brine solution (5 mL) and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude material was purified by preparative HPLC (using 0.1% TFA in water: acetonitrile gradient). The collected pure fractions were lyophilized to give 5-(3-chloro-5-fluoro-4-hydroxybenzamido)-2-(2-fluoro-5-(pyrrolidin-1-ylmethyl)phenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.012 g, 9.28%). LCMS (ES): m / z: Calculated for C30H24ClF5N4O3S: 650.12; Found: 651.4 (M+H). 1H NMR (400 MHz, DMSO-d6) δ 12.31 (s, 1H), 10.87 (bs, 1H), 9.27 (bs, 1H), 8.45 (d, J = 6.8 Hz, 1H), 7.77 (d, J = 7.6 Hz, 1H), 7.71-7.63 (m, 4H), 7.57 (d, J = 6.8 Hz, 2H), 7.52-7.50 (m, 1H), 4.82 (d, J = 6 Hz, 2H), 4.30 (s, 2H), 3.16 (m, 4H), 1.92 (m, 4H). LC-purity: 99.62% at 240 nm.
[0686] Example 106: Synthesis of N-(bicyclo[1.1.1]pentan-1-ylmethyl)-5-(3-chloro-5-fluoro-4-hydroxybenzamido)-2-(2-fluorophenyl)thiazole-4-carboxamide
[0687]
[0688] Step 1: Preparation of methyl 2-(2-fluorophenyl)thiazole-4-carboxylate
[0689] To 2-bromo-1,3-thiazole-4-formic acid methyl ester (50g, 225mmol) in 1,4-dioxane (750mL), water (125mL) stirring solution, add (2-fluorophenyl) boronic acid (47.25g, 337.5mmol) and potassium carbonate (93.5g, 67.5mmol). The reaction mixture is purged with nitrogen for 15 minutes and then Pd (dppf) Cl2.DCM complex (9.2g, 0.05 equivalent, 2.25mmol) is added at room temperature. The resulting reaction mixture is heated to 100 ° C for 2h. The progress of the reaction is monitored by TLC. The reaction mixture is filtered through a diatomaceous earth pad, the diatomaceous earth pad is washed with EtOAc (2L), the filtrate is washed with water (2x 1000ml), a saline solution (500mL) and dried over Na2SO4, concentrated and dried to obtain a crude product. The crude material was purified by column chromatography using 5% EtOAc: Hexanes as eluent to give methyl 2-(2-fluorophenyl)-1,3-thiazole-4-carboxylate (41 g, 77% yield) as a white solid. LCMS (ES): m / z: Calculated for C5H5BrN2O2S: 237.03; Found: 237.9 (M+H).
[0690] Step 2: Preparation of methyl 5-bromo-2-(2-fluorophenyl)thiazole-4-carboxylate
[0691] At room temperature, NBS (45g, 253mmol) was added to a stirred solution of 2-(2-fluorophenyl)-1,3-thiazole-4-formic acid methyl ester (20g, 84.3mmol) in acetonitrile. The resulting reaction mixture was refluxed for 24h and then another portion of NBS (30g) was added, and stirring was continued for an additional 24h at reflux temperature. The progress of the reaction was monitored by TLC. After the reaction was completed, the reaction mixture was poured into ice-cold water (2L), the precipitated solid was filtered and washed with water (1L), and dried to obtain 5-bromo-2-(2-fluorophenyl)thiazole-4-formic acid methyl ester (20g, 75% yield) as a white loose solid. LCMS (ES): m / z: calculated for C11H7BrFNO2S: 314.94; found: 316.0 (M+H).
[0692] Step 3: Preparation of 5-bromo-2-(2-fluorophenyl)thiazole-4-carboxylic acid
[0693] To a stirred solution of 5-bromo-2-(2-fluorophenyl)-1,3-thiazole-4-carboxylic acid methyl ester (16 g, 50.6 mmol) in tetrahydrofuran (200 mL), methanol (75 mL) and water (30 mL) was added LiOH.H2O (3.64 g, 152 mmol) at room temperature. The resulting reaction mixture was stirred at 60 ° C for 16 hours. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was poured into cold water and acidified to pH ~ 2 by dilute HCl solution. The precipitated solid was filtered and washed with water (1 L), dried to give 5-bromo-2-(2-fluorophenyl)-1,3-thiazole-4-carboxylic acid (14 g, 96%) as a white solid. LCMS (ES): m / z: calculated for C10H5BrFNO2S: 300.92; found: 301.9 (M+H).
[0694] Step 4: Preparation of N-(bicyclo[1.1.1]pentan-1-ylmethyl)-5-bromo-2-(2-fluorophenyl)thiazole-4-carboxamide.
[0695] At room temperature, to a stirred solution of 5-bromo-2-(2-fluorophenyl)-1,3-thiazole-4-carboxylic acid (0.2g, 0.66mmol) in N,N-dimethylformamide (5ml), bicyclo[1.1.1]pentyl-1-ylmethylamine (0.064g, 0.66mmol), HATU (0.3g, 0.794mmol) and triethylamine (0.37mL, 2.65mmol) were added. The resulting reaction mixture was stirred at room temperature for 2 hours. The progress of the reaction was monitored by TLC and LCMS. The reaction mixture was poured into ice-cold water (10mL) and extracted with ethyl acetate (2x 20mL), the combined organic layer was washed with water, saline solution, dried over Na2SO4, concentrated and dried to obtain a crude product. The crude material was purified by flash column chromatography using 5% ethyl acetate in hexanes as eluent to give N-(bicyclo[1.1.1]pentan-1-ylmethyl)-5-bromo-2-(2-fluorophenyl)thiazole-4-carboxamide (0.075 g, 30%) as a white solid. LCMS (ES): m / z: Calculated for C16H14BrFN2OS: 380.00; Found: 380.9 (M+H).
[0696] Step-5: Preparation of N-(bicyclo[1.1.1]pentan-1-ylmethyl)-5-(3-chloro-5-fluoro-4-hydroxybenzamido)-2-(2-fluorophenyl)thiazole-4-carboxamide
[0697] To a stirred solution of N-(bicyclo[1.1.1]pentyl-1-methyl)-5-bromo-2-(2-fluorophenyl)thiazole-4-carboxamide (0.07 g, 0.184 mmol) and 3-chloro-5-fluoro-4-hydroxybenzamide (0.052 g, 0.275 mmol) in tert-butyl alcohol (2 mL) was added cesium carbonate (0.18 g, 0.55 mmol). Then under nitrogen, the reaction mixture was degassed for 10 min. Then at room temperature, Xanthphos (11 mg, 0.018 mmol) and Pd2(dba)3 (15 mg, 0.018 mmol) were then added and the reaction mixture was heated to 100 ° C for 16 hours. The progress of the reaction was monitored by LCMS and TLC. The reaction mixture was poured into water (100 ml) and extracted with ethyl acetate (3 x 100 ml), the combined organic layer was washed with water, brine, dried over Na2SO4 and concentrated under reduced pressure to obtain a crude product. The crude solid was stirred with diethyl ether (10 ml) for 30 min, and then the solid was filtered. The solid was further triturated with methanol, filtered and dried to give N-(bicyclo[1.1.1]pentan-1-ylmethyl)-5-(3-chloro-5-fluoro-4-hydroxybenzamido)-2-(2-fluorophenyl)thiazole-4-carboxamide (0.012 g, 12%). LCMS (ES): m / z: calculated for C23H18ClF2N3O3S: 489.07; found: 490.2 (M+H); 1H NMR (400 MHz, DMSO-d6): δ12.53 (s, 1H), 11.65 (bs, 1H), 8.79 (t, J=6.0 Hz, 1H), 7.73 (s, 1H), 7.69-7.66 (m, 1H), 7.58-7.39 (m, 3H), 3.43 (d, J=6.4 Hz, 2H), 1.69 (s, 6H); LC-purity: 99.84% at 240 nm.
[0698] Example 107: Synthesis of 5-(4-chloro-6-fluoro-5-hydroxypicolinamido)-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0699]
[0700] Step-1: Preparation of methyl 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-carboxylate
[0701] At ambient temperature, to 5-amino-2-bromothiazole-4-methyl-formiate (1g, 4.22mmol) in tetrahydrofuran (20mL, 246mmol) stirring solution, add di-tert-butyl dicarbonate (1.45mL, 6.33mmol), DIPEA (2.2mL, 12.7mmol) and DMAP (0.520g, 4.22mmol) and then stir extra 2h at the same temperature.Reaction mixture is poured in water (40mL) and extracted with ethyl acetate (50mL x 3).The organic phase merged is washed with water, salt water and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to obtain crude product.Crude material is purified by flash column chromatography using 30% ethyl acetate in hexane as eluent to obtain 2-bromo-5-((tert-butoxycarbonyl) amino) thiazole-4-methyl-formiate (0.9g, 63%) as white solid. LCMS (ES): m / z: Calculated for C10H13BrN2O4S: 335.98; found: 337.0.
[0702] Step-2: Preparation of methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluorophenyl)thiazole-4-carboxylate
[0703] To 2-bromo-5-((tert-butoxycarbonyl)amino)thiazole-4-formic acid methyl ester (0.460g, 1.36mmol) and (2-fluorophenyl)boric acid (0.382g, 2.73mmol) in 1,4-dioxane: water 8:2 (6mL) in a stirred solution and potassium carbonate (0.566g, 4.09mmol) and degassed with nitrogen for 10min, then bis(tri-tert-butylphosphine)palladium (0.0697g, 0.136mmol) was added and stirred at 100°C for 16h. The progress of the reaction was monitored by TLC / LCMS. After the reaction was completed, the reaction mixture was filtered through a diatomaceous earth pad, the filtrate was diluted with ethyl acetate (50mL), washed with water (25x 2mL), a saline solution and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to obtain a crude product. The crude product was purified by flash column chromatography using 20% ethyl acetate in hexanes as eluent to give methyl 5-((tert-butoxycarbonyl)amino)-2-(2-fluorophenyl)thiazole-4-carboxylate (0.350 g, 73%) as a brown solid. LCMS (ES): m / z: Calculated for C16H17FN2O4S: 352.09; Found: 353.1.
[0704] Step-3: Preparation of tert-butyl (2-(2-fluorophenyl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate
[0705] At 0 ℃, to 5-((tert-butoxycarbonyl)amino)-2-(2-fluorophenyl)thiazole-4-formic acid methyl ester (0.3g, 0.851mmol) in toluene (5mL) stirring solution, add 1-[2-(trifluoromethyl)phenyl]methylamine (0.119mL, 0.851mmol) and 2M trimethylaluminum (0.245mL, 2.55mmol) in toluene. The resulting reaction mixture was stirred at 100 ℃ for 16 hours. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (25mL), and extracted with ethyl acetate (25x2mL). The organic phase merged was washed with saline solution (15mL) and dried over anhydrous sodium sulfate, filtered and evaporated under vacuum to obtain a crude product. The crude material was purified by flash column chromatography using 30% EtOAc:hexanes as eluent to give tert-butyl (2-(2-fluorophenyl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.3 g, 71%) as an off-white solid. LCMS (ES): m / z: Calculated for C23H21F4N3O3S: 495.12; Found: 496.1.
[0706] Step-4: Preparation of 5-amino-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0707] To a suspension of tert-butyl (2-(2-fluorophenyl)-4-((2-(trifluoromethyl)benzyl)carbamoyl)thiazol-5-yl)carbamate (0.250 g, 0.505 mmol) in methanol (1 mL) at 0°C was added 4M HCl in dioxane (5 mL, 144 mmol) and then stirred at room temperature for 1 h. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phase was washed with water (10 ml), brine (5 ml) and dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give 5-amino-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.170 mg, 85%) as a white solid. LCMS (ES): m / z: Calculated for C18H13F4N3OS: 395.07; Found: 396.1.
[0708] Step-5: Preparation of 5-(4-chloro-6-fluoro-5-methoxypicolinamido)-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0709] To a suspension of 5-amino-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.1 g, 0.25 mmol) in chlorobenzene (0.5 mL) was added 4-chloro-6-fluoro-5-methoxypyridine-2-carboxylic acid (0.065 g, 0.30 mmol) and phosphorus trichloride (0.03 mL, 0.25 mmol). The resulting reaction mixture was heated to 120 ° C for 3 h. The progress of the reaction was monitored by LCMS. The reaction mixture was cooled to ambient temperature and quenched with ice-cold water (10 mL), the solid was collected by filtration to give a crude residue, which was purified by flash column chromatography using 30% ethyl acetate in hexanes as eluent to give 5-(4-chloro-6-fluoro-5-methoxypicolinamido)-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (0.08 g, 54%) as an off-white solid. LCMS (ES): m / z: Calculated for C25H16ClF5N4O3S: 582.06; Found: 583.1 (M+H); 1H NMR (400MHz, DMSO-d6): δ12.78 (s, 1H), 9.37 (t, J = 5.6 Hz, 1H), 8.48-8.45 (m, 1H), 8.18 (s, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.66-7.63 (m, 1H), 7.54-7.45 (m, 2H), 7.42-7.37 (m, 3H), 4.76 (d, J = 5.6 Hz, 2H), 19F NMR (400MHz, DMSO-d6): δ-50.05 (m, 3F), -77.37 (1F), -112.88 (1F). LC purity: 99.1% at 254nm.
[0710] Step-6: Preparation of 5-(4-chloro-6-fluoro-5-hydroxypicolinamido)-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide
[0711] To a stirred solution of 4-chloro-6-fluoro-N-[2-(2-fluorophenyl)-4-({[2-(trifluoromethyl)phenyl]methyl}carbamoyl)-1,3-thiazol-5-yl]-5-methoxypyridine-2-carboxamide (80 mg, 0.137 mmol) in NMP (1 mL) was added lithium chloride (17.5 mg, 0.412 mmol) and p-TSA (78.3 mg, 0.412 mmol). The reaction mixture was heated at 100 ° C for 3 h. Upon completion, the reaction mixture was quenched with water (5 mL) and the solid was collected by filtration to give a crude product. It was purified by flash chromatography using 0-10% MeOH / DCM as eluent to give 5-(4-chloro-6-fluoro-5-hydroxypicolinamido)-2-(2-fluorophenyl)-N-(2-(trifluoromethyl)benzyl)thiazole-4-carboxamide (30 mg, 38%). LCMS (ES): m / z: calculated for C24H14ClF5N4O3S: 568.04; found: 569.2 (M+H); 1 H NMR (400MHz, DMSO-d6): δ12.68(s,1H),9.39(t,J=6.4Hz,1H),8.50-8.46(m,1H),8.14(S ,1H),7.77(d,J=7.6Hz,1H),7.69-7.65(m,1H),7.58-7.38(m,5H),4.78(d,J=6.4Hz,2H). 19 F NMR (400 MHz, DMSO-d6): δ -59.10 (3F, -CF3), -81.55 (1F, -ArF), -112.92 (1F, -ArF). LC purity: 99.5% at 240 nm.
[0712] Example A: Estrone Detection Assay for Assessing HSD17β13 Activity and Identifying Inhibitors
[0713] Liquid chromatography / mass spectrometry (LC / MS) estrone detection assay monitors the conversion of estradiol to estrone by HSD17B13. This assay was performed in a 96-well plate format (Eppendorf deep well plate 96 / 500) with an 80 μl reaction volume containing: 4 μM estradiol (E2; Cayman; #10006315), 6 mM NAD +(Sigma; #N0623) and 30 nM HSD17B13 enzyme (homemade; His-tagged purified soluble protein expressed in E. coli) in a reaction containing 1 M potassium phosphate buffer (pH 7.4) and 0.5% vehicle (DMSO). The reaction was incubated at 26.5°C for 2 hours, and the conversion of estradiol (E2) to estrone (E1) was quantified by LC-MS / MS-based analyte detection for both E2 and E1 using LCMS-grade reagents.
[0714] The reaction was terminated by adding two volumes of acetonitrile (MeCN; LCMS grade; CAS#75 / 05 / 8) containing deuterated (D4)-E1 (Clear Synth; #CS-T-54273; 500 ng / mL final concentration) used as an internal standard. The sample was applied to a pre-prepared Bond Elut-C18 extraction cartridge (3 mL; Agilent; #12102028), washed and eluted in MeCN. The eluate was dried under nitrogen and resuspended in 60% methanol (LCMS grade methanol; CAS#67 / 56 / 1) before submitting for analysis. Aqueous solutions including E2 and E1 were linear for quantitation.
[0715] Analysis of samples was performed on an XBridge BEH C18 column (Waters; #186003033) using 0.1% diethylamine in MeCN (mobile phase A; DEA CAS #109-89-7) and 0.1% diethylamine in milli-Q water (mobile phase B) with a 3 min gradient allowing 25% B. Analytes were detected in negative mode using MRM analysis with E2 having an RT of 1.85 min and E1 having an RT of 2 min. The presence of NAD in the presence of + The specificity of conversion was assessed by enzyme activity under 1:100. Enzyme activity under 1:100 was expressed as the percentage of uninhibited enzyme activity in the presence of the test sample, and plotted relative to the inhibitor concentration. Nonlinear regression was performed using a four-parameter logistic model and GraphPad Prism software (GraphPad Software, La Jolla, CA). All evaluations were performed with duplicate assessments and merged during the extraction process, and duplicate injections were subsequently used for LC-MS / MS analysis.
[0716] Example B: Estrone Detection Assay for Assessing HSD17B14 Activity and Identifying Inhibitors via Detection of Estrone Product
[0717] Liquid chromatography / mass spectrometry (LC / MS) estrone detection assay monitors the conversion of estradiol to estrone by HSD17B14. This assay was performed in a 96-well plate (Eppendorf deep well) in an 80 μl reaction volume containing: 8 μM estradiol (E2; Cayman); 4 mM NAD + (Sigma); 120 nM HSD17B14 enzyme (self-made His-tagged purified soluble protein expressed in E. coli); 1 M potassium phosphate buffer (pH 7.4) and 1.2% vehicle (DMSO). The reaction was incubated at 37°C for 2 hours. The conversion of estradiol (E2) to estrone (E1) was quantified by LC-MS / MS-based analyte detection for E1 using LCMS-grade reagents.
[0718] The reaction was terminated by adding two volumes of acetonitrile (MeCN; LCMS grade) containing deuterated (D4)-E1 (Clear Synth; 500 ng / mL final concentration) used as an internal standard. The samples were applied to a pre-prepared Bond Elut-C18 extraction cartridge (3 mL; Agilent). The cartridges were washed with 1.5 mL of water, then with 1.5 mL of 5% aqueous methanol, and dried under vacuum for 5 minutes. They were then eluted with 4.5 mL of MeCN. The eluate was dried under nitrogen and resuspended in 200 μL of 60% methanol (LCMS grade) before being submitted for analysis. A standard curve of E2 and E1 in 4% DMSO was included for quantification.
[0719] The samples were analyzed on an XBridge BEH C18 column (Waters) using 0.1% diethylamine in MeCN (mobile phase A) and 0.1% diethylamine in milli-Q water (mobile phase B) with a gradient of 0-25% B over 3 min. The analytes were detected in negative mode using MRM analysis with E2 having an RT of 1.89 min and E1 having an RT of 2.07 min. The chromatograms were taken in the absence of NAD using a 50 μl column. + The specificity of the conversion was assessed by the enzyme activity under 1.2% DMSO. The enzyme activity in the presence of the test sample was expressed as the percentage of the uninhibited enzyme in the presence of 1.2% DMSO vehicle alone and plotted against the inhibitor concentration. Nonlinear regression was performed using a four-parameter logistic model and GraphPad Prism software. All evaluations were performed in duplicate, which were combined during the extraction process and subsequently injected in duplicate for LC-MS / MS analysis.
[0720] Example C: Assessment of HSD17B2 activity and identification of inhibitors via detection of reduced nicotinamide adenine dinucleotide (NADH) product
[0721] Fluorescence-based detection assay to monitor the cofactor NAD + The conversion of estradiol to NADH occurs simultaneously with the conversion of estradiol to estrone by HSD17B2. These assays were performed in 384-well plates (Greiner V-type PP microplates). The 20 μl reaction volume contained: 0.7 μM estradiol (E2); 6 mM NAD + (Sigma); 250 nM HSD17B2 enzyme (Origene; Cat. No. TP303293); 0.25 M potassium phosphate buffer (pH 7.4), 0.75% vehicle (DMSO). The reaction was incubated at 37°C for 2 hours and stopped by freezing the reaction plate at -80°C. The zero time sample was frozen immediately.
[0722] NAD was quantified using the NAD-Glo kit (Promega; catalog number G9062) according to the manufacturer's instructions. + Conversion to NADH. A volume of 15 μL of the enzyme reaction mixture was added to 15 μL of the reconstituted Glo reagent and the plate was incubated at room temperature for 30 minutes. A standard curve of NADH (0.1-50 μL) in potassium phosphate buffer (pH 7.4 / 1% DMSO) was run on each plate.
[0723] The specificity of conversion was assessed using enzyme activity in the absence of E2. Enzyme activity in the presence of the test sample was expressed as the percentage of the uninhibited enzyme in the presence of 1% DMSO vehicle alone and plotted relative to inhibitor concentration. Nonlinear regression was performed using a four-parameter logistic model and GraphPad Prism software. All evaluations were performed in duplicate.
[0724] The data from Examples A, B and C are shown in Tables 2 and 3 below:
[0725] Table 2
[0726]
[0727] In the case of estradiol, the IC 50
[0728] A is less than or equal to 0.1 μM;
[0729] B is greater than 0.1 μM and less than or equal to 0.5 μM;
[0730] C is greater than 0.5 μM and less than or equal to 1.0 μM;
[0731] D is greater than 1.0 μM and less than or equal to 10 μM;
[0732] E is greater than 10μM.
[0733] Table 3
[0734]
[0735]
[0736] HSD17B13 Inhibition_Estradiol Substrate_LCMS: Ki
[0737] A is less than or equal to 50 nM;
[0738] B is greater than 50 nM and less than or equal to 100 nM;
[0739] C is greater than 100 nM and less than or equal to 500 nM.
Claims
1. A compound of formula (I) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof: in: Ring A is thiazolyl; R 1 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl or C1-C6 aminoalkyl; R 2 is hydrogen or C1-C6 alkyl; R 3 It is C1-C 10 Alkyl, C1-C 10 Halogenated alkyl, C1-C 10 Deuterated alkyl, C1-C 10 Hydroxyalkyl, C1-C 10 Aminoalkyl, C1-C 10 Heteroalkyl, C2-C 10 Alkenyl, C2-C 10 wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 3a replace; Each R 3a are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NHS(=O)2R a 、-C(=O)R a 、-C(=O)C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d 、-C(=O)C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or two R on the same atom 3a Together they form an oxo group; R 4 is deuterium, halogen, C1-C6 alkyl, C2-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally replaced by one or more R 4a replace; Each R 4a are independently deuterium, halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NHS(=O)2R a 、-C(=O)R a 、-C(=O)C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d 、-C(=O)C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently substituted with one or more R; or two R on the same atom 4a Together they form an oxo group; or two R on the same carbon 4a together form a cycloalkyl or heterocycloalkyl; each optionally substituted by one or more R; or two R on different atoms 4a together form a cycloalkyl, heterocycloalkyl, aryl or heteroaryl; each optionally substituted with one or more R; X is N or CR X ; R X It is hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl; R 5 It is hydrogen, deuterium, halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl; Each R 6 are independently halogen; Each R a is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R; Each R b is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene(cycloalkyl), C1-C6 alkylene(heterocycloalkyl), C1-C6 alkylene(aryl) or C1-C6 alkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted by one or more R; and Each R c and R d R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted with one or more R; or R c and R d together with the atoms to which they are attached form heterocycloalkyl, which is optionally substituted with one or more R; Each R is independently halogen, -CN, -OH, -OC1-C3 alkyl, -OC1-C3 haloalkyl, -SC1-C3 alkyl, -S(=O)C1-C3 alkyl, -S(=O)2C1-C3 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C3 alkyl, -S(=O)2N(C1-C3 alkyl)2, -NH2, -NHC1-C3 alkyl, -N(C1-C3 alkyl) -C(═O)C1-C3 alkyl, -C(═O)OH, -C(═O)OC1-C3 alkyl, -C(═O)NH2, -C(═O)NHC1-C3 alkyl, -C(═O)N(C1-C3 alkyl)2, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 deuterated alkyl, C1-C3 hydroxyalkyl, C1-C3 aminoalkyl, C1-C3 heteroalkyl or C3-C6 cycloalkyl; Or two R's on the same atom form an oxo group.
2. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein the compound has formula (Ia):
3. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein the compound has formula (Ib):
4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 1 It's hydrogen.
5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 2 It's hydrogen.
6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 3 It is C1-C 10 Alkyl, C1-C 10 Halogenated alkyl, C1-C 10 Deuterated alkyl, C1-C 10 Hydroxyalkyl, C1-C 10 Aminoalkyl, C1-C 10 C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 3a replace.
7. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 3 It is C4-C 10 Alkyl, C1-C 10 Halogenated alkyl, C1-C 10 Deuterated alkyl, C1-C 10 Hydroxyalkyl, C1-C 10 Aminoalkyl, C1-C 10 C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 3a replace.
8. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 3 It is C1-C 10 C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 3a replace.
9. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 3 It is C4-C 10 C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally and independently replaced by one or more R 3a replace.
10. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 3 It is C1-C 10 Alkyl or C1-C6 alkylene (aryl); wherein the alkyl, alkylene and aryl are optionally and independently replaced by one or more R 3a replace.
11. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 3 It is C4-C 10 Alkyl or C2-C6 alkylene (aryl); wherein the alkyl, alkylene and aryl are optionally and independently replaced by one or more R 3a replace.
12. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 3 is optionally and independently replaced by one or more R 3a Substituted C1-C 10 alkyl.
13. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 3 is optionally and independently replaced by one or more R 3a Substituted C4-C 10 alkyl.
14. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 3 It is C4-C 10 alkyl.
15. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 3 is C1-C6 alkylene (aryl); wherein the alkylene and aryl are optionally and independently replaced by one or more R 3a replace.
16. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 3 is C2-C6 alkylene (aryl); wherein the alkylene and aryl are optionally and independently replaced by one or more R 3a replace.
17. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 3a are independently deuterium, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl; or two R on the same atom 3a Together they form an oxo group.
18. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 3a are independently deuterium, halogen, -OH, -OR a , C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 deuterated alkyl; or two R 3a Together they form an oxo group.
19. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 3a are independently halogen, -OR a Or C1-C6 haloalkyl.
20. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 3a are independently C1-C6 haloalkyl.
21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein X is N.
22. The compound of any one of claims 1 to 20, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein X is CR X .
23. A compound according to any one of claims 1 to 20 or 22, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R X It is hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl.
24. A compound as described in any one of claims 1-20 or 22 or 23, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R X It is hydrogen or C1-C6 alkyl.
25. A compound according to any one of claims 1 to 20 or 22 to 24, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R X It's hydrogen.
26. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 5 It is hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl.
27. The compound of any one of claims 1 to 26, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 5 It is hydrogen or C1-C6 alkyl.
28. A compound according to any one of claims 1 to 27, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 5 It's hydrogen.
29. The compound of any one of claims 1 to 28, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 6 It's chlorine-based.
30. The compound of any one of claims 1 to 28, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 6 It is fluorine-based.
31. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 4 is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted by one or more R 4a replace.
32. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 4 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted by one or more R 4a replace.
33. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 4 is optionally replaced by one or more R 4a Substituted cycloalkyl.
34. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 4 is optionally replaced by one or more R 4a Substituted heterocycloalkyl.
35. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 4 is aryl or heteroaryl; wherein the aryl and heteroaryl are optionally substituted by one or more R 4a replace.
36. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 4 is optionally replaced by one or more R 4a Substituted aryl.
37. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein R 4 is optionally replaced by one or more R 4a Substituted heteroaryl.
38. A compound as described in any one of claims 1 to 37, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 4a are independently deuterium, halogen, -CN, -OH, -OR a 、-S(=O)R a 、-NR c R d , C1-C6 alkyl or C1-C6 haloalkyl; wherein the alkyl is optionally and independently substituted with one or more R; or two R on the same atom 4a Together they form an oxo group.
39. A compound as described in any one of claims 1 to 37, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 4a are independently deuterium, halogen, -CN, -OH, -OR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl; or two R on the same atom 4a Together they form an oxo group.
40. The compound of any one of claims 1 to 37, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 4a are independently deuterium, halogen, -CN, -OH, -OR a 、-S(=O)R a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuterated alkyl, cycloalkyl or heterocycloalkyl; or two R on the same atom 4a Together they form an oxo group.
41. A compound as described in any one of claims 1 to 37, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 4a are independently halogen, -CN, -OH, -OR a 、-S(=O)R a 、-NR c R d , C1-C6 alkyl or C1-C6 haloalkyl; or two R 4a Together they form an oxo group.
42. A compound as described in any one of claims 1 to 37, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein each R 4a are independently halogen, -S(=O)R a , C1-C6 alkyl or C1-C6 haloalkyl; or two R 4a Together they form an oxo group.
43. A compound selected from the compounds found in Table 1a or Table 1b, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
44. A pharmaceutical composition comprising the compound of any one of claims 1-43 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof and a pharmaceutically acceptable carrier.
45. A method of treating a disease in a subject in need thereof, the method comprising administering a pharmaceutically effective amount of a compound according to any one of claims 1 to 43 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, or a pharmaceutical composition according to claim 44.
46. The method of claim 45, wherein the disease is a liver disease, a metabolic disease, or a cardiovascular disease.
47. The method of claim 45 or 46, wherein the disease is NAFLD.
48. The method of claim 45 or 46, wherein the disease is NASH.
49. The method of claim 45 or 46, wherein the disease is drug-induced liver injury (DILI).
50. The method of claim 45 or 46, wherein the disease is associated with HSD17B13.
51. The method of claim 45 or 46, wherein the disease is alcoholic liver disease.
52. The method of claim 45 or 46, wherein the disease is cirrhosis of the liver.
53. The method of claim 45 or 46, wherein the disease is decompensated portal hypertension.
54. The method of claim 45 or 46, wherein the disease is a cholestatic liver disease.
55. A method for selectively inhibiting HSD17B13, comprising administering a pharmaceutically effective amount of a compound according to any one of claims 1 to 43 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
56. The method of claim 55, wherein the compound selectively inhibits HSD17B13 over HSD17B2, HSD17B14, or any combination thereof.
Citation Information
Cited By
Pyrimidine ring-substituted thiazole amide compound and preparation method therefor, insecticidal composition thereof, and use thereof
WO2026166395A1
